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1. Summary 
Alternative treatment strategies for pancreatic cancer are urgently needed as all available therapies 
fail to work efficiently. Oncolytic adenoviruses are promising agents as they can be engineered to 
specifically replicate in tumor cells and subsequently lyse them (oncolysis). Oncolytic adenoviruses 
have shown an excellent safety profile in phase 1 and 2 clinical trials. However, these studies 
revealed a need for improvement of the therapeutic efficiency of the viral agents. The critical issues 
were the limited efficiency of tumor cell lysis and the poor delivery of the virus to the tumor site 
after systemic administration due to clearance by neutralizing antibodies and liver sequestration. The 
delivery problem was approached by using mesenchymal stem cells (MSCs), isolated from human 
bone marrow, as carrier cells to shield the virus from nonspecific uptake and neutralization. MSCs are 
established carriers to mediate targeted delivery of oncolytic adenoviruses to tumor sites in animal 
models. In this study, genetic modifications of oncolytic adenovirus were explored for improvement 
of the viral agent in the context of MSC delivery. The overall aim of the study was to identify those 
modifications, which mediated optimized adenovirus transduction and replication in MSCs, allowed 
unimpeded migration of infected MSCs for the time required for tumor homing, and mediated 
improved killing of the pancreatic cancer cells. 
From a set of capsid variants, performed transduction experiments identified the fiber chimera 5/3, 
derived from adenovirus serotype 5 fiber with the cell binding domain of serotype 3, to consistently 
mediate most efficient transduction in MSCs as well as in established and low-passage pancreatic 
tumor cells. Ad5/3 served as capsid background in the subsequently investigated set of modified, 
replication-competent, oncolytic adenoviruses. The modifications included: i. the deletion of the viral 
gene E1B19K aiming at improved virus replication and release kinetics, ii. the transgene insertions of 
the shedded death ligand TRAIL to mediate bystander killing, and iii. the transgene insertion of the 
prodrug-converting enzyme FCU1, which mediates conversion of the systemically administered 
prodrug 5-Fluorocytosine to the chemotherapeutic agent 5-Fluorouracil, for additional tumor cell 
killing. Infection of MSCs with the E1B19K-deleted or TRAIL-modified viruses resulted in dramatically 
improved virus replication and release kinetics compared to a matching control virus. Further, it was 
shown that MSCs infected with the E1B19K-deleted or TRAIL-modified viruses maintained their 
migration properties over 2 days. This time span corresponds to the reported time MSCs need in vivo 
to home to a tumor after systemic administration. From these observations it was concluded that the 
investigated modifications have the potential to improve MSC-mediated virus delivery. Subsequently, 
the E1B19K-deleted, TRAIL-expressing, and FCU1-expressing viruses were tested in established 
pancreatic tumor cell lines for improved killing. All modified viruses showed enhanced tumor cell 
killing in a subset of cell lines. Further, virus spread and killing was investigated in low-passage 
pancreatic tumor cell cultures, as a clinically relevant model, and in MiaPaCa-2 spheroids, to mimic 
viral behavior in a 3D tumor structure. Also in these models, the results indicated that the analyzed 
virus modifications are suited to achieve more efficient tumor cell killing.  
In the course of this study, virus mutants were identified, which possessed improved replication and 
release kinetics in MSCs, allowed unimpeded MSC migration, and showed enhanced pancreatic 
tumor cell killing abilities. Therefore, strategies to improve oncolytic adenoviruses for MSC-mediated 
delivery to pancreatic tumor sites were derived, which can contribute to improve clinical efficiency of 
adenovirotherapy. 
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2. Zusammenfassung 
Behandlungsalternativen für Pankreastumore sind dringend notwendig, da derzeitige Therapien 
keinen ausreichenden therapeutischen Nutzen zeigen. Onkolytische Adenoviren sind hier 
vielversprechend, da sie so spezifisch modifiziert werden können, dass sie bevorzugt in Tumorzellen 
replizieren und sie anschließend töten (Onkolyse). In Studien der klinischen Phase 1 und 2 haben 
onkolytische Adenoviren ein gutes Sicherheitsprofil  bewiesen. Es wurde jedoch die Notwendigkeit 
einer Effizienzverbesserung der viralen Vektoren aufgezeigt. Als kritisch erwiesen sich hierbei die 
Effizienz der Tumorzelllyse, sowie der Weg der Viren zum Tumor nach systemischer Applikation, da 
die meisten Viren entweder von Antikörpern neutralisiert oder von der Leber aufgenommen wurden. 
Der ungewünschte Verlust wurde durch die Verwendung von aus menschlichem Knochenmark 
isolierten mesenchymalen Stammzellen (MSCs) als Transportzellen umgangen, die das Virus vor 
ungewünschter Aufnahme und Neutralisation schützen. MSCs sind in Tiermodellen als spezifische 
Transportzellen von onkolytische Adenoviren zu Tumoren etabliert. In der vorliegenden Studie 
wurden genetische Modifikationen von onkolytische Adenoviren untersucht, die auf die 
Verbesserung der Viren im Kontext des MSC-Transports abzielten. Das Ziel des Projekts war, 
diejenigen Modifikationen zu identifizieren, die Virustransduktion, -replikation und -transport in 
MSCs, sowie anschließende Tumorzelltötung optimierten. 
Aus einer Auswahl von Kapsidvarianten konnte in durchgeführten Transduktionsexperimenten die 
Fiberchimäre 5/3, die sich aus Adenovirus Serotyp 5 Fiber mit der zellbindenden Domäne von 
Serotyp 3 zusammensetzt, als am besten transduzierende Kapsidvariante bestimmt werden, sowohl 
in MSCs als auch in etablierten und niedrig-passagigen Pankreaskrebszellen. Das Ad5/3 Kapsid wurde 
für die anschließend untersuchten modifizierten, replikations-kompetenten, onkolytischen 
Adenoviren verwendet. Diese Modifikationen waren: i. die Deletion des viralen E1B19K Gens, um 
eine verbesserte Virusreplikation und -freisetzung zu erreichen, ii. die Insertion des Gens des 
Todesliganden TRAIL, für die Zerstörung benachbarter Tumorzellen, und iii. die Insertion des Gens 
FCU1, das die Prodrug 5-Fluorocytosin nach systemischer Applikation in das Chemotherapeutikum 
5-Fluorouracil umwandelt, das zusätzlich Tumorzellen tötet. Die Infektion von MSCs mit den E1B19K-
deletierten oder TRAIL-modifizierten Viren zeigte deutlich verbesserte Virusreplikations- und 
Virusfreisetzungs-Kinetiken. Ferner wurde gezeigt, dass die Migrationseigenschaften der MSCs über 
2 Tage beibehalten wurden, auch wenn MSCs mit den E1B19K-deletierten oder TRAIL-modifizierten 
Viren infiziert waren. Diese Zeitpanne entspricht der Zeit, die MSCs in vivo benötigen, um den Tumor 
zu erreichen. Demzufolge waren die analysierten Modifikationen zur Verbesserung des Transports 
der Viren zum Tumor potentiell geeignet. Anschließend wurden die modifizierten Viren hinsichtlich 
ihrer Fähigkeit zur verbesserten Tumorzelltötung in etablierten Pankreaskrebszelllinien getestet. Alle 
modifizierten Viren zeigten verbesserte Lyse in einem Teil der Zelllinien. Weiterhin wurde 
Virusausbreitung und Zelltötung in niedrig-passagigen Zellkulturen, als ein klinisch relevantes Modell, 
und in MiaPaCa-2 Spheroiden, um das Virusverhalten in einer 3D-Tumorstruktur nachzustellen, 
analysiert. Auch in diesen Modellen wiesen die Ergebnisse darauf hin, dass die analysierten 
Modifikationen geeignet sind, um die Tumorzellzerstörung zu verbessern.  
Im Laufe dieser Studie wurden Virusmutanten identifiziert, die verbesserte Replikations- und 
Freisetzungs-Kinetiken in MSCs zeigten, die Migration von infizierten MSCs zuließen, sowie eine 
verbesserte Tumorzelltötung aufzeigten. Daraus lassen sich Strategien ableiten, die zur verbesserten 
klinischen Effizienz der Adenovirotherapie beitragen können.  
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4. Abbreviations 
 
5-dUMP 5-Fluorodeoxyuridine monophosphate 
5-FC 5-fuorocytosine 
5-FU 5-flurouracil 
5-FUMP 5-Fluorouridine monophosphate 
ADP adenovirus death protein 
ALDH aldehyde-dehydrogenase 
Amp ampicillin 
AMP adenosine 5′-monophosphate 
ANOVA analysis of variances 
Apo-1 apoptosis antigen 1 
APS ammounium persulfate 
AraC arabinosyl cytosine 
ATP adenosine 5′-triphosphate 
Bcl-2 B cell lymphoma 2 protein 
bp base pair 
BPSA human beta globin splice acceptor 
BSA bovine serum albumin 
CAR coxackie and adenovirus receptor 
CD cytosine deaminase 
CDKN2A cyclin-dependent kinase inhibitor 2A 
CDx cluster of differentiation 
CMV cytomegalovirus 
CsCl caesium chloride 
DKFZ German Cancer Research Center 
DMEM Dulbecco’s Modified Eagle’s Medium 
DMSO demethyl sulfoxide 
DNA deoxyribonucleic acid 
dNTP deoxyribonucleotide triphosphates 
DTT dithiothreitol 
EC50 effective concentration 50 
EDTA ethylenediaminetetraacetic acid 
EGTA ethylene glycol tetraacetic acid 
ESA epithelial surface antigen 
EtOH ethanol 
FBS fetal bovine serum 
FCU1 yCD-UPRT gene 
fw forward 
GFP green fluorescent protein 
GM-CSF granulocyte-macrophage colony-stimulating factor 
HCl hydrochloric acid 
HEK  human embryonic kidney  
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HNSSC head and neck squamous cell carcinoma 
HR1/2 homologous region 1/2 
HRP horseradish peroxidase 
HSV herpes simplex virus 
i..p. intra-peritoneal 
i.a. intra-arterial 
i.t. intra-tumoral 
i.v. intra-venous 
IFN-β interferon-β 
IL interleukin 
IMDM Isocove’s modified Dulbecco’s medium 
IRES internal ribosomal entry site 
Kan kanamycin 
kb kilo base pairs 
KCl potassium chloride 
kDa kilo Dalton 
K-Ras Kirsten rat sarcoma viral oncogene homolog 
LB Luria Bertani medium 
LB Luria Broth medium 
LDH lactate dehydrogenase 
LiCl lithium chloride 
LITR left inverted terminal repeat 
Luc firefly luciferase 
MgCl2 magnesium chloride 
MgSO4 magnesium sulfate 
min minutes 
MLP major late promoter 
mRNA messenger ribonucleic acid 
MSC mesenchymal stem cell 
n.s. not significant 
NaCl sodium chloride 
NDV newcastle disease virus 
NF-κB nuclear factor kappa-light-chain-enhancer of activated B cells 
NH medium nonhematopoietic stem cell expansion medium 
NSC neuronal stem cell 
OD optical density 
p.i. post-infection 
pA polyadenylation 
Pb Polybrene 
PBS phosphate buffered saline 
PCR polymerase chain reaction 
PMSF phenylmethylsulfonyl 
pRb retinoblastoma protein 
RITR right inverted terminal repeat 
RLU relative luminescence units 
rpm rounds per minute 
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RPMI Roswell Park Memorial Institute medium 
rv reverse 
s.c. subcutaneously 
SA splice acceptor site 
SD standard deviation 
SDS sodium dodecyl sulfate 
SDS-PAGE discontinuous sodium dodecyl sulfate polyacrylamide gel 
electrophoresis 
sn supernatant 
SV40 simian virus 40 
TCID50 tissue culture infectious dose 50 
TEMED N,N,N’,N’-tetra-methylethylenediamine 
TNF tumor necrosis factor 
TRAIL TNF-related apoptosis-inducing ligand 
Tris trizma base 
Tris-HCl trizma hydrochloride 
T-VEC Talimogene Laherparepvec 
UPRT uracil phosphoribosyltransferase 
UV ultraviolet 
v/v volume per volume 
vp viral particles 
VSV vesicular stomatitis virus 
w/v weight per volume 
XTT 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-
carboxanilide 
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5. Introduction 
5.1. Pancreatic Adenocarcinoma 
5.1.1. The Pancreas and Pancreatic Cancers 
The pancreas is a gland in proximity to the duodenum and behind the stomach. It is anatomically 
subdivided into tail, body, and head and traversed by a duct system (Figure 1). Histologically, the 
pancreas is composed of gland tissue that can be distinguished into an endocrine and an exocrine 
part. The exocrine gland cells produce fluids containing digestive enzymes, which are transported via 
the drainage duct system into the duodenum [2]. The endocrine gland cells of the pancreas are 
clustered in the Langerhans islets and produce a variety of hormones, including insulin and glucagon, 
which after release into the blood are responsible for regulating the blood glucose level [3]. 
 
 
Figure 1: Anatomy of the Pancreas and its Surroundings. The pancreas is structurally subdivided into tail, body, and head, 
traversed by a duct system which ends in the pancreas head into the duodenum. The right panel shows a histological image 
of a duct and Langerhans islets surrounded by the exocrine gland cells. (Adapted from http://upload.wikimedia.org and 
http://www.siumed.edu) 
 
Malignant transformation of cells in the pancreas leads to pancreatic cancer. Pancreatic cancer 
accounts for 3% of all newly detected cancer cases and is the 10th most frequently occurring cancer 
[4]. Due to a 5-year-survival rate of only 6%, it accounts for 6% of cancer death cases. It is therefore 
the 4th most frequent cause of cancer death in the US [4]. However, a differentiation of the 
pancreatic cancer cases is necessary as the pancreas is composed of many different cell types which 
lead to a variety of tumors with different prognoses and treatment requirements. 
The by far most frequent entity, with >85% of occurring pancreatic cancers, are adenocarcinomas [5], 
which arise from malignant transformation of the exocrine cells lining the ducts [5, 6]. These tumors 
are poorly treatable and the reason for the bad prognosis for pancreatic adenocarcinomas [4]. Other 
exocrine cell types present in the pancreas, like acinar cells, giant cells, mucinous cells, or signet ring 
cells can also form tumors, but these are very infrequent [7]. Cancers of the endocrine pancreatic 
islet cells are very rare (1% of pancreatic cancer cases) [7]. These cancers are characterized by 
production of vast amounts of the hormones insulin or glucagon, but are often slow-growing, better 
treatable, and have a 5-year survival rate of 42% [8].  
In public discussions, the term pancreatic cancer is usually used synonymously for pancreatic 
adenocarcinomas [7], as all other occurring tumors neither show a similar frequency nor similar 
Duct
Langerhans islet
Exocrine gland cells
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treatment difficulties. Long-term statistics show that survival for pancreatic adenocarcinoma patients 
has not significantly improved over the last three decades [4]. Therefore, this cancer is considered 
one of the most aggressive occurring cancers with urgent need for treatment improvement. 
 
5.1.2. Pancreatic Adenocarcinoma Genetics and Risk Factors 
Tumorigenesis is a multistep process that requires the accumulation of genetic mutations. Cancers of 
one cell type in different individuals can therefore be genetically very different. However, there are 
some common mutations which can be found in the majority of pancreatic adenocarcinomas. 
Common modifications are activating mutations of K-Ras (95%) [9] and inactivating mutations of p16 
(CDKN2A, 98%) [5]. Furthermore, mutations in p53 are frequently occurring (70%) [10]. 97% of 
pancreatic adenocarcinomas show chromosomal instability [5]. Familial pancreatic cancer seems to 
be rare, though germline mutations of e.g. CDKN2A (p16) have been reported [11]. Identified risk 
factors include cigarette smoking, increased body mass index, and the consumption of red meat and 
dairy products, though the contribution of the dietary factors is controversially discussed [12, 13]. 
Also diabetes mellitus, alcohol intake, and chronic pancreatitis are considered to be risk factors [12].  
 
5.1.3. Treatment of Pancreatic Adenocarcinomas 
If pancreatic adenocarcinoma are detected in the early stages of tumor development, a resection is 
possible following the Whipple procedure (pancreaticoduodenectomy), where part of the pancreas, 
duodenum, gallbladder, and part of the bile duct are removed [12]. However, due to the lack of 
symptoms during the early stages of the tumor, 80% of the tumors are diagnosed in advanced stages, 
where resection is already impossible 
because of locally advanced disease 
and metastases [12]. Metastases 
often occur in abdomen, liver, lung, 
bone, and brain [14]. In this stage, 
chemotherapy is the method of 
choice. The most commonly used 
chemotherapeutics are gemcitabine 
and 5-Fluorouracil (5-FU) [14, 15] 
(Figure 2). However, both drugs do 
often not have a significant 
therapeutic effect, even though some 
studies suggest that gemcitabine has a 
slightly better effect than 5-FU [16, 
17]. For treatment, both of them are 
combined with radiation (here, they 
function as sensitizers [18]) or other chemotherapeutic agents, such as cisplatin and oxaliplatin [19]. 
The median survival of the resectable pancreatic adenocarcinomas is between 15 to 19 months and 
the 5-year survival is around 20% [12]. For advanced disease, treatment usually only aims for 
palliative care and prolonged survival. Even with treatment, the median survival after diagnosis is less 
than 12 months [12]. 
Figure 2: Gemcitabine and 5-Fluorouracil. A: Gemcitabine is a 
nucleoside analog and, when introduced instead of cytidine, 
during DNA replication, causes growth arrest and apoptosis. B: 5-
FU is an antimetabolite of thymidine and an irreversible inhibitor 
of the thymidylate synthase. Thymidylate synthase converts 5-
dUMP into dTMP and inhibition therefore leads to nucleotide 
shortage [1]. (Images taken from www.sigmaaldrich.com) 
A B
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5.2. Cancer Stem Cell Theory 
The theory that tumors are composed of a heterogeneous mass of cells was first published in 1976 
[20]. The theory that every cancer cell can equally acquire genetic alterations that lead to improved 
growth and metastatic behavior (stochastic model), is today complemented by the theory of a 
hierarchical order in cancer tissue similar to normal tissue (hierarchical model) [21]. According to the 
hierarchical model, a distinct subpopulation of tumor cells has the ability for tumor initiation, 
progression, persistence, and development of metastasis [22]. Referring to the parallels of the 
function of stem cells in normal tissue, these cells are termed cancer stem cells. The origin of these 
cells is discussed controversially. They could either rise from somatic stem cells and acquire genetic 
alterations or from lineage-committed cells that re-acquire stem cell-like characteristics [23]. 
Previous studies have described the cancer stem cells as highly resistant to chemotherapy due to 
high expression of membrane transporters, distinct DNA repair mechanisms, reduced 
immunogenicity, increased expression of anti-apoptotic genes, low proliferation rate, and high levels 
of telomerase [23]. Due to the predominantly quiescent state of cancer stem cells [24] the impact of 
cell cycle-dependent chemotherapeutics, like gemcitabine and 5-FU, is very limited [25]. 
Chemotherapy often even led to selective killing of non-stem-cell-like cancer cells and consequently 
to an enrichment of the cancer stem cell population, which can lead to tumor reoccurrence [26] and 
re-establishing of a tumor with a similar morphology than the original tumor [27, 28]. As a 
consequence, a successful cancer therapy should aim to target these tumor-initiating cells with a 
new generation of therapeutic agents, which do not depend on replication of the cancer cells and 
overcome the described resistance mechanisms. 
In pancreatic adenocarcinomas, cancer stem cells were first described in 2007. Li et al. [28] identified 
a small subpopulation of cancer cells, which after subtransplantation in mice could undergo self-
renewal and could re-establish the tumor with a morphology similar to the primary tumor. This 
subpopulation with tumor-renewal capacity was identified to have a characteristic surface marker 
pattern of CD44+/CD24+/ESA+. This population of cells made up <1% of the entire cancer cells 
population, but had a 100-fold increased tumorigenic potential than the bulk tumor cells [28]. In the 
same year, CD133+ was reported to be another cancer stem cell marker [29] and later, c-Met was 
added to the list of potential marker candidates to identify cancer stem cells [27, 30]. The 
identification of these cells is not only possible based on surface marker profile, but characteristics as 
K-Ras/p53 mutation, colony/spheroid formation ability, ALDH activity, E-cadherin expression, and 
Vimentin overexpression [31] are also used.  
These characteristics and the variety of possible markers indicate that the cancer stem cells might 
not be an exclusive subpopulation of cells, but subject to clonal evolution themselves [32]. 
 
5.3. Virotherapy 
A very promising approach to overcome chemotherapy resistance of cancers and targeting the 
cancer stem cells is virotherapy. Virotherapy uses a replication-competent virus that selectively 
infects, replicates, and kills the tumor cells through oncolysis. The released progeny viral particles 
lyse in the following replication rounds initially uninfected tumor cells (Figure 3). The key advantages 
of these therapeutical agents are that: i. the viral agent is propagating itself and producing progeny 
therapeutic material, ii. it is specific for cancer cells and has therefore limited side effects in normal 
tissue, iii. killing by some viruses (e.g. oncolytic adenovirus) does not depend on replication of the 
cancer cell and therefore stem cells cannot escape the treatment.  
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Figure 3: Principle of Virotherapy. The virus infects the tumor cells and replicates. The host cell is killed through oncolysis 
and viral progeny is released, which spreads to the initially uninfected tumor cells. Non-malignant cells are not able to 
propagate the virus. Therefore, virus spread is aborted with the complete lysis of the tumor. 
 
In the past years, several viruses have been investigated as oncolytic agents. These included viruses 
with inherent pathogenicity towards tumors, as NDV (newcastle disease virus), VSV (vesicular 
stomatitis virus), or reovirus [33]. Their selectivity for tumor cells as hosts is due to the similarity of 
the cellular modifications during virus infection and carcinogenesis, e.g. Ras-pathway activation, and 
IFN-pathway deregulation [33]. These viruses therefore preferentially replicate in cells featuring 
these mutations. Other viruses were specifically engineered to target tumor cells, as adenovirus, 
vaccinia, influenza, polio, measles, or herpes simplex virus [34]. Some of the engineering strategies 
for oncolytic adenoviruses are explained in section 5.5. 
So far, performed clinical trials with oncolytic viruses resulted in low toxicity and very few adverse 
side effects, which disproved safety concerns of uncontrolled virus effects in non-target regions [34]. 
However, therapeutic efficiency still needs to be improved for most viruses. The first clinical 
approved oncolytic virus is the oncolytic adenovirus H101 in China [35]. Several viruses are in 
advanced phases of clinical trials in Europe and the USA. T-VEC, an oncolytic herpes simplex virus 
expressing GM-CSF, is close to approval. With this virus, several clinical trials in head and neck cancer 
(NCT01161498) and melanoma (NCT00769704 and NCT01368276) were successfully completed. In a 
clinical Phase 3 trial of intralesional injection of melanoma with T-VEC compared to GM-CSF alone 
(NCT00769704), the virus was superior to the single treatment with GM-CSF and reached the primary 
endpoint (6 months durable response) [36, 37]. Further viruses, which are also in Phase 3 trials, are 
CG0070, an oncolytic adenovirus expressing GM-CSF against bladder cancer (NCT01438112), 
oncolytic herpes simplex virus HSV1716 against glioblastoma (UK-0177 and UK-0136), and an 
oncolytic reovirus, Reolysin, in combination with chemotherapy against head and neck cancer 
(NCT01166542). 
Besides the direct oncolysis, other mechanisms were shown to contribute to tumor cell killing. First, 
oncolytic viruses where shown to have antivascular function by either anti-angiogenic properties 
(e.g. downregulation of VEGF by oncolytic adenovirus) [38] or infection and lysis of tumor endothelial 
cells (e.g. vaccinia virus, HSV) [39]. In clinical trials, antivascular activity has been shown for the 
oncolytic vaccinia virus JX-594 [40]. Second, oncolytic viruses were shown to induce the adaptive 
immune system [34, 41]. The infection and lysis by the oncolytic viruses causes the releases of 
danger signals and tumor cell proteins, which function as tumor-associated antigens. Following 
presentation, they elicit a tumor-specific immune response [41]. The presence of tumor-specific T-
cells following infection with oncolytic viruses was shown in clinical studies with the modified 
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oncolytic adenovirus Ad5/3-Δ24-GM-CSF [42], oncolytic HSV T-Vec [43], and the oncolytic vaccinia 
virus JX-594 [44]. However, these alternative targeting strategies were not pursued in the course of 
this thesis. 
In summary, the outcome of the clinical trials was very promising. However, the viral agents need to 
be further modified to gain specific and improved oncolytic activity.  
 
5.4. Adenovirus 
5.4.1. Structure and Serotypes 
Adenoviruses are classified in four genera. The human adenoviruses belong to the genera 
Mastadenovirus and are subdivided into 52 serotypes. Diseases caused by adenoviruses in humans 
include infections of the upper respiratory track, conjunctivitis, and pneumonia. In immuno-
competent individuals, all serotypes cause relatively mild infections [45]. 
The adenoviral capsid has an icosahedral structure with a diameter of 80-110 nm and is non-
enveloped. The capsid contains three major proteins: hexon, penton base protein, and fiber (Figure 
4A). The sides of the surface areas are multimeres of hexons. Each corner is composed of a pentamer 
of penton base proteins, which are the anchor for the fiber. The fiber is a trimeric protein, which is 
structurally divided in a tail, shaft, and knob (Figure 4B). The tail mediates the binding of the fiber to 
the penton base. The central fiber shaft varies in lengths and flexibility dependent on the adenovirus 
serotype. The initial attachment to the host cell is mediated by the knob, the structure at the outer 
tip of the fiber. The knob binds to a receptor, which differs depending on the adenovirus serotype, 
e.g. for HAdV-3: Desmoglein-2 [46] and CD46 [47], for HAdV-5: Coxsackie and Adenovirus Receptor 
(CAR) [48]. Subsequently, internalization is mediated by binding of integrins of the host cell to the 
penton base (Figure 4C).  
 
Figure 4: Adenovirus Particle Composition and Description of Attachment. A: Structure of the viral particle. The core is 
composed of hexon proteins and the corners of the icosahedron of penton base proteins, which are the anchor for the 
fiber. B: Detailed structure of the fiber. The tail is mediating the contact to the penton base. C: Two-step process of viral 
attachment and internalization.  
 
5.4.2. Replication Cycle 
The adenovirus replication cycle can be subdivided into several steps [45] (Figure 5). First, the 
adenovirus knob binds to the primary receptor on the host cell surface (HAdV-5: CAR, HAdV-3: 
Desmoglein-2, CD46). Following this first attachment, a second interaction is mediated via an RGD 
motif in the penton base with integrins ανβ3 or ανβ5 on the host cell. This interaction results in 
internalization of the surface-bound viral particles via clathrin-coated vesicles. In the endosome, the 
pH falls, the viral particles dissociate from the endosome membrane, and subsequently the 
endosomes are lysed. After shedding of capsid-associated proteins, the remaining capsid parts with 
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the viral DNA bind to dynein and are transported into the nucleus via the nuclear pores. In the 
nucleus, the virus DNA is replicated and transcribed in the following order: i. transcription of 
immediate early genes, ii. transcription of early genes, iii. DNA replication, iv. transcription of late 
genes. Following translation, several proteins, including hexon, penton base, and fiber, assemble into 
capsomeres with the help of chaperones, and the viral DNA is integrated into the particle. Finally, 
through induction of host cell desintegration, release of progeny viral particles is initialized. 
 
 
Figure 5: Schematic Outline of the Viral Replication Cycle. Binding to the primary receptor (1) and to integrins (2) triggers 
clathrin-dependent endocytosis (3). After acidic endosomal escape (4), the genome is translocated into the nucleus. 
Transcription is initiated (5), following adenoviral genome replication (6) and adenoviral protein synthesis (7). Finally, the 
progeny viral particles are assembled (8) in the nucleus and are released from the cell by host cell lysis (9). (Modified from 
http://ssg-adenovirus.blogspot.de/) 
 
5.4.3. Genome Organization and Viral Proteins 
The genome of adenoviruses is a linear, double-stranded DNA with both strands having coding 
function. The genome is structurally subdivided into 5 areas (Figure 6) [45]: Four for early expressed 
gene regions (E1-E4) and one for late gene expression (L, encoding mainly structural proteins). The 
genome is flanked on each site by inverted terminal repeats, which have a function in the initiation of 
virus replication. The order of transcription initiation is progressive, starting with the immediate early 
E1 genes, E1A and E1B. The E1 gene products mediate the activation of the transcription factor E2F. 
The products of E2F-mediated transcription activate the viral DNA polymerase which leads to 
transcription of the other early genes in the order E2 to E4. Finally the major late promoter (MLP) is 
activated, starting the transcription of the late genes (L1-L5). The transcription of E1 itself depends 
on host cell proteins.  
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Figure 6: Scheme of the Adenovirus Genome. ITR: inverted terminal repeat, Ψ: packaging signal, E1 to E4: early genes, L1 
to L5: structural genes, MLP: major late promoter. Modified from [49] 
 
Key functions of viral proteins are i. the modification of cell cycle factors to support virus replication 
and ii. the regulation of host cell death to allow a full viral replication cycle. This is achieved through 
the interaction of viral proteins with apoptosis and cell cycle-regulating proteins of the host cell.  
The E1A proteins are the key players for transforming the host cell from a quiescent into a 
proliferating state. Through binding of E1A to the retinoblastoma protein (pRb), the E2F transcription 
factor is released and mediates cell cycle progression [50, 51].  
The regulation of host cell death is mediated by a variety of viral proteins. On the one hand, the viral 
life cycle kinetics aim for efficient viral replication and progeny release, but on the other hand viral 
replication needs to be regulated in a way that the host cell integrity is maintained until the progeny 
viral particles are fully developed. Release of premature virus particles would not support maximal 
further spread and is therefore evolutionary unreasonable. Several viral proteins featuring pro- and 
anti-host cell survival functions regulate this process. The key players featuring anti-apoptotic 
functions are the two E1B gene products, E1B55K and E1B19K. E1B55K binds to p53, therefore 
abrogates the normal apoptotic mechanisms of the cell [52], and inhibits the induction of apoptosis 
[53]. E1B19K is a Bcl-2 analog [54]. It can bind and therefore neutralize the action of pro-apoptotic 
Bax protein [55], and thus interferes with the intrinsic apoptosis pathway. Additionally to the two 
E1B proteins, products of the E3 gene block the extrinsic induction of apoptosis. Proteins encoded by 
the E3B gene region (E310.4K/14.5K) down-modulate apoptosis by inducing internalization of the 
apoptosis receptor Fas/Apo-1 [56].  
The key player featuring pro-apoptotic function is the E1A protein. The E1A protein can induces 
apoptosis via accumulation of p53 through inhibition of p53-degrading processes [57], but also 
through p53 independent processes [58]. Additionally, the virus expresses a protein which is 
necessary for efficient lysis, called the adenovirus death protein, ADP [59], encoded in the E3 region. 
In summary, all these proteins regulate a fine tuned balance to achieve optimal virus replication and 
release kinetic for optimized progeny spread. 
 
The following summary of adenoviral genes and proteins (Table 1) is not complete but explains the 
proteins’ functions with importance for this project: 
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Table 1: Adenoviral Genes, Gene Products, and Function.  
 
5.5. Oncolytic Adenoviruses 
Adenoviruses are frequently used as oncolytic tools. Historically, adenoviruses can be considered as a 
prototype for virology research. Several aspects of early basic virology studies have been elucidated 
with adenoviruses, including host cell transformation mechanisms [60, 61]. This early research 
resulted in a good genomic and functional characterization, which made it possible that adenovirus 
genomes can be easily manipulated and that the virus can be purified to high-titers [62]. These were 
prerequisites for their use as oncolytic agents. Early clinical studies in the 1950’s started to test wild 
type adenoviruses of different serotypes for treatment of cancer patients [63]. The results showed 
that the viruses were generally safe, as no severe side effects were observed, but not sufficient to 
induce durable effects [63]. In the 1990’s, the next generations of oncolytic viruses had modifications 
for cancer cell specificity as well as improved oncolysis [63]. Still, no severe adverse side effects were 
observed whereas the oncolytic efficiency still needed to be improved in terms of effective infection, 
effective replication, and effective lateral spread [62, 63]. The means to improve these features are 
modifications of the viral capsid for improved entry, modification of viral genes for improved 
replication kinetics, and the insertion of transgenes for improved killing. The following paragraphs 
describe the most common modifications and primarily the ones that were employed in this study.  
 
Immediate early genes Protein functions 
E1  Responsible for modification of the host cell 
 E1A 3 strongly conserved regions (CR1-CR3), induces transcription of E2 - E4: 
CR1 and CR2 interact with tumor suppressor pRb, abolishes pRb binding 
to the E2F transcription factor, E2F initiates transcription  
Mediates apoptosis induction 
 E1B E1B19K: inhibits the intrinsic apoptosis pathway through binding of the 
Bax proteins and therefore counteracts the pro-apoptotic function of 
E1A 
  E1B55K: interaction with the transactivation domain of p53, leads to 
ubiquitinylation and therefore proteolytic degradation of p53 
Early genes   
E2 E2A, E2B Codes for proteins with function in replication of viral DNA and viral 
DNA-polymerase 
E3  7 proteins, not essential for viral replication but for persistent virus 
infection 
 gp19K Reduces concentration of MHCI proteins on host cell surface 
 E3B Reduce sensitivity towards TNFα-induced apoptosis via Fas receptor 
internalization 
 ADP Responsibilities in cell lysis and release of virus progeny from host cell 
E4  ORF 1-7, various functions in transcription control, regulation of splicing 
of late genes 
 ORF6 binds p53 like E1B55K 
Late genes   
L1-L5  Structural proteins, transcription under control of the major late 
promoter, 30 kb pre-transcript 
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5.5.1. Capsid Engineering for Improved Infection 
Historically, oncolytic adenoviruses are typically based on human Adenovirus Serotype 5 (HAdV-5), as 
were all the viruses used for this study. The receptor of HAdV-5, CAR (Coxsackie- and Adenovirus 
Receptor), was demonstrated to be poorly expressed on tumor cells in previous studies [64, 65]. 
Therefore, alteration of the fiber in order to re-target virus entry to proteins that are more 
abundantly expressed on tumor cells is essential. 
A promising modification is the substitution of the knob region of HAdV-5 by the knob of HAdV-3, 
resulting in a fiber Ad5/3 chimera [66]. The initial host cell contact is then retargeted to Desmoglein-
2 [46], which is part of the desmosomes and ubiquitously expressed on normal and cancer cells. As 
the penton base and the fiber shaft remain unaltered, the secondary interaction for internalization is 
still mediated by integrin binding (as explained in Figure 4C). An alternative modification is the 
introduction of an RGD peptide into the HI-loop in the virus HAdV-5 knob, resulting in the Ad5RGD 
variant [67]. In this case, the initial and the secondary binding are depending on integrins, which are 
also ubiquitously expressed on cancer cells. Studies reported that both capsid modifications have 
resulted in improved transduction of tumor cells [66, 68-70]. It is important to note that these 
modifications improve tumor cell targeting, but they are not tumor specific. Tumor specificity is 
achieved by targeted delivery and transcriptional regulation, which are explained below. 
 
5.5.2. Viral Gene Modification for Selective Replication 
The safety of the viral agents has always been an issue in oncolytic virotherapy. It has to be assured 
that cancer cells are targeted while normal cells remain unaffected by exploiting molecular 
differences between these cells. In order to make viral replication specific for cancer cells, the 
immediate early genes E1A and E1B55K have been altered. E1A and E1B55K bind to pRb and p53 
respectively, and mediate cell cycle progression and inhibition of apoptosis induction ([51, 52] and 
section 5.4.3). These functions are crucial for the performance of the virus life cycle. Modifications 
that abrogate the functionality of these proteins would promote viral replication selectively in cells, 
where these pathways are otherwise deregulated, namely in cancer cells. The functional E1A and 
E1B55K proteins are then not necessary to initiate viral replication or to inhibit apoptosis. Therefore, 
E1A and E1B55K modified viruses would preferentially replicate in cancer cells and not in normal 
cells.  
Binding of the viral protein E1A to pRb releases the transcription factor E2F, which then initiates S-
phase entry of the host cell cycle. This is a prerequisite for viral DNA replication (Figure 7A, B). Whyte 
et al [71] reported that the binding of E1A to pRb is mediated by two regions (amino acids 30-60 and 
120-127 of E1A) and deletion of either one abrogates binding to pRb. Heise et al. [72] and Fueyo et 
al. [73] were the first to report an adenovirus mutant with a deletion in E1A (24 bp, which refer to 
amino acids 121-128). The mutated gene is referred to as E1AΔ24. Through this mutation, the viral 
E1A protein is unable to bind to pRb, E2F is not activated, S-phase entry is not triggered, and 
therefore viral replication is not induced in untransformed quiescent cells (Figure 7C). Consequently, 
the E1AΔ24 mutation makes viral replication selective for cancer cells with mutated pRb and 
constitutively active E2F, where the S-phase entry initiation through the virus E1A protein is not 
necessary for induction of virus replication (Figure 7D). Previous publications showed that the 
E1AΔ24 deletion does not interfere with virus replication in various cancer types [73, 74]. All of the 
described oncolytic viruses in this project have the E1AΔ24 deletion. 
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Figure 7: Mechanistic Overview of E1A / E1AΔ24 and S-Phase Induction. A: In untransformed, quiescent cells, pRb binds to 
the E2F transcription factor. In order to enter the S-phase, pRb needs to be phosphorylated by cyclin-dependent kinases, 
which releases its binding to E2F. E2F can then acts as a transcription factor and initiate replication. B: When adenoviral E1A 
protein is present, E1A binds to pRb, which therefore releases E2F. This initiates cell cycle progression as well as viral 
replication. C: When the amino acids responsible for E1A-binding to pRb are deleted (Δ24), binding is inhibited and 
therefore S-phase entry and initiation of viral replication is abrogated. D: In cancer cells with mutated pRb, the progression 
of the cell cycle is not anymore controlled by the interaction of pRb and E2F and cell cycle progression is continuous. 
Therefore, viral replication of an E1AΔ24 virus can be initiated without an interaction of E1A and pRb. 
 
Through deletion of E1B55K, which was first described by Bischoff et al. [75], viral replication was 
supposed to take place in p53-mutated cells only, where the p53 function is already deregulated. 
However, studies showed that this selectivity was not achieved due to several mechanisms as 
reviewed in Everts et al. [33]. The strategy of ΔE1B55K modification was not investigated during this 
project. 
 
5.5.3. Viral Gene Modification for Improved Replication and Release 
As already mentioned above, adenovirus has evolved mechanisms to ensure the completion of the 
viral life cycle via proteins with anti-apoptotic functions. These are, beside E1B55K, E1B19K and E3B. 
Deletion of these anti-apoptotic genes aims for improvement of the oncolytic properties and 
therefore tumor lysis. The mechanistic rationale behind this strategy is that the pro-apoptotic 
function of the E1A protein is more pronounced when the anti-apoptotic proteins E1B19K and/or E3 
are deleted [76]. Therefore, the virus life cycle kinetics could be enhanced and therefore the viral 
agent improved for virotherapy. Concerns that the deletion of anti-apoptotic genes could lead to 
premature abrogation of the viral life cycle proved to be untrue in cancer cells [77]. The outcomes of 
performed studies are summarized in the following.  
Several studies have analyzed viruses with deleted E1B19K and/or E3B [76, 78-81]. Deletion of 
E1B19K resulted in enhanced viral replication and release in a variety of tumor cell lines including 
pancreatic adenocarcinoma [76, 79]. The therapeutic effect was even more increased in combination 
with chemotherapeutics and was sufficient to overcome chemotherapy-resistance in cell lines [76, 
82]. These studies also reported that the observed phenotype was greatly impaired in normal cells 
compared to cancer cells [76, 79, 80]. It was suggested by Liu et al. [78] that this can possibly be 
explained with the regulation state of the apoptosis pathways. In normal cells, infection with a virus 
without a functional E1B19K and, therefore, with a pronounced pro-apoptotic phenotype, causes 
abrogation of viral replication due to increased apoptosis induction. In cancer cells, the apoptosis 
pathways are deregulated. Infection with the same virus cannot induce apoptosis and the viral 
replication cycle is thus maintained. While the detailed mechanisms are not fully understood, it 
seems that deletion of E1B19K can contribute to tumor cell-specific viral replication [80]. 
The deletion of E3B was also shown to enhance viral replication [79]. However, all the oncolytic 
viruses used in this study are E3 deleted. In order to generate oncolytic viruses with additional 
E2F
Rb
E2F
pRb
E1A
Progession in
Cell cyclus
Virus 
replication
E2F
pRb
E2F
pRb
quiescent cell quiescent cell + wild type virus quiescent cell + E1AΔ24 virus cancer cell + E1AΔ24 virus
E1  A
E1  A
A B C D
Introduction 22 
 
transgenes in the genome, inherent genome parts need to be deleted. The total adenovirus genome 
size cannot be enlarged much as capsid capacity is limited. Some studies advised the retention of the 
wild type E3 [79], as deletion of E3B was shown to enhance clearance, and the ADP protein promotes 
viral spread [83]. Yet, the E3 protein is not essential for viral replication. Therefore, deletion of E3 is a 
strategy which is widely used for transgenes carrying adenoviruses in ongoing clinical trials and was 
the strategy of choice in this project.  
 
5.5.4. Transgene Insertions for Improved Lateral Killing 
One challenge of efficient oncolytic adenovirus therapy is the limited spread of the virus through the 
tumor mass. Due to the strong stromal reaction in pancreatic adenocarcinomas [84], which is not 
permeable for viral particles, some parts of the tumor might not be reached by the virus [85, 86]. As 
a consequence, the insertion of transgenes into the virus genome, which induces bystander killing of 
neighboring, non-infected cells, has been exploited. One possible “arming” strategie is the insertion 
of genes encoding pro-apoptotic proteins, which are small enough to diffuse across the stromal 
barrier [87]. 
In this study, this problem was approached by the insertion of a gene, whose protein product induces 
tumor cell-specific apoptosis. The sheddable membrane protein TRAIL (TNF-related apoptosis 
inducing ligand) binds to death receptors and induces the extrinsic apoptosis pathway [88]. Clinical 
trials have shown its cancer cell-specific toxicity [89] compared to non-malignant cells. Further, the 
feasibility of TRAIL delivery by a replication-deficient viruse was shown [90]. In a mouse model, a 
therapeutic benefit was achieved through the combination of oncolysis and TRAIL killing by i.t. 
injection of a replication-competent, TRAIL expressing adenovirus, compared to virus treatment 
alone in bladder cancer xenografts [91]. These studies indicate that improved tumor cell killing by 
arming oncolytic adenoviruses with TRAIL is feasible. 
A critical point of arming viruses with genes encoding toxic proteins is to not interfere with the viral 
replication cycle. The virus produces a toxic protein, which is shedded and kills the tumor cells, 
including the ones with ongoing viral replication. However, the virus needs a viable tumor host cell to 
perform the complete replication cycle. Premature apoptosis of an infected tumor cell could abort 
the virus life cycle and no functional progeny virus would be produced. Studies evaluating insertion 
strategies for transgenes have revealed that expression with the late viral genes under control of the 
major late promoter towards the end of the viral replication cycle allows both, efficient transgene 
expression as well as completion of the viral life cycle [92]. An identified successful strategy was to 
couple transgenes via an IRES (internal ribosomal entry site) to a late gene, like the fiber gene [93]. 
Further studies showed that transgene expression can also be successfully achieved by insertion via a 
splice acceptor site (SA) downstream of the E4 gene [93, 94]. 
Other possibilities to improve tumor killing via “arming” include degradation of the tumor stroma via 
insertion of genes encoding hyaluronidase [95] or metalloproteinases [96] for improved viral spread. 
Further, genes encoding antiangiogenic proteins such as endostatin [97], immunomodulators like 
GM-CSF [98] or interleukins (reviewed in [99]) to induce a tumor-specific immune response have 
been investigated. One of the most widely used methods of arming is the insertion of genes encoding 
prodrug converting enzymes, which was used in this study and is discussed in the following section. 
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5.6. Prodrug Activation System 
Common chemotherapeutics have the disadvantage that after being applied systemically, they do 
not specifically target tumor cells but all dividing cells in the body, which causes severe side effects. 
Further, due to various reasons including drug dose limitations, the tumor cannot be completely 
eradicated and the treatments are therefore insufficient. The principle of a prodrug activation system 
is that a non-endogenous enzyme is delivered to the tumor site, which can convert a non-toxic, 
systemically-applied prodrug into a tumor-toxic drug. If the drug is diffusible, an effective bystander 
killing can be accomplished at the tumor site. Therefore, this strategy avoids systemic side effects, as 
occurring during treatment with standard chemotherapeutics, and achieves higher concentration of 
the drug at the tumor site.  
Oncolytic viruses armed with genes encoding prodrug activating enzymes mediate the expression of 
the enzyme in a virus replication- and location-dependent manner. As the viruses are engineered to 
specifically target tumor cells, the prodrug activating enzyme expression is restricted to the tumor 
site. Following prodrug administration and conversion, cancer cell are being killed. As the prodrug 
application can be timed, interference of toxic therapeutics after prodrug conversion with viral 
replication can be avoided.  
One of the best studied prodrug activation systems is CD/5-FC (Figure 8). CD (cytosine deaminase) 
converts the prodrug 5-FC (5-Fluorocytosine) into the active chemotherapeutic 5-FU (5-Fluorouracil), 
which can freely diffuse without using gap junctions [100]. Feasibility of CD expression by an 
adenoviral vector, leading to efficient prodrug conversion, was shown in vivo [101]. However, it was 
reported that some pancreatic cancer cells have intrinsic or acquired resistance against 5-FU, which 
was correlated with overexpression of 5-FU degrading enzymes in patients [102]. This resistance can 
be overcome through expression of UPRT (uracil phosphoribosyltransferase), a pyrimidine salvage 
enzyme originating from yeast, which converts 5-FU into 5-FUMP and 5-dUMP [103]. The adenoviral 
delivery of UPRT in combination with 5-FU was shown to be able to sensitize or enhance the 
cytotoxic effect in some cancer cells [104, 105]. This was due to increased levels of 5-dFUMP and 
subsequently increased inhibition of the thymidylate synthase and DNA synthesis [103] (Figure 8). An 
optimized enzyme comprising the activities of yeast CD and yeast UPRT, called FCU1, was developed 
in the context of adenovirus-mediated gene therapy [106]. 
 
 
Figure 8: Mechanism of CD/UPRT (FCU1) Prodrug Conversion. 5-FC is converted by cytosine deaminase (CD) into 5-FU. 5-
FU is diffusible and further converted by the salvage enzyme UPRT in the active metabolites 5-FUMP and 5-dFUMP. 
This prodrug activation system was further shown to be promising in experiments with FCU1-
expressing oncolytic adenoviruses [107]. As 5-FU is one of the standard chemotherapeutic 
treatments for pancreatic adenocarcinomas, the insertion of FCU1 in an improved oncolytic 
adenovirus was chosen for a combination therapy in this thesis. 
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5.7. Performed Clinical Trials with Oncolytic Adenoviruses 
Several oncolytic adenoviruses are currently tested in clinical studies and are listed in Table 2.  
The first oncolytic virus that went into clinical studies was Onyx-015, an E1B55K-deleted adenovirus 
[108]. For this virus, clinical data was acquired in a variety of tumor entities and via different 
application routes [109-112]. However, the Onyx-015 project showed that safety and tumor 
selectivity was well reproducible, although therapeutic efficiency of solely the virus agent was very 
limited [111]. The Onyx-015 project was stopped and the rights sold to a Chinese company, which 
developed it to the first approved oncolytic virus, now named H101 or Oncorine, in China [35].  
However, it has no approval in Europe or the US for patient treatment. 
Therefore, the challenge remains to improve the potency of oncolytic viruses by gene modifications 
or arming with transgenes. Several trials, mostly in Phase 1 are testing further modified oncolytic 
viruses. These viruses feature a variety of modifications (Table 2), as capsid modifications (Ad5RGD, 
Ad5/3), transgene insertions (GM-CSF, Hyaluronidase), and different promoters for tumor specific 
viral replication (E2F-1). Some of these viruses are tested in combination with standard treatment 
chemotherapeutics, as cisplatin, 5-FU, or gemcitabine, as possible future combination approaches 
(see references and clinical trials registry numbers in Table 2).  
Table 2: Oncolytic Adenoviruses Tested in Clinical Trials 
Phase virus virus genetics tumor entity Admin. 
route 
combination reference 
Phase 1 
and 2 
Onyx-015 HAdV-5,  
E1B 55K deletion, 
lung metastasis i.v. - PMID11420638 
Phase 2 Onyx-015 E3B deletion, HNSSC i.t. cisplatin, 5-FU PMID 10932224 
Phase 1/2 Onyx-015 Ad5 wild type capsid pancreatic cancer i.t. Gemzar PMID 12576418 
Phase 2 Onyx-015  pancreatic cancer i.a. - PMID 12414631 
Phase 1 Ad5Delta24RGD E1AΔ24 deletion,  
Ad5RGD fiber 
 
ovarian cancer i.p. - NCT00562003 
Phase 1 DNX-2401 former Ad5Delta24RGD recurrent malignant 
glioma 
i.t. - NCT00805376 
Phase 1 DNX-2401 former Ad5Delta24RGD recurrent 
glioblastoma 
i.t. or i.m. temozolomide NCT01956734 
Phase 1 CGTG-102 Ad5/3-d24-GMCSF 
 
E1AΔ24 deletion,  
GM-CSF is in the place 
of deleted gene for 
gp19k/6.7K in the E3 
region, 
Ad5/3 fiber 
 
malignant solid 
tumors 
i.t. cyclophos-
phamide 
NCT01598129 
Phase 1 ICOVIR-5 Ad-DM-E2F-K-∆24RGD 
 
E1A transcpription 
under E2F promoter, 
E1AΔ24 deletion,  
Ad5RGD fiber 
 
advanced or 
metastatic 
melanoma 
endo-
venous 
_ NCT01864759 
Phase 1 VCN-01 encoding human PH20 
hyaluronidase 
downstream E4 via SA 
site,  
Ad5RGD fiber 
 
advanced pancreatic 
adenocarcinoma 
i.t. gemcitabine NCT02045589 
Phase 2/3 CG0070 E2F-1 promoter, 
expresses GM-CSF 
replacing E319K, 
Ad5 wild type capsid 
bladder cancer intra-
vesical 
gemcitabine NCT01438112 
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Most of the clinical trials are in Phase 1, testing safety or dosage. The oncolytic adenovirus CG0070 
has recently entered a Phase 2/3 trial (NCT01438112), looking for improvement of therapeutic 
efficiency compared to the available standard treatments of bladder cancer. 
 
5.8. Virus Shielding and Targeted Delivery 
After systemic application, only a very small fraction of the adenoviruses reaches the tumor sites. 
Causes for this limitation are liver sequestration and antibody neutralization. In mice, two minutes 
after i.v. injection of adenoviruses, the majority of virus particles is cleared from the blood stream 
[113]. This is due to recognition of hexon, to binding to blood components (coagulation factors IX, X, 
and complement factor C4 [62, 114, 115]), and to heparan sulfate proteoglycans [116], which 
mediates or leads to hepatocyte transduction. Further, viruses can transduce Kupffer cells by direct 
binding to scavenger receptors [117]. 
Additionally, most adults have neutralizing antibodies against HAdV-2 and HAdV-5, or undergo 
seroconversion after the first viral application.  
Therefore, strategies were investigated to limit the delivery problem of oncolytic adenoviruses, 
especially the liver sequestration. The most straightforward approach is to shield the virus from 
uptake by the liver cells, which can be done in several ways [62]: 
i. Chemical shielding: polymers, such as polyethylene glycol, which become chemically 
cross-linked to the virus surface. The method was shown to shield virus from neutralizing 
antibodies without inhibiting infectivity [118]. 
ii. Biological shielding: changing the virus tropism by modifying the capsid can inhibit specific 
binding processes, but not unspecific, receptor-independent uptake as described above. 
iii. Carrier cells: see section 5.8.1.  
 There are also possibilities to circumvent neutralization by the immune system, which are: 
i. Change the capsid an therefore switch the serotype of the virus [119] 
ii. Temporary immune suppression: cyclophosphamide, a DNA-alkylating agent with chemo-
therapeutic and immunosuppressive functions [87]. 
 
5.8.1. Carrier Cells for Oncolytic Adenovirus Delivery 
In order to overcome the challenges of virus delivery, cells with tumor-homing properties are used as 
carriers for the virus. The viruses, bound or incorporated in these cells are therefore protected from 
neutralizing antibodies or unspecific sequestration on their way to the tumor. A variety of cells are 
utilized as carrier cells for oncolytic viruses to tumor sites.  
i. Some studies have investigated tumor cells themselves to deliver oncolytic viruses (example: 
irradiated osteosarcoma cells as cell carrier for canine oncolytic adenovirus, [120]). The rationale 
behind this strategy is that tumor cells of the same kind will find the same niche and therefore 
deliver the virus to the tumor. Further, it was suggested that a cancer cell vehicle would propagate 
the virus best on the way to the tumor, as oncolytic viruses are designed to selectively replicate in 
tumor cells. However the difficulty here is that the targeted tumor and the cancer cell used for 
delivery need to be highly similar [121], which is difficult in a clinical setting. 
ii. Cells like tumor-associated macrophages, endothelial progenitor cells, or mesenchymal stem cells 
(MSCs) do not target directly the tumor cells, but follow stimuli produced by the tumor stroma. They 
follow, according to their natural tropism to wounded tissue, tumor-induced gradients of angiogenic 
factors (endothelial progenitor cells), released inflammatory cytokines (MSCs, neuronal stem cells 
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[122]) or hypoxic factors [123]. The virus is therefore transported into the direct vicinity of the tumor. 
For all these cells, the isolation procedures are established and they can be expanded in vitro. 
Further, they allow productive infection and therefore propagate the virus on their way to the tumor. 
Several studies have investigated the delivery of oncolytic adenoviruses by macrophages [123], MSCs 
[124-126], and neuronal stem cells [122].  
iii. Immune cells, e.g. tumor patient’s T-cells with specificity for tumor-associated antigens, have a 
natural tumor tropism and can serve as a Trojan horse for the virus to be transported to the tumor 
site [127]. Studies have shown that the virus does not infect but just hitchhikes on the surface of 
these cells [127]. Therefore, virus propagation during migration is not possible. The disadvantage of 
this system is the difficulty of isolation of T-cells against highly tumor-specific antigens and the 
possibility of autoimmunity [121]. This approach has not been utilized for oncolytic adenoviruses. 
 
5.8.2. MSCs as Carrier Cells for Oncolytic Adenovirus 
In this study, mesenchymal stem cells were used as carrier cells since they have obvious advantages 
compared to other possible carriers as mentioned above. MSCs can be easily isolated from almost 
every tissue in the body [128]. For clinical and research purposes, they are mostly isolated from bone 
marrow, as for this study, or adipose tissue [129]. In bone marrow aspirates, they only account for 
<0.1% of the nucleated marrow cells and need to be expanded in vitro to obtain sufficient amounts 
([130] and references therein). The isolation is based on surface markers and plastic adherence [131]. 
The expansion is well described and established [132]. Further, the identity of the cells is confirmed 
through the differentiation into chrondogenic, adipogenic, and osteogenic lineages [131, 133]. 
The natural tropism of MSCs is to follow a chemotactic gradient to inflamed or wounded tissue and 
to mediate repair [128]. MSCs express a number of growth hormone receptors, chemokine 
receptors, adhesion molecules, and toll-like receptors, which were identified to be associated with 
cell migration [128]. Tissue repair capacity of MSCs has been investigated in clinical trials for various 
diseases (reviewed in [134]). For their application as carriers of chemotherapeutic agents, the same 
characteristics are utilized. Dvorak et al. [135] compared tumor tissue to a chronic wound that 
constantly releases inflammatory mediators. Especially the tumor stroma is a source of continuous 
release of growth factors, hypoxic factors, and inflammatory mediators [130]. MSCs follow these 
gradients to the tumor stroma, as they would to wounded tissue [128, 136]. Therefore, they were 
used as vehicle to deliver therapeutic agents to the vicinity of the tumor, including TRAIL [137-139] 
and oncolytic adenoviruses. After an initially study of MSCs loaded with an IFN-β expressing 
replication-deficient adenovirus [140], the concept was studied with a variety of differently altered 
oncolytic adenovirus targeting different tumor entities including breast, ovarian, melanoma, glioma, 
and neuroblastoma [125, 141-144]. These studies provided the proof-of-principle that oncolytic 
adenoviruses are able to infect MSCs, are amplified in MSCs, and are delivered to the tumor site after 
i.t. [125], i.v [126], or i.p [124] administration in in vivo mouse models. It was further shown that MSC 
homing was unaltered by viral infection [145] and that the virus was handed-on to tumor cells [144]. 
In view of possible treatment options of cancer patients later on, MSCs can be transplanted 
allogeneically, meaning that donor and recipient are from different individual, i.e. healthy donors. 
This is possible, because MSCs have intrinsic immunomodulatory functions [130] that inhibit 
rejection, inhibit innate and adapted immunity, but also actively induce immune tolerance. This is of 
special interest as it was reported that the quality of MSCs decreases with age in humans [146]. 
Therefore in this study, MSCs from 4 different healthy donors were used, who were between 20 and 
30 years old. Figure 9 summarizes the advantages of MSCs as carriers compared to virus i.v. injection. 
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Figure 9: Systemic Effects of Direct Virus Injection Versus Virus Delivery by MSCs for Pancreatic Adenocarcinoma in 
Human. A: After systemic injection of the virus, the majority of viral particles are cleared by neutralizing antibodies or 
sequestered by the liver. Only the minority of virus particles reaches the pancreatic tumor (red). B: MSCs are isolated (e.g. 
from the bone marrow of the iliac crest) and after purification, expansion, and infection are administered systemically. The 
MSCs home to the tumor site, protecting the virus particles from sequestration by the liver and neutralizing antibodies. 
(Elements taken from: www.clipartbest.com, blog-static.hellomagazine.com/thenakednutritionist/files/2012/05/liver3.jpg, 
www.sign-lang.uni-hamburg.de/glex/illusgr/l74290.jpg) 
 
5.8.3. The Delivery System  
The delivery approaches for oncolytic adenoviruses by MSCs, all underlie the same principle, which is 
described schematically in (Figure 10).  
MSCs are isolated from bone marrow donations of healthy donors and expanded. Afterwards, they 
become infected ex-vivo and systemic applied to a tumor patient. The MSCs home to the tumor site, 
while the virus is replicating.  At the end of the viral life cycle, the progeny virus particles are released 
at the tumor site and infect a subset of the tumor cells. The virus then replicates in the tumor cells, 
performs oncolysis, and the progeny viruses further spread through the tumor.  
The critical factors for the kinetics of the system are viral replication and release in MSCs and tumor 
cells. Premature virus release in the bloodstream during delivery would subvert the system. 
Therefore, the system required that virus release kinetic is accordant with the time the MSCs need to 
reach the tumor site in an in vivo setting. The same virus needs subsequently to efficiently replicate 
in and lyse the tumor cells.  
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Figure 10: Summary of The Delivery System of Oncolytic Adenovirus by MSCs. MSCs are loaded with virus ex vivo and are 
systemically applied. The virus is replicating in MSCs during homing. After being delivered to the tumor site, the virus is 
released and infects the tumor cells including tumor stem cells and subsequently spreads through the tumor. 
An exploratory clinical trial was performed using CELYVIR (MSCs loaded with the oncolytic adenovirus 
ICOVIR-5) [147]. This clinical trial used a similar delivery approach as the one described above. 
Autologous MSCs were infected ex vivo. Four children with metastatic neuroblastoma were treated 
with 2-4 i.v. infusions of CELYVIR. In 3 out of 4 children, relapse occurred after a first complete 
response. In the fourth child, after a progression phenotype, complete remission occurred after 36 
months. The data suggests that the immunological response correlates with the good outcome. 
Another clinical trial has been opened testing CELYVIR and is recruiting patients currently 
(NCT01844661).  
 
5.8.4. Optimizing Oncolytic Adenoviruses for Delivery in MSCs 
A major advantage of this system is the propagation of the viral agent during transport. Therefore, 
two approaches for optimization are rational: i. optimization of transduction in order to have a high 
initial titer to start with and ii. the optimization of the replication and release kinetics of the virus in 
MSCs. 
Several studies have analyzed transduction of oncolytic viruses in MSCs. It was reported that the 
receptor for the HAdV-5 wild type virus CAR is lowly expressed on MSCs [125, 136, 148], which 
resembles the situation in cancer cells described in section 5.5.1. In cancer cells, adenoviruses capsid 
variants Ad5/3 and Ad5RGD showed improved transduction by retargeting the virus to Desmoglein-2 
and integrins, respectively. Several studies investigated whether transduction with Ad5/3 and 
Ad5RGD could improve transduction of MSCs and which capsid variant resulted in best transduction. 
At least for integrins, studies confirmed their expression on undifferentiated MSCs [125, 136, 148]. 
The outcomes of the transduction experiments showed, that the mentioned modifications improved 
transduction in almost all studies. However they did not accord on which capsid variant transduced 
best [124, 125, 136, 149].  
Optimization of viral replication and release in MSCs for optimized delivery has not been analyzed so 
far and is the topic of this thesis.  
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6. Aim of the study 
Alternative treatment procedures for pancreatic cancer are urgently needed. Oncolytic adenoviruses 
have a great potential for tumor treatment and have shown an excellent safety profile. However, 
virus mediated oncolysis still needs to be improved. Further, neutralizing antibodies and liver 
sequestration presented a major roadblock for efficient virus delivery to the tumor site after systemic 
application. In this study, the problems of virus delivery and efficiency were approached. 
Mesenchymal stem cells (MSCs), isolated from human bone marrow, are established as carrier cells 
and would be utilized for targeted and therefore more efficient virus delivery to the tumor site. 
Modified oncolytic viruses, which carry modifications that aimed for improved tumor cell killing, 
would be investigated. The overall aim was to identify the virus modifications, which best improved 
virus delivery and tumor cell killing, including the tumor stem cells, in the context of the delivery 
system. 
The first specific aim of this study was to identify the best transducing virus capsid variant. Optimized 
viral cell entry would be needed for MSCs, to optimize the amount of viral particles delivered by 
MSCs, and for tumor cells, to optimize tumor cell killing efficiency. Therefore, Ad5, Ad5/3, and 
Ad5RGD capsid variants were going to be tested on MSCs as well as on established pancreatic tumor 
cell lines and low-passage pancreatic tumor cell cultures. The capsid variant, which would be 
identified as best transducing, was aimed to be used as capsid background for the further 
investigated modified oncolytic adenoviruses.  
For the second aim, a set of further modified viruses should be tested for improved replication and 
release kinetics in MSCs as well as for maintenance of migration capacity of virus-infected MSCs. 
Three virus modifications were aimed to be investigated: the deletion of the early gene E1B19K for 
improved virus kinetics, TRAIL expression for bystander killing, and FCU1 expression for prodrug 
conversion. A set of replication-competent viruses carrying the modifications had to be generated. 
Virus replication and release kinetic analysis in MSCs were planned. The more progeny virus particles 
would be produced and released, the more efficient the virus delivery would be. However, these 
improved kinetics needed to allow maintenance of migration properties of MSCs and further, viral 
release kinetics had to correspond to the time the MSCs needed to reach the tumor site. Therefore, a 
subsequent transwell migration assay was planned in which migration behavior had to be assessed 
over 2 days, as the in vivo relevant time span for MSC tumor homing. The combined information of 
the migration assay and the obtained release kinetics would give insight on which modifications 
allows unimpeded migration combined with optimized amount of virus progeny delivery.  
For the third aim, the modified viruses should be tested on established pancreatic tumor cell lines, 
spheroids, and low-passage cultures in order to identify the virus modification resulting in best 
oncolysis performance. As it has been shown that the targeting of cancer stem cells was very 
important for successful cancer therapy, this would be a special focus of this aim. Here, the cell lines, 
which were planned to be used, were known to have cancer stem cell-like characteristics. Further, in 
order to analyze virus spread and killing in a 3D tumor structure, the modified viruses were aimed to 
be tested in pancreatic tumor cell line spheroids. Finally, the viruses should be investigated in low-
passage pancreatic tumor cell cultures to obtain data in patient’s tumor resembling material. 
Combination of the obtained data of virus life cycle kinetics in MSCs, migration of infected MSCs, and 
oncolysis in pancreatic cancer cells, aimed to identify an optimized oncolytic adenovirus for delivery 
by MSCs. 
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7. Results 
7.1. Defining the Best Adenovirus Capsid Variant for Transduction in MSCs and Tumor 
Cells 
In order to improve delivery of oncolytic adenoviruses by MSCs, virus entry optimization was a first 
approach. It is critical for transduction of MSCs in order to optimize the amount of delivered viral 
particles as well as for transduction of tumor cells in order to optimize viral lysis. Therefore, the aim 
of this transduction experiment was to identify the best suited capsid variant for transduction of 
MSCs as well as pancreatic adenocarcinoma cell lines. 
Oncolytic viruses are historically based on human adenovirus serotype 5 (HAdV-5). The physiological 
receptor of HAdV-5, CAR (Coxsackie- and Adenovirus Receptor), was demonstrated to be poorly 
expressed on tumor cells [64, 65, 150] as well as on MSCs [125, 136, 148, 151] in previous studies. In 
order to optimize transduction, viruses with altered capsid variants were tested. These were Ad5/3 
(HAdV-5 shaft and HAdV-3 knob fiber chimera, mediating binding to Desmoglein-2 and CD46) [66] 
and (RGD peptide introduced in the HI loop of the knob, mediating binding to integrins) Ad5RGD [67]. 
Both capsid variants containing adenoviruses had been tested on MSCs [124, 125, 136, 149] and a 
variety of cancer cell lines, including pancreatic cancer, before [66, 68-70]. However, these studies 
did not consent to which virus variant led to best transduction. Therefore, the aim of this set of 
experiments was to define the best suited capsid variant for the MSCs and pancreatic cancer cells 
used in this study. Ad5/3, Ad5RGD, as well as unaltered wild type HAdV-5 (Ad5) were tested on MSCs 
isolated from healthy donors, established pancreatic adenocarcinoma cell lines, and low-passage 
pancreatic adenocarcinoma cultures. MSCs were isolated from bone marrow of healthy donors and 
characterized through their differentiation potential by the group of Ingrid Herr (University Hospital 
Heidelberg). They were used in passages 5-9. Low-passage pancreatic ductal adenocarcinoma 
cultures PacaDD-159 and JoPaca-1 were provided and characterized by the group Pilarsky [152] 
(University Hospital Mannheim) and the group Hoheisel [153] (DKFZ, Heidelberg), respectively.  
 
7.1.1. Viruses Used for Transduction Experiments and Luciferase Assay 
For the analysis of transduction efficiency, a set of replication-deficient, luciferase expressing viruses 
was used. For virus outlines see Figure 11. 
 
 
Figure 11: A Schematic Genome Outline of Viruses Used for Transduction Experiments. LITR/RITR: left/right inverted 
terminal repeat, Ψ: packaging signal, all viruses were E1- and E3-deleted, the firefly-luciferase gene (Luc) under CMV-
promoter control was introduced replacing E1, capsid variants: Ad5 contained serotype 5 wild type capsid, Ad5/3 expressed 
a chimeric capsid composed of HAdV-5 shaft and HAdV-3 knob, while for Ad5RGD the CRCRGDCFC peptide was introduced 
into the Ad5 HI-loop. 
Ad5
Ad5/3
Ad5RGD
LucCMV 5
5/3
5RGD
LucCMV
LucCMV
fiber E4ΔE1 ΔE3LITR RITRΨ
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In all viruses, the E1 region was substituted by a firefly luciferase (Luc) gene under CMV promoter 
control. The viral genomes only varied in the fiber modifications (5, 5/3, 5RGD). The viruses were 
previously amplified and purified in our group (see Methods section 10.3.2/10.3.3), and prior to this 
study proof-characterized and titered. Physical virus particle concentrations of the preparations were 
measured by OD260 and infectious viral particles were determined by TCID50 assay on HEK293 cells., 
HEK293 cells were used for TCID50 determination for the replication-deficient viruses, since they are 
able to substitute the deleted E1 gene and therefore enable virus replication (see Methods section 
10.3.5). The ratios of physical and infectious viral particles were between 2 and 50. 
In the performed reporter gene assay, cells were plated and transduced 24 hours later with the same 
amount of viral particles of Ad5, Ad5/3, Ad5RGD, or mock-transduced. Because transduction of 
viruses with identical virus backbones and different capsids was analyzed, physical virus particles (vp) 
were used for virus titer calculation. The use of vp is the standard in the field for transduction 
experiments analyzing capsid-modified viruses (capsid variations were shown to affect the infectious 
virus particles (TCID50) titers). 2 days post-infection, the cells were lysed, luciferase substrate was 
added, and relative luminescence units (RLU) were measured. Measured RLU were proportional to 
the amount of expressed luciferase and further to the numbers of viral particles which had entered 
the host cell. This correlation was possible as all viruses carry the same CMV-Luc reporter cassette, 
making luciferase activity per transduced genome comparable between the virus variants. Observed 
differences in RLU intensities were correlated to the amount of transduced luciferase transgenes and 
therefore to differences in entry efficiency of the capsid modified viruses. The assay was used to 
define the best transducing capsid variant in MSCs and pancreatic tumor cells. 
 
7.1.2. Capsid Variants Transduction Analysis in MSCs 
The graphs in Figure 12 show the results of the transduction experiments with the three virus capsid 
variants in MSCs from 4 different donors. RLU measured in Ad5-transduced MSCs were comparable 
to mock-infection levels and on average 2 RLU. Transduction with Ad5/3 resulted in measured RLU of 
1029/ 130/ 3310/ 3922, respectively for Donor 1 to 4 and transduction with Ad5RGD in measured 
RLU of 144/ 117/ 74/ 34, respectively for Donor 1 to 4.  
 
Figure 12: Luciferase Activity Following Transduction of MSCs. MSCs of 4 different healthy donors were transduced with 
1,000 vp/cell of capsid-modified adenoviral vectors. Luciferase activity of cell lysates was determined 2 days post-infection. 
Columns show mean relative luminescence units. Error bars show SDs of triplicate transductions. 
 
Comparing the measured RLU of the capsid variants, transduction with Ad5/3 resulted in the 
strongest measured luminescence signals. These were 386-/ 35-/ 3310-/ 1961-fold higher (respective 
Donor 1-4) than measured RLU levels for transduction with Ad5 and 7-/ 1.1-/ 45-/ 101-fold higher 
than measured RLU for transduction with Ad5RGD. Therefore, only for Donor 2 measured RLU for 
Ad5/3 and Ad5RGD were similar. For Donor 1, 3, and 4, transduction with Ad5/3 resulted in superior 
luciferase activity compared to Ad5RGD. 
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Assuming that measured luminescence units correlate with the amount of transduced viral particles 
as explained above, it can be concluded that transduction with Ad5/3 resulted in most efficient 
transduction compared to the other capsid variants. Noteworthy was that despite expected donor 
variation, the Ad5/3 could be identified as best transducing capsid variant accordantly. 
 
7.1.3. Capsid Variants Transduction Analysis in Established Cell Lines and Low-Passage 
Pancreatic Adenocarcinoma Cultures 
Further, established and low-passage pancreatic adenocarcinoma cell lines and cultures were 
transduced with the virus capsid variants. For the established pancreatic cell lines (Figure 13A), 
transduction with Ad5 led to measured RLU of 42/ 66/ 28/ 301 (for MiaPaCa-2/ BxPc-3/ AsPc-1/ 
Panc-1, respectively), which was above the mock-transduced level of 0 RLU. Transduction with Ad5/3 
led to measured RLU of 311/ 897/ 39/ 494 and transduction with Ad5RGD to measured RLU of 26/ 
84/ 14/ 209 (for MiaPaCa-2/ BxPc-3/ AsPc-1/ Panc-1, respectively). Therefore, RLU values following 
transduction with Ad5/3 were between 1.4 - 13.7-fold higher (AsPc-1 and BxPc-3, respectively) 
compared to Ad5 and for all cell lines higher than measured RLU for Ad5RGD.  
For the low-passage pancreatic adenocarcinoma cultures, PacaDD-159 and JoPaca-1, transduction 
with Ad5 resulted in measured RLU of 589 and 25, respectively (Figure 13B). Transduction with 
Ad5/3 resulted in 7435 and 1527 and transduction with Ad5RGD in 1161 and 14 measured RLU for 
PacaDD-159 and JoPaca-1, respectively. Therefore, transduction with Ad5/3 led to 13.1-fold (PacaDD-
159) and 61.9-fold (JoPaca-1) higher luminescence units compared to Ad5 and to 6.4-fold (PacaDD-
159) and 111.7-fold (JoPaca-1) higher luciferase activity than Ad5RGD. 
 
 
Figure 13: Luciferase Activity Following Transduction of Established and Low-Passage Pancreatic Adenocarcinoma Cells. 4 
established pancreatic tumor cell lines (A) and 2 low-passage pancreatic ductal adenocarcinoma cultures (B) were 
transduced with 100 vp/cell of capsid-modified adenoviral vectors. Luciferase activity of cell lysates was determined 2 days 
post-infection. Columns show mean relative luminescence units. Error bars show SDs of triplicates. 
 
Transduction with the Ad5/3 adenoviral vector resulted in superior luciferase activity compared to 
Ad5 and Ad5RGD in MSCs and pancreatic adenocarcinoma cells. Therefore, correlating the measured 
RLU to transduction efficiency of the capsid variant viruses, it can be concluded that Ad5/3 
transduced the MSC carrier cells as well as the established and low-passage tumor cells best. Based 
A
B
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on this conclusion, the fiber 5/3 background was chosen for the generation or selection of improved 
oncolytic viruses in the next step.  
 
7.2. Replication and Release Analysis of Modified Viruses in MSCs  
Utilizing MSCs as carrier cells exploits two mechanisms to improve delivery of oncolytic adenoviruses. 
One aspect is the shielding function of the virus from the immune system and the prevention of viral 
particle sequestration by the liver. The second function involves the propagation of the replication-
competent viral agent during the homing process. The aim of this thesis was to optimize this second 
function by developing modified oncolytic adenoviruses with optimized replication and release 
kinetics in MSCs. To this end, two modified viruses were tested. The aim was to identify the 
modifications which improved virus replication best. However, it is crucial to consider that the virus 
release kinetics from MSCs have to correlate with the time the MSCs need to reach the tumor site 
after systemic application. Therefore, the focus of the experiment lay on the influence of the 
introduced viral modifications on total infectious viral particle production as well as the kinetics of 
virus release into the supernatant. The obtained data was combined with a following migration study 
(see section 7.5) in order to identify the best suited virus variant for optimized delivery.  
 
7.2.1. Modified Oncolytic Viruses  
Two modified viruses were tested for improved replication in and release from MSCs. The viruses 
pursued two different strategies to improve kinetics: i. deletion of a viral gene with function in the 
viral life cycle (Ad-Δ19K-Luc) and ii. insertion of a transgene mediating bystander killing (Ad-TRAIL). 
For the virus outlines see Figure 14. 
The E1B19K gene was shown to have anti-apoptotic function [154] and its deletion resulted in 
improved replication and release kinetics in tumor cells [76, 79, 81, 84]. In this study, an E1B19K-
deleted adenovirus was tested for its replication and release behavior in MSCs, which had not been 
investigated before. The adenovirus that carried a deletion in the early gene E1B19K, Ad-Δ19K-Luc 
was generated in the Nettelbeck group and was described in Rohmer et al [81]. For the second 
strategy, the insertion of the full-length gene of the TNF-related apoptosis-inducing ligand (TRAIL) 
into the viral genome aimed for improved virus kinetics in MSCs as well as for bystander killing. 
Bystander killing is needed to overcome the strong stromal reaction in pancreatic adenocarcinomas 
[84], which present a diffusion barriers to the virus, with a diffusible toxic ligand. The effect of the 
expression of the death ligand on virus replication and release in MSCs was unknown and explored in 
this experiment. Ad-TRAIL was generated in the course of this study (described in section 7.8.5). 
TRAIL was inserted via an internal ribosomal entry site (IRES) downstream of the fiber5/3 gene. For 
the confirmation of TRAIL transgene expression by immunoblot see Figure 22. Ad-Luc was used as 
control for the modified viruses. It was generated in the Nettelbeck group and was described in 
Rohmer et al. [81]. Ad-Luc and Ad-Δ19K-Luc contained a firefly luciferase gene (Luc), which was 
introduced downstream of the fiber5/3 via an IRES, following the same strategy as used for Ad-TRAIL. 
The insertion via IRES downstream of the fiber was identified as the preferential strategy of choice 
for strong transgene expression in previous studies [92]. The consistent strategy of transgene 
insertion was allowing comparison of the viruses in terms of replication and release in MSCs. 
All viruses were replication-competent in order to investigate replication in MSCs. Therefore, they 
carry a functional E1A gene. The 24 amino acid deletion in E1A (E1AΔ24) makes viral replication 
selective for proliferating cells (see Introduction section 5.5.2). In order to provide genome space to 
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introduce transgenes, the E3 gene is deleted. All viruses further contain the fiber 5/3 chimera, as 
identified as best transducing fiber variant in section 7.1. All viruses were amplified and purified (see 
Methods sections 10.3.1-10.3.3). Further, they were proof-characterized, viral particles determined 
by OD260 measurement and infectious viral particles determined by TCID50 assay on A549 cells (for 
details see Methods section 10.3.4/10.3.5). The ratios of physical and infectious viral particles were 
between 5 and 31, and therefore in the usual range, indicating proper virus preparations and virus 
vitality. 
 
Figure 14: Modified Oncolytic Adenoviruses Used for Replication/Release Experiments in MSCs. Genome outlines of 
viruses used for the replication and release experiment in MSCs. LITR/RITR: left/right inverted terminal repeat, Ψ: packaging 
signal, E1AΔ24: deletion of pRb-binding region in E1A for cancer selective replication, E1B19K: early gene with anti-
apoptotic features, E3-deleted, chimeric Ad5/3 fiber (5/3), Luc/TRAIL: firefly luciferase (Luc) and full-length TRAIL 
transgenes were inserted via IRES (internal ribosomal entry site) downstream of the fiber gene. 
 
7.2.2. Replication and Release Kinetics Study of the Modified Viruses in MSCs 
Figure 15 shows the results of the performed burst assay to determine infectious particles in cells 
and supernatant of infected MSCs. For this assay, MSCs were seeded and 24 hours later infected with 
the respective virus, Ad-Luc, Ad-Δ19K-Luc, or Ad-TRAIL. For infection, the TCID50 titers were used for 
infection titer calculation, as it is the standard in the field for experiments comparing viruses with 
identical capsids. Cells and supernatant of infected MSCs were harvested separately at 2, 4, 6, and 8 
days post-infection and the amount of infectious viral particles was determined by TCID50 assay on 
A549 cells for cells and supernatant separately. Here, the amount of infectious viral particle (and not 
physical viral particles) was determined, as only those contribute to further virus spread after release 
from MSCs. Figure 15A shows the development of infectious viral particle production in cells and 
supernatant of the virus-infected MSCs over time. The experiment was performed in MSCs from 3 
different donors. The acquired data allows the comparison of replication (total viral particles over 
time) and release (virus particles in the supernatant over time) kinetics between the modified viruses 
Ad-Δ19K-Luc and Ad-TRAIL to the control virus Ad-Luc.  
During infection with Ad-Luc the majority of viral particles were found in the cells throughout the 
experiment. In the case of Ad-Δ19K-Luc and Ad-TRAIL the amount of viral particles in the supernatant 
exceeds those in the cells at a certain time post-infection. The cross point was for Ad-Δ19K-Luc 
between day 3 to 4 and for Ad-TRAIL between day 5 to 8. The numbers included in each graph of 
Figure 15A describe total infectious virus particle in the supernatant at day 8 post-infection. For both 
viruses, an improvement in infectious viral particle release into the supernatant was observed. 
Compared to Ad-Luc, the release of infectious virus was for Ad-Δ19K-Luc factor 14/ 48/ 72 (for Donor 
1/ 2/ 4, respectively) and for Ad-TRAIL factor 3/ 16/ 18 (for Donor 1/ 2/ 4, respectively) higher. In 
terms of total infectious viral particles, Ad-Δ19K-Luc infection yielded on average in 6-fold more 
infectious particles, infection with Ad-TRAIL in 2-fold more particles compared to Ad-Luc. Therefore, 
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it can be concluded that both modified viruses led to earlier and more efficient virus release from 
infected MSCs compared to the control virus Ad-Luc. Further, the numbers of total virus particles at 
day 8 indicate that more infectious virus particles were produced when MSCs were infected with Ad-
Δ19K-Luc or Ad-TRAIL compared to Ad-Luc. 
 
 
Figure 15: Replication and Release Kinetics Analysis of Ad-Δ19K-Luc and Ad-TRAIL in MSCs. A: Viral replication and release 
in MSCs of three different donors. Cells were seeded and transduced with 1,000 TCID50/cell of viruses shown in Figure 14. 
After 2, 4, 6, and 8 days, supernatant (sn) and cells were harvested separately and total infectious viral particles in cells and 
supernatant were determined separately by TCID50 assay on A549 cells. The experiment was performed in triplicates. 
Symbols show mean infectious viral particle titers. Error bars show standard deviations of triplicate infections for cells and 
sn. Shown numbers in each graph indicate infectious viral particle amount in the supernatant at day 8 post-infection. B: The 
ratio of released  to total infectious virus particles determined by the ratio of TCID50 of sn to TCID50 of total (cells + sn) at 
day 8 post-infection in MSCs of the three tested donors.  
 
Figure 15B shows the ratios of released infectious virus particles to total (cell-bound and released) 
infectious virus particles at day 8 post-infection for each virus and MSC donor. The ratios were used 
to evaluate if increased release is proportional to the increase of viral particle production or if 
increased release is an additional contributing mechanism. The bars show that for both, Ad-Δ19K-Luc 
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and Ad-TRAIL, a much higher proportion of virus particles were released to the supernatant 
compared to Ad-Luc. This suggests that a mechanism, independent from increased total virus particle 
production, caused more efficient release. 
In summary, infection of MSCs with both modified viruses, Ad-Δ19K-Luc and Ad-TRAIL, resulted in the 
increase of infectious particles production as well as increased release compared to Ad-Luc. 
Therefore, improved replication and release were complementing mechanisms for the observed 
improved kinetics for Ad-Δ19K-Luc and Ad-TRAIL. Further, the enhancement was most prominent for 
infection with Ad-Δ19K-Luc. Noteworthy was that for MSCs from all three donors the replication and 
release kinetics for each of the three viruses were strongly comparable.  
The improved virus life cycle kinetics of Ad-Δ19K-Luc and Ad-TRAIL compared to Ad-Luc could also be 
confirmed microscopically (Figure 16). At day 6 post-infection, most of Ad-Luc infected MSCs were 
still attached and only few rounded-up cells were observed. In contrast, Ad-Δ19K-Luc-infected MSCs 
were almost completely detached and already started to disintegrate. For Ad-TRAIL, approximately 
half of the cells were detached. The observation that change in morphology was most progressed for 
Ad-Δ19K-Luc, was in line with the obtained data in Figure 15. However, note that rounded-up and 
floating cells do not necessarily indicate cell death, but progression of the viral life cycle and severe 
interference with host cell integrity/organization. The observations in Figure 16 for Donor 4 are 
representative and were also observed during infections of Donor 1 and 2. 
 
Figure 16: Differences in Morphology of Infected MSCs at Day 6 Post-Infection. During the burst assay shown in Figure 15, 
bright-field picture were taken of MSCs (Donor 4), infected with 1,000 TCID50/cell at day 6 days post infection. Attached 
MSCs (mainly seen in pictures of infection with Ad-Luc) have a fibroblast-like morphology, whereas rounded-up cells were 
detached MSCs (mainly seen in pictures of infection with Ad-Δ19K-Luc). 
 
7.2.3. Cytotoxicity Experiments of Modified Viruses in MSCs 
To further confirm the improved replication and release kinetics of Ad-Δ19K-Luc and Ad-TRAIL in 
MSCs as seen in the burst assay (Figure 15), MSC lysis was tested in a long-term cytotoxicity assay 
(Figure 17). MSCs of Donor 1 and 4 were incubated with serial dilution of Ad-Luc, Ad-Δ19K-Luc, or 
Ad-TRAIL from 100 to 0.001 TCID50/cell. At day 14 post-infection, the wells were stained with crystal 
violet. Adding of crystal violet simultaneously fixes and stains cells, which are attached in the well. 
When cells were killed or detached due to virus infection, wells appear clear; areas with intact cell 
layer appear dark. Therefore, stages of absent, starting, and complete cytopathic effect can be 
distinguished. By comparing the lowest concentrations at which the viruses were able to induce a 
starting or full cytopathic effect, the oncolytic efficiency of the viruses can be compared. Improved 
cytotoxic behavior of the modified viruses was present, if lysis at lower TCID50/cell compared to the 
control virus Ad-Luc was observed. 
As a replication-deficient control virus, Ad-CMV-GFP was used. The E1A gene was substituted by a 
GFP gene under CMV-promoter control. Further, the virus also had a 5/3 fiber. Ad-CMV-GFP was 
Ad-TRAILAd-Luc (control) Ad-Δ19K-Luc
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kindly provided by Igor Dmitriev and David Curiel, and was purified, characterized, and titered in the 
course of this study (see Materials section 10.3). The virus was used to verify that no cell-detachment 
independent of viral replication took place and that observed loss of cells was due to lysis in case of 
the replication-competent viruses. 
As shown in Figure 17 (first lanes), Ad-CMV-GFP did not induce lysis in any of the infected wells. In 
the following lanes, the cytotoxic potential of the modified oncolytic viruses Ad-Δ19K-Luc, and Ad-
TRAIL compared to Ad-Luc were tested. For MSC from both donors, infection with Ad-Δ19K-Luc led to 
about 100-fold increased lysis compared to Ad-Luc. In case of Ad-TRAIL, lysis was increased about 10-
fold for Donor 1 and 100-fold for Donor 4. The results confirmed the hypothesized improvement of 
replication and release by the E1B19K deletion and indicate that MSCs of both donors are TRAIL-
sensitive. The experiments also revealed a donor dependent susceptibility to virus infection, which 
was about 10-fold higher for Donor 4 than for Donor 1. Similar observations had already been made 
in the transduction experiments (Figure 12). 
 
Figure 17: Cytotoxicity of the Modified Oncolytic Viruses on MSCs. Cytotoxicity experiment to analyze cytotoxic potential 
of generated viruses. Cells were infected with indicated serial dilutions of TCID50/cell with indicated viruses. 14 days post-
infection cells were stained with crystal violet. Plates were dried and scanned. Ad-CMV-GFP: replication-deficient control 
virus. 
 
7.2.4. Characterization of Virus Progeny Produced in MSCs 
After virus release from MSCs at the tumor site, the virus needs to efficiently infect tumor cells. To 
test whether the virus progeny produced in MSCs maintains the same oncolytic qualities than 
purified virus, the oncolytic potential of MSC-produced virus particles was analyzed in the established 
pancreatic adenocarcinoma cell line MiaPaCa-2. Equal amount of infectious viral particles from 
purified virus and virus progeny produced in MSCs (supernatant from Figure 15A, Donor 4, day 4) 
were tested. MiaPaCa-2 lysis was analyzed by XTT cell viability assay (see Methods section 10.5.7). 
Due to limited sample amount, the experiment was only performed once in triplicates. No significant 
difference in absorbance was observed between purified and MSC-produced virus for equal 
conditions for each of the viruses (Figure 18). This indicated that viruses from both sources were able 
to induce cell killing equally well, and therefore, that virus progeny produced in MSCs had the same 
vitality than the purified virus. Further, the result indicated that MiaPaCa-2 were sensitive to TRAIL as 
most efficient cell killing was seen following infection with Ad-TRAIL compared to other tested 
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viruses. However, to obtain statistically significant data, the experiments needs to be repeated with 
virus progeny produced in a different MSC donor.  
 
 
Figure 18: Testing of Virus Progeny Produced in MSCs on MiaPaCa-2 for Maintenance of Virus Vitality. 15,000 MiaPaCa-2 
were infected either with purified virus or virus progeny produced in MSCs at indicated titers. Supernatant of virus-infected 
MSCs (Donor4) 4 days post-infection was obtained and titrated in the burst assay described in Figure 15. XTT assay of 
infected MiaPaCa-2 was performed 8 days post-infection. Columns show mean absorbance units. Error bars show SDs of 
triplicate infections.  
 
7.3. Testing Polybrene as Adenovirus Transduction Helper for MSCs  
7.3.1. Improving Adenovirus Transduction Efficacy for MSCs with Polybrene 
Although the Ad5/3 capsid variant was the best in terms of transduction efficiency in MSCs (Figure 
12), the measured RLU did not give information about the percentage of transduced cells. An 
oncolytic virus expressing GFP (Ad-GFP, Figure 19A) was generated to visualize infection.  
Ad-GFP was generated by inserting the GFP gene via a splice acceptor site (SA) downstream of the 
adenovirus E4 gene. By this means, GFP was expressed from the late viral transcription unit and 
therefore replication-dependent. Transgene expression had been shown to be efficient by this 
insertion strategy. [94]. For the cloning strategy see section 7.8.2. The virus genome was transfected, 
and viruses were amplified, purified, and proof-characterized. The physical viral particle titer was 
determined by OD260 measurement and infectious viral particles determined by TCID50 assay on 
A549 cells (for details see Methods section 10.4). The ratio of physical and infectious viral particles 
was 30. Ad-GFP was a replication-competent virus, containing E1AΔ24, E3 deletion, and a 5/3 fiber. 
Following MSC transduction, the GFP-signal started to appear after about 24 hours. Fluorescence 
pictures were taken 48 hours post-infection, when GFP expression was maximal but prior to the 
completion of the viral life cycle and cell lysis. The amount of green-fluorescent cells correlated with 
the amount of the initially infected cells.  
The left set of pictures in Figure 19B shows images of MSCs from three donors, which were 
transduced with serial dilutions of virus. Transduction with 100 TCID50/cell led to a very small fraction 
of GFP-positive cells (<5%). With 1,000 TCID50/cell, transduction efficiency was increased 
(approximately 50%), but still not sufficient. 10,000 TCID50/cell led to transduction of the majority of 
cells. As expected, some differences between the donors were observed. Donor 3 was better 
transducible, followed by Donor 1 and Donor 2 (this result is in accordance with the transduction 
experiments in Figure 12). Transduction of Donor 3 with 10,000 TCID50/cell led to a starting 
cytopathic effect. Therefore, the viral titers that were necessary for complete transduction were very 
high. In view of future in vivo experiments, when an initial infection of 100% is aimed for, these titers 
are problematic. Therefore, Polybrene, a cationic polymer, was tested as transduction helper. The 
Ad-Luc (control) Ad-Δ19K-Luc Ad-TRAIL
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use of Polybrene had been shown in several studies to greatly improve adenovirus transduction of 
epithelial and endothelial cells [155] as well as in mouse MSCs [156].  
The right part of Figure 19B shows transduction efficiency when Polybrene was used as transduction 
helper. MSCs were plated and 24 hours later infected with Ad-GFP in medium containing 8 ng/ml 
Polybrene for 2 hours. The fluorescent pictures were taken 48 hours post-infection. In pre-
experiments (data not shown), Polybrene concentrations between 2 and 16 ng/ml were tested, and 8 
ng/ml was identified as the optimal concentration. Now, 100 TCID50/cell + Polybrene led in case of 
Donor 1 and 3 to transduction of a major fraction of cells and for Donor 2 to about 50% transduction. 
1,000 TCID50/cell + Polybrene led to almost complete transduction for all donors. It was estimated 
from this experiment that the use of Polybrene allows a 10-fold viral particle reduction needed for 
efficient MSC infection. Additionally, the differences in donor transducibility led to the conclusion 
that every donor needs to be tested prior to experiments in order to assure sufficient infection.  
 
 
Figure 19: Adenoviral Infection Efficiency of MSCs With and Without Polybrene. A: Genome outlines of virus used for test 
infection of MSCs. LITR/RITR: left/right inverted terminal repeat, Ψ: packaging signal, E1AΔ24: deletion of pRb-binding 
region in E1A for cancer selective replication, E3-deleted, GFP was inserted via splice acceptor site (SA) downstream of E4. 
B: Fluorescence pictures to compare transduction with and without Polybrene (PB). MSCs of 3 different donors were 
transduced with 100, 1,000, or 10,000 TCID50/cell or with 100 or 1,000 TCID50/cell with 8 ng/ml PB. 48 hours post-infection 
cells were fixed with 4% paraformaldehyde, permeabilized with 0.5% Triton X-100 solution and stained with Hoechst 33258 
(blue fluorescence of nuclei). Fluorescence pictures were taken with 10x magnification.  
 
7.3.2. Virus Replication and Release Maintenance after Polybrene-Mediated Infection 
To verify that the use of Polybrene as transduction helper does not subsequently interfere with viral 
replication and release, a burst assay was performed with MSCs from Donor 1. The burst assay 
procedure was explained in section 7.2.2 before. The aim of the experiment was to infect MSCs in a 
way that the number of cell-associated viral particles after infection with and without Polybrene was 
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comparable. Therefore, over the course of 4 days, the amount of produced and released progeny 
viral particles would allow conclusions whether the replication and release kinetics were altered with 
Polybrene. The viral titers needed for similar initial infection were estimated, based on the 
fluorescence pictures of Figure 19B. Here, infection with 1,000 TCID50/cell without Polybrene and 100 
TCID50/cell with Polybrene resulted after 48 hours in comparable amount of transduced, green-
fluorescence cells. Therefore, these two titers were used to obtain roughly comparable initial 
infection levels. MSCs were infected, with the modified viruses Ad-Luc, Ad-Δ19K-Luc, and Ad-TRAIL, 
with or without Polybrene and the determined titers. At day 0 (2 hours post-infection), the cells were 
harvested in order to analyze initial transduction titers. At day 4 post-infection, cells and supernatant 
were harvested separately to obtain information about replication and release. In all obtained 
samples, infectious viral particles amounts were determined by TCID50 assay (see Methods section 
10.3.5.) 
 
 
Figure 20: Viral Replication and Release in MSCs After Polybrene-Mediated Infection. MSCs (Donor 1) were transduced 
with 1,000 TCID50/cell or with 100 TCID50/cell + Polybrene (PB). At day 0 (2 hours post-infection), cells were harvested. At 
day 4 post-infection, cells and supernatant (sn) were harvested separately. In all samples, infectious virus particle titers 
were determined by TCID50 assay on A549 cells. Bars show mean infectious viral particle titers and error bars SDs of 
triplicate infections. A: The graph shows infectious virus particles in cells at 0 days post-infection (black) and total viral 
particles at 4 days post-infection (white). B: The graph shows infectious virus particles in the supernatant (sn) at 4 days 
post-infection. The numbers shown on the right side of the graph describe the amount of released infection viruses, which 
was calculated from the ratio of TCID50 sn / TCID50 total (cells + sn) at day 4 post-infection. 
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The results shown in Figure 20A, describe the replication behavior of the modified viruses. The bars 
describe the amount of cell-bound viral particles at day 0 (black part) and total viral particles (cells + 
supernatant, white part) at day 4 post-infection. The experiment confirmed that viral infection titers 
of 1,000 TCID50/cell and 100 TCID50/cell + Polybrene at day 0 (black part of bars) resulted in roughly 
comparable amount of initially cell-associated virus. Titers for transduction with Polybrene were 
slightly higher, as already observed in the fluorescence pictures. The numbers of produced total 
infectious viral particles at day 4 post-infection (white part of bars) indicated no significant difference 
between samples with and without Polybrene in particle production. In accordance with the slightly 
higher starting viral particle amount, the numbers of produced viral particles were also slightly higher 
for 100 TCID50/cell with Polybrene when infected with Ad-Luc and Ad-Δ19K-Luc. Only for Ad-TRAIL, 
produced viral particles were a bit less, though not significant. Further replication assays with 
different donors are necessary to draw a final conclusion.  
Figure 20B describes infectious virus particles in the supernatant at day 4 post-infection and 
therefore the viral release behavior. As already shown in the burst assay over 8 days (Figure 15A), 
infection with Ad-Δ19K-Luc resulted in more efficient release, compared to Ad-TRAIL and Ad-Luc. For 
infections with Polybrene, this observation was recovered. Ad-Δ19K-Luc showed increased release 
compared to the other two viruses. Additionally, the graphs indicate that virus release was generally 
slightly improved compared to transduction without Polybrene. This was further analyzed by 
calculation of the TCID50 ratios supernatant/cells. This ratio was used to judge if increased release is 
proportional to the increase of viral particle production. For all viruses transduced with Polybrene, 
higher release ratio was observed (between 1.5-fold for Ad-Δ19K-Luc and 4-fold for Ad-TRAIL). 
However, the experiments indicate that Polybrene is feasible as transduction helper for MSCs and no 
significant inhibition of viral replication and release kinetics were observed. Again, this experiment 
only provides preliminary data and has to be repeated with MSCs of other donors in order to 
conclude about an effect. 
 
7.4. GFP-Transgene Viruses Generation and Characterization 
7.4.1. Genome Outlines and Verification of Transgene Expression 
For monitoring reasons, a set of replication-competent viruses expressing GFP additionally to 
E1B19K-deletion or TRAIL-insertion was generated (Figure 21). Further, an FCU1-expressing virus was 
added to the panel. The conversion of the prodrug 5-FC to the antimetabolite 5-FU aimed for an 
additionally killing effect. As long as the prodrug 5-FC was not added, virus properties of Ad-FCU1-
GFP were expected to be comparable with those of Luc-expressing control virus. In view of in vivo 
settings, the prodrug administration can be timed and would be added when the virus has reached 
the tumor site and the virus has spread at the tumor site. Therefore, the converted prodrug does not 
interfere with any processes while the virus is affiliated with MSCs and the virus was analyzed in 
combination with the prodrug 5-FU only in the context of pancreatic adenocarcinoma cells lines. 
In all viruses, the first transgene (Luc, TRAIL, or FCU1) was introduced via an IRES (internal ribosomal 
entry site) downstream of the fiber. The rational of the insertion strategy was described in section 
7.2.1. All viruses contained as second transgene GFP, which was introduced via a SA (splice acceptor 
site) downstream of the viral E4 gene. These strategies were chosen based on previous studies for 
optimized transgene insertions [92, 93]. They were shown to lead to efficient transgene expression 
but, due to late expression in the viral life cycle, did not interfere with viral replication. This was 
especially relevant in the case of infection of TRAIL-sensitive MSCs and cancer cells with Ad-TRAIL-
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GFP, as completion of the virus life cycle and therefore efficient production of viral progeny had to be 
ensured. Early expression of TRAIL might abrogate the viral life cycle in these cells. Further, all viruses 
contained a 24 amino acid deletion in E1A (E1AΔ24) for cancer cell-selective replication (see 
Introduction section 5.5.2), the deletion of E3 for genome size reduction in order to introduce 
transgenes, as well as the fiber5/3 chimera, as identified as best transducing fiber variant in section 
7.1. For cloning strategies see section 7.8.3, 7.8.4, 7.8.6, and 7.8.7. Virus genomes were transfected 
and viruses were amplified and purified (see Methods section 10.3.1-10.3.3). Further, they were 
proof-characterized, viral particles determined by OD260 measurement and infectious viral particles 
determined by TCID50 assay on A549 cells (for details see Methods section 10.3.4/10.3.5). The ratios 
of physical and infectious viral particles were between 16 and 65. 
 
 
 
Figure 21: A Schematic Outline of the Generated Virus Genomes. LITR/RITR: left/right inverted terminal repeat, Ψ: 
packaging signal, E1AΔ24: deletion of pRb-binding region in E1A for cancer selective replication, E1B19K: early gene with 
anti-apoptotic features, E3-deleted, chimeric Ad5/3 fiber (5/3). The viruses contain 2 transgenes cassettes inserted via two 
different strategies; Firefly-Luciferase (Luc), TRAIL, and FCU1 genes via internal ribosomal entry site (IRES) downstream of 
the fiber and GFP via splice acceptor site (SA) downstream of E4. 
 
Transgene expression of FCU1 and TRAIL were confirmed by immunoblots of infected cells (Figure 
22). To generate immunoblot samples, MiaPaCa-2 were infected with the indicated viruses, cells 
were harvested 48 hours post-infection and lysates were prepared and analyzed (for details see 
Methods section 10.5).  
For the TRAIL immunoblot, the two viruses generated in the course of this study, Ad-TRAIL-GFP and 
Ad-TRAIL, were analyzed for TRAIL transgene expression. In order to analyze if virus infection itself 
caused intrinsic TRAIL expression, Ad-Luc-GFP was used as control. recTRAIL was a recombinant, 
purified TRAIL (recombinant Super Killer TRAIL, AXXORA, Farmingdale, NY) including only amino acid 
95-281 (24 kDa) of the wild type sequence and was used as a positive control. In order to analyze 
intrinisic TRAIL background expression of the cells, a mock-infection control (medium only) was 
included. The TRAIL immunoblot shows two bands for virus-expressed TRAIL, correlating with the 
membrane-bound and shedded form. The loaded amount of purified TRAIL (recTRAIL) was 10 ng. The 
comparison of the band intensities of purified and virus-produced TRAIL allows only a rough 
estimation of TRAIL protein produced by the virus, however it indicates that TRAIL protein 
production by the virus is efficient. For Ad-Luc-GFP and mock-infection, no TRAIL signal was 
observed, indicating that no significant background TRAIL expression was present. 
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For the FCU1 immunoblot, the replication-deficient Ad-CMV-FCU1 virus, described in [106], was used 
as positive control. In both blots, Ad-Luc-GFP was included as negative, virus-infected control. Mock 
refers to uninfected, medium only-treated cells. For Ad-FCU1-GFP and Ad-CMV-FCU1 a band for 
FCU1 was seen. β-Actin blots confirmed equal sample loading for both immunoblots. 
 
Figure 22: Confirmation of TRAIL and FCU1 Transgene Expression by Immunoblotting. MiaPaCa-2 were infected with 10 
TCID50/cell or mock-infected. 48 hours post-infection, lysates were prepared and TRAIL (left panel) and FCU1 (right panel) 
were detected by immunoblot. β-Actin was used as loading control. Ad-Luc-GFP: control virus, recTRAIL: KillerTRAIL™, 
soluble/human/recombinant (AXXORA), Ad-CMV-FCU1: replication-deficient, FCU1-expressing control virus; full-length 
TRAIL: 32 kDa, soluble TRAIL: 28 kDa, recTRAIL: 24 kDa. 
 
7.4.2. Analyzing Differences in Transgene Expression 
In subsequent infection experiments, A549 cells were infected with the viruses described in Figure 21 
and GFP expression was monitored. It was observed that GFP-intensities of infected A549 cells 
differed between the generated viruses. The pictures in the upper panel of Figure 23A show that GFP 
intensities for cells infected with Ad-TRAIL-GFP, Ad-FCU1-GFP, or Ad-GFP were stronger than for cells 
infected with Ad-Luc-GFP or Ad-Δ19K-Luc-GFP at 30 hours post-infection. PCR analysis confirmed that 
no sequence irregularities were present. To further confirm proper functionality of the viruses, the 
same set of images was taken, adding the antimetabolite AraC to the medium. AraC blocks cell and 
viral replication and therefore viral transgene expression, including GFP. 48 hours post-infection, 
fluorescence images were taken (Figure 23A, lower panel). In all virus-transduced wells, GFP 
expression was significantly reduced after adding of AraC, confirming that GFP transgene expression 
was under viral late promoter control and not irregularly independently expressed. Some observed 
residual GFP expression was most probably due to incomplete viral replication suppression because 
of the high virus input titers. 
In order to analyze whether differences in GFP intensities could possibly be explained with 
differences in amounts of synthesized GFP protein, a Western blot was performed to quantify GFP 
protein in cells infected with the generated viruses (Figure 23B). It was observed that less GFP 
protein was expressed in Ad-Luc-GFP and Ad-Δ19K-Luc-GFP-infected cells, which correlates with the 
weaker GFP intensity seen in the pictures of Figure 23A. Control blots of hexon and fiber using the 
same samples, however, resulted in comparable band intensities of all samples, suggesting that there 
was no general problem with viral infection, replication, or synthesis of virus proteins.  
As the genetic background was accurate and infectious viral particle production was not affected, 
experiments were continued and differences in GFP intensities were considered in fluorescence 
picture settings. 
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Figure 23: Analyzing Differences in GFP Expression of the Generated Oncolytic Viruses. A: Infection experiment utilizing 
AraC as viral replication inhibitor. A549 cells were infected with 100 TCID50/cell of the indicated virus. 2 hours post-infection 
medium containing 25 µg/ml AraC or medium without AraC was added as indicated. AraC was replenished every 12 hours. 
30 hours post-infection, fluorescence pictures were taken to monitor GFP intensities. B: Analysis of GFP, hexon, and fiber 
expression by immunoblotting. A549 cells were infected with 10 TCID50/cell, 48 hours post-infection lysates were prepared 
and hexon/fiber and GFP were detected by immunoblot. β-Actin was used as loading control. Ad-Luc-GFP: control virus. 
Molecular weights: hexon: 130 kDa, fiber: 70 kDa, GFP: 27 kDa.  
 
7.5. Migration Assay of Virus-Infected MSCs 
A transwell migration assay (12 µm pore size) was performed to analyze whether MSCs migration 
capacity was affected by infection with the modified viruses. The aim was to analyze whether virus 
infection itself affected the migration behavior of MSCs and especially, whether the deletion of 
E1B19K or insertion of TRAIL affected MSC migration. The modifications showed improved 
replication and release kinetics from MSCs (Figure 15). Following, it was crucial to analyze whether 
they allow MSC migration maintenance for the length of time the MSCs need to reach the tumor. 
Transduced MSCs were allowed to migrate towards 10% FBS as chemoattractant for 38 hours (for 
procedure overview see Figure 24A). 38 hours correlates to the time reported in the literature that 
the MSCs need to home to a tumor in vivo after systemic application [142-144]. Further, this time 
period was reasonable since it was prior to virus release but guaranteeing sufficient GFP-transgene 
expression for monitoring. 
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The day before the experiment, MSCs were stained with PKH26 Red Fluorescent Cell Linker Kit 
(Sigma). 2 hours prior to the initiation of migration, MSCs were transduced with 2,500 TCID50/cell of 
Ad-Luc-GFP, Ad-Δ19K-Luc-GFP, Ad-TRAIL-Luc, or Ad-FCU1-GFP or were mock-infected. The infectious 
titer was determined in a pre-experiment to sufficiently transduce MSCs of this donor without 
inducing an unspecific cytotoxic effect caused by an excess of physical viral particles. MSCs were 
added into the inside of the transwell insert (migration) or were plated in one well of a 24-well plate 
(controls).  
At the end of the migration time the inserts were removed, non-migratory cells were removed from 
the upper side of the transwell membranes and fluorescence pictures of the lower side of the 
membranes were taken (Figure 24B, upper panel). The pictures show red-fluorescent cell 
membranes of all MSCs as well as a population of green-fluorescent virus-infected MSCs. The fraction 
of infected, migrated cells was determined by counting green and red fluorescent cells. However, this 
was not easily done for the transwells due to focusing problems of the sloping membrane surfaces, 
identification of cells which are still partly stuck in one of the pores, and high background 
fluorescence due to auto-fluorescence of the membranes. The counting resulted in approximately 
80% infected migrated cells for all infections. The same analysis was done with the infected control 
MSCs, which had been plated in the 24-well plate (Figure 24B, middle panel). Here, green and red 
fluorescent cells were easily identifiable. After counting, the transduction rate was determined to be 
about 80%. The results showed that the ratio of uninfected to infected MSCs was the comparable, 
namely 80%, for migrated MSCs and MSCs plated in the 24-well plate (control). Therefore, the ratio 
of uninfected to infected cells remained the same after migration. This indicates that infected and 
uninfected cells migrated equally well. This was observed for infections with all modified viruses. 
The control fluorescent pictures further show that Ad-Δ19K-Luc-GFP and (to lesser extend) Ad-TRAIL-
Luc infected MSCs differed in morphology and were more rounded-up, while Ad-Luc-GFP and Ad-
FCU1-GFP infected MSCs appeared morphologically similar to uninfected MSCs. This was according to 
the observations during the burst assay described in Figure 16. However, the fluorescence pictures 
suggest that these morphological differences had no effect on migratory competency. 
Further, to determine the number of migrated cells quantitatively, a colorimetrical assay was 
performed. The transwell membranes were stained with crystal violet. Prior to dye extraction, 
pictures of the stained membranes were taken (Figure 24B, lower panel). Here again, the mentioned 
morphological differences were seen, especially in the picture of Ad-TRAIL-GFP-infected MSCs, where 
most of the cells were rounded-up. The dye was extracted and OD at 560 nm was measured. The 
colorimetrical evaluation resulted in no significant difference of infected MSCs compared to 
uninfected MSCs (Figure 24C), which indicates that the same total number of MSCs migrated in case 
of all samples.  
Overall, it can be concluded that the infection of MSCs with the modified viruses retained unimpeded 
migration during the first 2 days post-infection. Therefore, neither the infection with oncolytic 
adenovirus itself (Ad-Luc-GFP) nor the effects of further viral modifications (deletion of E1B19K, the 
insertion of TRAIL, or the insertion of FCU1) affected the migration behavior of MSCs. 
Results 46 
 
 
Figure 24: Migration Analysis of MSCs Infected With the Modified Oncolytic Viruses. A: Outline of the procedure of the 
MSC migration assay. MSCs were labeled with a red-fluorescent dye, infected, and allowed to migrate for 38 hours towards 
medium containing 10% FBS. The assay was evaluated qualitatively by fluorescent and bright-field pictures as well as 
quantitatively by colorimetrical measurement of the extracted dye solution. B: Qualitative evaluation of migration assay. 
Fluorescence pictures: overlay of red (MSCs) and green (virus-transduced MSCs) fluorescence images of migrated cells. For 
controls of transduction efficiency, half of the cells used for migration were plated in wells of a 24-well plate to determine 
transduction efficiency. Blue staining: MSCs on the membranes were stained with blue dye and bright-field pictures were 
taken prior to dye extraction. Scale bar = 200 µm. C: Quantitative evaluation of migration assay. Extracted dye solutions 
from the stained membranes were transferred to a 96-well plate, scanned, and OD560 was measured. Columns show mean 
OD readings, error bars show standard deviations of triplicate migrations. n.s.: no significant difference compared to mock-
infected cells determined by one-way ANOVA. 
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7.6. Cytotoxicity Experiments in Established Pancreatic Adenocarcinoma Cell Lines 
Following the proposed delivery model (Figure 10), the viruses need to infect and lyse the pancreatic 
tumor cells, including the tumor stem cells after being delivered at the tumor site by MSCs. 
Therefore, the killing properties of the generated oncolytic viruses, Ad-Δ19K-Luc-GFP, Ad-TRAIL-GFP, 
and Ad-FCU1-GFP/5-FC, were tested on established pancreatic adenocarcinoma cell lines MiaPaCa-2, 
BxPc-3, AsPc-1, and Panc-1. The investigated established pancreatic tumor cell lines can be 
associated with the different subpopulations of a tumor. In previous studies of our cooperation 
partner (group Ingrid Herr, University Hospital Heidelberg), the cell lines were characterized in terms 
of their stem cell resemblance based on the degree of differentiation, mutations in KRas/p53, 
colony/spheroid formation, ALDH activity, tumorigenicity in mice, and E-cadherin/Vimentin 
expression [31]. Based on this study, MiaPaCa-2 and AsPc-1 had been categorized as stem cell-like 
with the majority of the population showing stem cell characteristics; in contrast, BxPc-3 had been 
categorized as non-stem cell-like [31]. For Panc-1 it was reported, that a subpopulation with stem 
cell-like features was present (characterized by CD24+/CD44+, Vimentin, E-Cadherin,[157]). The 
provided data in the two publications did not allow a comparative grading of the stem cell-likeness. 
However, the oncolytic behaviour of the modified oncolytic viruses may give a first indication, 
whether tumor stem cells can be efficiently killed by oncolysis or bystander effects. 
 
7.6.1. Cytotoxicity Assay in Pancreatic Adenocarcinoma Cell Line Monolayers 
The generated viruses (Figure 21) were tested on established pancreatic adenocarcinoma cell lines to 
analyze, whether the modifications improved killing behavior compared to the control virus Ad-Luc-
GFP. The aim of the study was to test whether improved oncolysis could be mediated by the E1B19K-
deleted virus and whether improved tumor cell killing by bystander effects of TRAIL and the FCU1/5-
FC prodrug system. Cells were plated and infected 24 hours later with serial dilution of viruses. The 
plates were incubated for 6 or 8 days. Afterwards, crystal violet was added to each well, which fixed 
and stained the remaining viable cells. Plates were dried and scanned (Figure 25). The wells, where 
the virus was able to lyse the cells, appear clear, whereas the wells, which were not affected by the 
virus, show an intact, stained cell layer (experiment was previously explained in section 7.2.3). 
Improved killing was defined by lysis at lower virus concentrations compared to the control virus Ad-
Luc-GFP. 
In the left lane of each plate in Figure 25, Ad-CMV-GFP was used as replication-deficient control virus 
(described in section 7.2.3). For BxPc-3 and AsPc-1, cells detached when they were infected with 100 
TCID50/cell Ad-CMV-GFP. As Ad-CMV-GFP was a replication-deficient virus, this effect was due to 
toxicity induced by the excess of physical viral particles. Starting at 10 TCID50/cell, no cell loss was 
observed anymore. This replication-deficient virus control validated for the oncolytic replication-
competent viruses that observed lysis with 10 TCID50/cell or lower virus concentrations was due to 
oncolytic or bystander killing activity and not to unspecifically induced cell death. In the second lane 
of Figure 25, the control oncolytic virus Ad-Luc-GFP was administered followed by the modified 
oncolytic viruses. The following listing summarizes the killing behavior of the improved oncolytic 
viruses compared to Ad-Luc-GFP:  
• Ad-Δ19K-Luc-GFP improved lysis in Panc-1 about 10-fold; in MiaPaCa-2, BxPc-3 and AsPc-1 
killing was about 10-fold poorer compared to Ad-Luc-GFP. 
• Ad-TRAIL-GFP improved lysis in Panc-1 (about 10-fold), strongly in AsPc-1 (about 100-fold), 
weakly in MiaPaCa-2 (<10-fold), but not in BxPc-3 compared to Ad-Luc-GFP. 
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• Ad-FCU1-GFP without the prodrug 5-FC was tested to confirm that the oncolytic behavior is 
similar to Ad-Luc-GFP; this was the case for all analyzed established pancreatic 
adenocarcinoma cell lines. 
• Addition of 5-FC improved toxicity of Ad-FCU1-GFP in BxPc-3 and AsPc-1, and slightly in 
MiaPaCa-2; no improvement was seen in Panc-1.  
In the last two lanes, 5-FU and 5-FC were tested independently from Ad-FCU1-GFP combination 
treatment. These controls were used to estimate 5-FU sensitivity of each cell line as well as to rule 
out unspecific effects of 5-FC prodrug background toxicity. The 5-FU sensitivity was shown to be 
different in the cell lines. The EC50, estimated from the cytotoxic effect seen on the plates, varied 
between 0.01 (BxPc-3), 0.05 (MiaPaCa-2 and Panc-1), to 0.001 (AsPc-1) TCID50/cell. Finally in the last 
lane, it was verified that 10 µM of 5-FC, which was the concentration used in combination with Ad-
FCU1-GFP, was not toxic itself to any of the cell lines. In Lane 6, the combination treatment, Ad-
FCU1-GFP + 10 µM 5-FC was tested. In BxPc-3 and AsPc-1, cytotoxicity was increased 10-100-fold 
compared to the control virus Ad-Luc-GFP. Therefore, the prodrug was efficiently converted and was 
contributing to the cytotoxic effect in addition to viral oncolysis in responsive cells. In MiaPaCa-2 and 
Panc-1, no or a very little beneficial effect was observed.  
 
 
Figure 25: Cytotoxicity of the Modified Viruses on Pancreatic Adenocarcinoma Cell Lines. Cells were infected with serial 
dilutions of TCID50/cell with the indicated viruses. 5 days prior to staining, 5-FC and 5-FU were added in concentrations 
indicated on the right side of the picture panel. 10 µM 5-FC was added to wells of lane 6 (Ad-FCU1-GFP + 5-FC). 6 days 
(MiaPaCa-2 and AsPc-1) or 8 days (BxPc-3 and Panc-1) post-infection cells were stained with crystal violet. Plates were dried 
and scanned. Ad-CMV-GFP: control virus, 5-FC: 5-Fluorocytosine, 5-FU: 5-Fluorouracil.  
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In conclusion, the cytotoxicity experiment revealed that the modified oncolytic viruses were able to 
improve killing in a subset of tumor cells: 2 established pancreatic tumor cell lines were TRAIL-
sensitive, 1 cell line showed improved killing for Ad-Δ19K-Luc-GFP, and 2 were sensitive for the 
effects of the prodrug activation system Ad-FCU1-GFP/5-FC. They also revealed variations in 
sensitivity between cell lines to the different killing strategies. 
 
7.6.2. Analysis of Transduction, Spread, and Cytotoxicity in MiaPaCa-2 Spheroids 
Next, viral spread and cytotoxicity was aimed to be monitored in a 3D tumor-mimicking model. 
Further, the experiment was aimed to give indications if tumor stem cells can be targeted with the 
improved viruses in a 3D model. Therefore, MiaPaCa-2 cells grown in spheroids were chosen. 
MiaPaCa-2 cells had been characterized as tumor-stem-cell-like with spheroid forming capacity [31]. 
The spheroids were provided by the Herr group (University Hospital Heidelberg). 5,000 MiaPaCa-2 
cells were seeded in 100 µl medium containing 0.25 % methylcellulose in a well of a round-bottom 
96-well plate. Within 24 hours, the cells gathered at the well bottom and formed the spheroid. The 
methylcellulose was adding viscosity to the medium and therefore improving spheroid cell cohesion. 
Spheroids were infected 24 hours after seeding with the modified viruses Ad-Luc-GFP, Ad-Δ19K-IL-
GFP, Ad-TRAIL-GFP, and Ad-FCU1-GFP (described in Figure 21). Virus spread was monitored via GFP 
fluorescence imaging. Fluorescent pictures were taken for 8 days in 2 day intervals (Figure 26). Since 
the spheroids were cultivated separately in 96-wells, each spheroid could be monitored in a steady 
position over the whole time span. 
 
 
Figure 26: Monitoring and Analysis of MiaPaCa-2 Spheroids Following Infection With the Modified Viruses. MiaPaCa-2 
spheroids were infected with 100 TCID50/cell of indicated viruses or mock-infected. Virus spread was monitored via GFP 
expression at 2, 4, 6, and 8 days. Fluorescence and bright-field pictures were taken. Scale bar = 600 µm, magnified picture 
scale bar = 300 µm.  
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Increase in fluorescence intensity was observed until day 6 for all viruses. At day 8, fluorescence 
decreased probably due to progressing oncolysis, but also to nutrition depletion in the spheroid core 
[158]. Noticeable was that spheroid shapes differed depending on the virus variant. Ad-Luc-GFP and 
Ad-FCU1-GFP did not differ in size and shape from the mock-infected control spheroids throughout 
the experiment. The Ad-Δ19K-Luc-GFP and Ad-TRAIL-GFP-infected spheroids lost integrity around the 
outer rim loose, where cells were observed that made the rim seemed diffuse (Figure 26, 8d). For the 
Ad-TRAIL-GFP-infected spheroids, the images suggest that spheroids remained smaller in size 
compared to Ad-Luc-GFP and mock starting from day 4 post-infection.  
This observation was quantitatively investigated by measuring the spheroid surface area. For this, the 
program Histo® was provided by the Herr group (University Hospital Heidelberg), with which the 
spheroid size was determined in pixels in the taken images. The results of two independent 
experiments are shown in Figure 27. The results show a significantly smaller spheroid size for Ad-
TRAIL-GFP-infected spheroids compared to Ad-Luc-GFP in both experiments and compared to mock 
in experiment 2. 
 
Figure 27: Surface Area Determination of Infected and Mock-Infected MiaPaCa-2 Spheroids. The spheroid sizes were 
determined from images at 4x magnification at day 6 post-infection. Spheroid sizes were determined in pixels (see Methods 
section 10.5.9). Columns show mean values and error bars show standard deviations of three spheroids per group. n.s.: not 
significant, *: p < 0.05, **: p < 0.01 determined by one-way ANOVA. 
 
The disintegration of the spheroid rim seen during spheroid infection with Ad-Δ19K-IL-GFP and Ad-
TRJAIL-GFP in Figure 26 was further pursued. One assumption was that these diffuse layers were the 
remains of cells lysed by the virus and therefore were not attached to the spheroid body anymore. 
An LDH assay was performed to assay possible differences of spheroid integrity. In viable cells, LDH is 
only found intracellularly. Measuring LDH activity in the medium therefore gave an indication about 
the number of disintegrated, dead cells. LDH activity was measured in the supernatant of infected 
spheroids at day 4 and day 6 post-infection. In correlation to LDH activity measured in mock-infected 
and complete lysis controls, the amount of dead cells for virus-infected spheroids was determined 
(also see Methods section 10.5.8).  
Consistent observations in two independent experiments (Figure 28) showed that at day 4, LDH 
release of Ad-TRAIL-GFP-infected spheroids was greatest followed by Ad-Δ19K-Luc-GFP. Vice versa at 
day 6, Ad-Δ19K-Luc-GFP-infected spheroids showed the greatest LDH release followed by Ad-TRAIL-
GFP. Infections with Ad-Luc-GFP and Ad-FCU1-GFP led to lower, but above mock-infected levels of 
LDH release. Comparing the two experiments, it was noticed that the background LDH activity levels 
of the mock-infected controls were significantly different. Looking at day 6 post-infection for mock-
infected control spheroids, in experiment 1 about 45% of spheroid cells were dead cells, while in 
experiment 2 only about 8% of cells were dead. This difference also translated into the increase of 
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dead cells caused by virus infection. In experiment 1 on day 6, the difference of mock- and Ad-Δ19K-
Luc-GFP-infected samples was 1.4-fold (mock: 45.19% dead cells, Ad-Δ19K-Luc-GFP: 63.64% dead 
cells). For experiment 2, the factor was 4-fold (mock: 7.65% dead cells, Ad-Δ19K-Luc-GFP: 30.78% 
dead cells). This outcome suggests that critical conditions, e.g. the quality of spheroids, varied 
between experiments. However, while the background killing was different, the toxicity induced by 
the virus was very similar (absolute differences mock and Ad-Δ19K-Luc-GFP: 18% in experiment 1 and 
23% in experiment 2). Further, examination of the measured LDH activity and therefore the amount 
of dead cells over time revealed an overall tendency, which was a fast onset-killing by Ad-TRAIL-GFP 
and the best longer-term killing by Ad-Δ19K-Luc-GFP. 
 
Figure 28: Determining the Amount of Dead Cells Following MiaPaCa-2 Spheroid Infection With the Modified Viruses. 
MiaPaCa-2 spheroids were infected with 100 TCID50/cell of indicated viruses or mock-infected. LDH release was monitored 
in infected MiaPaCa-2 spheroid supernatants at day 4 and day 6 post-infection. Graphs shows means of % of dead cells 
compared to total lysis control; error bars show standard deviations of three spheroids per condition. n.s.: not significant, *: 
p < 0.05, **: p < 0.01, ***: p < 0.001 determined by one-way ANOVA. 
 
In conclusion, Ad-Δ19K-Luc-GFP and Ad-TRAIL-GFP changed morphology of tumor spheroids and 
caused enhanced LDH release from the spheroid cells, indicating improved oncolysis. Interestingly, 
oncolysis experiments in MiaPaCa-2 monolayers (Figure 25) did indicated weak sensitivity for TRAIL 
and even a poorer oncolytic activity of Ad-Δ19K-Luc-GFP compared to the Ad-Luc-GFP control virus. 
The effects of the viruses on the tumor cells were apparently different when MiaPaCa-2 were grown 
as spheroids. 
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7.7. Experiments in Low-Passage Pancreatic Ductal Adenocarcinoma Cell Cultures 
Two low-passage pancreatic ductal adenocarcinoma cell cultures, which were established from 
tumor material of patients, were tested for transduction and oncolytic capacity.  
JoPaca-1 cells were described in Fredebohm et al. [153] and were isolated from poorly differentiated 
pancreatic ductal adenocarcinoma. The authors reported that they identified three different cell 
subpopulations by shape and spreading behavior. Further, FACS analysis revealed that a large 
fraction of cells in the culture expressed stem cell markers (CD133+/ALDH1+: 21%; 
CD44+/CD24+/ESA+: 10%, capability of tumor sphere formation). PacaDD-159 cells were described in 
Rückert et al. [152, 159]. These cells were also isolated from pancreatic ductal adenocarcinoma. qPCR 
analysis revealed that the amount of  stem cell marker mRNA is similar to those of Capan-1, which 
had been reported to be stem cell-like [31]. Therefore it can be concluded that both cell cultures 
contained a heterogeneous subpopulation of cells, including a fraction which was expressing tumor 
stem cell markers. This subpopulation can be claimed to mirror the tumor-initiating cells in 
pancreatic adenocarcinomas and analysis of these cell lines therefore gave strong indications for in 
vivo situations.  
Transduction experiments were already shown in Figure 13B, which identified the Ad5/3 capsid 
variant virus to perform best transduction. To gain information about transducibility, both cell lines 
were infected with serial dilutions of Ad-GFP (virus and experiment described in section 7.3.1). 48 
hours post-infection images were taken and GFP-positive cells were correlated with transduction 
efficiency. Fluorescence pictures are shown in Figure 29.  
 
 
Figure 29: Adenoviral Infection Efficiency of Low-Passage Pancreatic Adenocarcinoma Cell Cultures. Fluorescence pictures 
to determine infection efficiency. Low-passage pancreatic ductal adenocarcinoma cell lines PacaDD-159 and JoPaca-1 were 
infected with 1, 10, 100, or 1,000 TCID50/cell of Ad-GFP. 48 hours post-infection cells were fixed with 4% paraformaldehyde, 
permeabilized with 0.5% Triton-X 100 solution and stained with Hoechst 33258. Fluorescence pictures were taken with 10x 
magnification. 
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the cytopathic effect were increasing. Even with the highest tested titer of 1,000 TCID50/cell, not all 
cells were GFP-positive. Therefore full transduction was not reached even though all cells, including 
the non-GFP-positive ones, were rounded up and apparently affected by virus infection. In JoPaca-1 
cells, the observations were similar. Here, it was remarkable that infected cells seem to cluster, 
which could indicate that there might be a difference in infectibility of the reported subpopulation of 
cells. 
 
A cytotoxicity assay was performed testing the improved oncolytic viruses on the two cell cultures 
(Figure 30). The experimental set-up was described in section 7.6.1 before. In PacaDD-159, Ad-Δ19K-
Luc-GFP showed no improvement in killing compared to the control virus Ad-Luc-GFP. Ad-TRAIL-GFP 
as well as Ad-FCU1-GFP + 5-FC led to an about 10-fold increased cytotoxicity compared to Ad-Luc-GP. 
JoPaca-1 showed about 100-fold better infectibility. Though here, no improvement in lysis was 
observed for infection with Ad-TRAIL-GFP or Ad-FCU1-GFP + 5-FC. Infection with Ad-Δ19K-Luc-GFP 
led to an about 10-fold reduced induction of oncolysis. 
Compared to the cytotoxicity assay performed with established pancreatic adenocarcinoma cell lines 
in Figure 25, it was observed that the overall infectibility was lower. While infection with 1 TCID50/cell 
of control virus Ad-Luc-GFP was sufficient to lyse 3 out of 4 established cells within 6 or 8 days, 100 
TCID50/cell were needed for PacaDD-159. 
 
 
Figure 30: Cytotoxicity of the Modified Viruses on Low-Passage Pancreatic Ductal Adenocarcinoma Cultures. Cells were 
infected with serial dilutions of TCID50/cell of indicated viruses. 5 days prior to staining, 5-FC and 5-FU were added in 
concentrations indicated on the right of the picture panel. To lane 6 (Ad-FCU1-GFP + 5-FC) were 10 µM 5-FC added. 12 days 
post-infection cells were stained with crystal violet. Plates were dried and scanned. Ad-CMV-GFP: control virus, 5-FC: 5-
Fluorocytosine, 5-FU: 5-Fluorouracil.  
 
In conclusion, variations between low-passage pancreatic adenocarcinoma cell lines were observed. 
In PacaDD-159, the infection with the improved oncolytic viruses resulted in improved cytotoxicity 
through the additional effect of TRAIL- or 5-FU-mediated killing, while in JoPaca-1 cells the improved 
viruses could not perform improved oncolysis. This indicates that a subset of pancreatic ductal 
adenocarcinomas was susceptible to improved lysis by the tested, modified viruses. 
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7.8. Virus Cloning  
This section describes the cloning of the viruses which were generated during the course of this 
project. For the origin of the other viruses, see the references in the previous sections or Materials 
section 9.9. 
 
7.8.1. General Cloning Strategies 
The principle strategy, which was followed for cloning, was first described by He et al [160]. The 
complete adenovirus genome size with approximately 36 kbp is too big to introduce modifications 
directly into the genome by restriction enzyme digestions. Therefore, a system of shuttle plasmids 
was used. The shuttle plasmids had a size of about 10 kb and contained the parts of the viral 
genome, where modifications needed to be introduced. The genes were modified in the shuttle 
plasmid and subsequently introduced into the full viral genome via homologous recombination of the 
modified shuttle plasmid with a viral backbone plasmid. 
Figure 31 describes the general cloning strategies, which were used for this project. Modifications 
were introduced into three different areas of the viral genome: 
i. Into the E1 region (deletion of E1B19K) 
ii. Transgene insertion via IRES downstream of the fiber5/3 (Luc, TRAIL) 
iii. Transgene insertion via SA downstream of E4 (GFP) 
Due to the shuttle system, two strategies were necessary to introduce the transgenes, whereas i. and 
iii. used the same shuttle plasmid system (Strategy 1, left panel of Figure 31), while ii. required 
another (Strategy 2, right panel of Figure 31).  
 
Strategy 1: The shuttle plasmids pShuttleX contained the viral genes E4, the left and right inverted 
terminal repeats (LITR, RITR), and the early genes E1A and E1B. In the plasmid map of pShuttleX in 
Figure 31 are in red the two sites shown, where modifications were introduced, namely the E1B19K 
deletion and the site of transgenes insertion. The bacterial elements (origin and antibiotic resistance) 
were between LITR and RITR. HR1 and HR2 refer to the homologous regions to the viral backbone 
vector. The modifications were introduced via restriction enzyme digestion and re-ligation. The 
modified pShuttleX was then digested with PmeI, which linearized the plasmid. Linearization opens 
the plasmid in a way that the homologous regions were on either side of the free ends.  
The vectors, which contain the entire viral genome and where the modifications have to be 
introduced, are called pVKs. The pVKs used in this study and from which one is shown in Figure 
31/Strategy1 already contained modifications in other parts of the viral genome (deletion of E3: ΔE3, 
fiber5/3).  
Both plasmids were electroporated into BJ5183 bacteria. The pShuttleX aligns to the pVK via the 
homologous regions and the bacterial enzymes catalyze the homologous recombination. This leads 
to an exchange of the pShuttle sequence with the according sequence of the pVK plasmid, including 
the antibiotic resistance genes. This allowed a subsequent selection for kanamycin-resistant clones. 
The DNA of the resulting colonies was isolated and genomes were analyzed by restriction enzyme 
digestion. Finally, the DNA of the recombined constructs were PacI digested, which removed all 
sequences with bacterial origin. The viral DNA was then transfected into A549 cells (see Methods 
section 10.3.1) resulting in infectious viral particles production within 1-2 weeks. 
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Figure 31: Strategies of Virus Cloning. Shuttle plasmids pShuttleX (strategy 1) or pfiberX (strategy 2) were modified by gene 
modification or transgene insertion. Via homologous recombination with the pVK plasmid, which contained the viral 
backbone, the modifications were introduced into the viral genome. LITR/RITR: left/right inverted terminal repeat, Ψ : 
packaging signal, E1A, E1B: immediate early genes, E3 gene, ΔE3: deletion of E3, fiber5: HAdV-5 wild type fiber, fiber 5/3: 
HAdV-5 shaft/HAdV-3 knob fiber chimera, IRES: internal ribosomal entry site, E4 gene, SA: splice acceptor site, HR1/HR2: 
homologous regions 1 and 2, ori: origin, Amp: ampicillin resistance gene, Kan: kanamycin resistance gene. 
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Strategy 2:  Via this strategy, a transgene was inserted downstream of the fiber5/3. In order to allow 
transgene translation with the fiber, an internal ribosomal entry site (IRES) sequence was introduced 
as connector between the two genes. The shuttle plasmids pfiberX contained the viral genes E3 (in 
this case ΔE3), the fiber5/3, the IRES sequence, and the transgene. The plasmid map of pfiberX in 
Figure 31 shows in red the sites where a transgenes was inserted. The homologous region 1 and 2 
flank the viral sequence. The bacterial elements (origin and antibiotic resistance) were between HR1 
and HR2. The transgene was introduced via restriction enzyme digestion and re-ligation. The 
modified pfiber was then linearized by digestion with PmeI. 
The homologous recombination procedure was analogous as described for Strategy 1. Here, 
linearization of the pVK vector with SwaI was essential, as the original pVK and the recombination 
product contained the same antibiotic resistance. The recombined constructs were PacI digested to 
remove bacterial sequences and transfected into A549 cells.  
 
In the following chapters, the cloning of the individual viruses is explained, referring to either 
strategy 1 or 2. 
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7.8.2. Cloning of Ad-GFP 
pGL3-BPSA-GFP was generated by replacing Luciferase of pGL3-BPSA-Luc (described in [93]) with GFP 
(from Clontech, Mountain View, CA). The BPSA-GFP-SV40polyA cassette was then introduced into the 
pShuttle plasmid pSΔ24 (described in [161]). Following strategy 1 (Figure 31), the generated pSΔ24-
GFP was recombined with pVK500 5/3 ΔE3 (generated in the Nettelbeck lab), resulting pVK500 5/3 
Δ24 ΔE3 GFP. Subsequent PacI digestion resulted in the genome of Ad-GFP (Figure 32). 
 
 
Figure 32: Outlines of Cloning Intermediate Constructs for the Generation of Ad-GFP. LITR/RITR: left/right inverted 
terminal repeat, Ψ: packaging signal, E1A, E1B: immediate early genes, E1AΔ24: deletion of pRb-binding region in E1A for 
cancer selective replication, ΔE3: deletion of E3, fiber 5/3: HAdV-5 shaft/HAdV-3 knob fiber chimera, E4 gene, SA: splice 
acceptor site, GFP: gene encoding green fluorescent protein, pA: SV40polyA, HR: homologous region. 
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7.8.3. Cloning of Ad-Luc-GFP 
Following strategy 1, pSΔ24-GFP, generated in section 7.8.2, was recombined with pVK500 5/3 ΔE3 IL 
[81], resulting in pVK500 5/3 Δ24 ΔE3 Luc GFP. Subsequent PacI digestion resulted in the genome of 
Ad-Luc-GFP (Figure 33). 
 
 
Figure 33: Outlines of Cloning Intermediate Constructs for the Generation of Ad-Luc-GFP. LITR/RITR: left/right inverted 
terminal repeat, Ψ: packaging signal, E1A, E1B: immediate early genes, E1AΔ24: deletion of pRb-binding region in E1A for 
cancer selective replication, ΔE3: deletion of E3, fiber 5/3: HAdV-5 shaft/HAdV-3 knob fiber chimera, IRES: internal 
ribosomal entry site, Luc: gene encoding firefly luciferase, E4 gene, SA: splice acceptor site, GFP: gene encoding green 
fluorescent protein, pA: SV40polyA, HR: homologous region. 
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7.8.4. Cloning of Ad-Δ19K-Luc-GFP 
From pSΔ24-E1B19K- (described in [81]), the E1B19K deletion was inserted into the pSΔ24-GFP 
(generated in section 7.8.2) via restriction enzyme digestion. The resulting vector was called pSΔ24-
ΔE1B19K-GFP. Following strategy 1, pSΔ24-ΔE1B19K-GFP was recombined with pVK500 5/3 ΔE3 IL 
[81], resulting in pVK500 5/3 Δ24 ΔE1B19K ΔE3 Luc GFP. Subsequent PacI digestion resulted in the 
genome of Ad-Δ19K-Luc-GFP (Figure 34). 
 
 
Figure 34: Outlines of Cloning Intermediate Constructs for the Generation of Ad-Δ19K-Luc-GFP. LITR/RITR: left/right 
inverted terminal repeat, Ψ: packaging signal, E1A, E1B: immediate early genes, E1AΔ24: deletion of pRb-binding region in 
E1A for cancer selective replication, ΔE1B19K: deletion of a 19 kDa protein coding region of E1B, ΔE3: deletion of E3, fiber 
5/3: HAdV-5 shaft/HAdV-3 knob fiber chimera, IRES: internal ribosomal entry site, Luc: gene encoding firefly luciferase, E4 
gene, SA: splice acceptor site, GFP: gene encoding green fluorescent protein, pA: SV40polyA, HR: homologous region. 
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7.8.5. Cloning of Ad-TRAIL 
pGL3-IRES-TRAIL was generated by replacing Luciferase of pGL3-IRES-Luc (described in [93]) with 
TRAIL (full-length TRAIL provided by AG Herr, University Heidelberg). The BPSA-TRAIL-SV40polyA 
cassette was then introduced into the shuttle plasmid pfiber5/3 ΔE3 IRES Luc (generated in the 
Nettelbeck lab). Following strategy 2 (Figure 31), the generated pfiber5/3 ΔE3 IRES TRAIL was 
recombined with pVK500 Δ24 (generated in the Nettelbeck lab), resulting in pVK500 5/3 Δ24 ΔE3 
TRAIL. Subsequent PacI digestion resulted in the genome of Ad-TRAIL (Figure 35). 
 
 
Figure 35: Outlines of Cloning Intermediate Constructs for the Generation of Ad-TRAIL. LITR/RITR: left/right inverted 
terminal repeat, Ψ: packaging signal, E1AΔ24: deletion of pRb-binding region in E1A for cancer selective replication, E1B: 
immediate early genes, ΔE3: deletion of E3, fiber5: HAdV-5 wild type fiber, fiber 5/3: HAdV-5 shaft/HAdV-3 knob fiber 
chimera, IRES: internal ribosomal entry site, TRAIL: gene encoding TNF-related apoptosis-inducing ligand, pA: SV40polyA, E4 
gene, HR: homologous region. 
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7.8.6. Cloning of Ad-TRAIL-GFP 
Following strategy 1, pSΔ24-GFP, generated in section 7.8.2, was recombined with pVK500 5/3 Δ24 
ΔE3 IRES TRAIL (generated in section 7.8.5) resulting in pVK500 5/3 Δ24 ΔE3 TRAIL GFP. Subsequent 
PacI digestion resulted in the genome of Ad-TRAIL-GFP (Figure 36). 
 
 
Figure 36: Outlines of Cloning Intermediate Constructs for the Generation of Ad-TRAIL-GFP. LITR/RITR: left/right inverted 
terminal repeat, Ψ: packaging signal, E1AΔ24: deletion of pRb-binding region in E1A for cancer selective replication, E1B: 
immediate early genes, ΔE3: deletion of E3, fiber 5/3: HAdV-5 shaft/HAdV-3 knob fiber chimera, IRES: internal ribosomal 
entry site, TRAIL: gene encoding TNF-related apoptosis-inducing ligand, E4 gene, SA: splice acceptor site, GFP: gene 
encoding green fluorescent protein, pA: SV40polyA, HR: homologous region. 
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7.8.7. Cloning of Ad-FCU1-GFP 
Following strategy 1, pSΔ24-GFP, generated in section 7.8.2, was recombined with pVK500 5/3 ΔE3 
IRES FCU1 (generated in the Nettelbeck group), resulting in pVK500 5/3 Δ24 ΔE3 FCU1 GFP. 
Subsequent PacI digestion resulted in the genome of Ad-FCU1-GFP (Figure 37). 
 
 
Figure 37: Outlines of Cloning Intermediate Constructs for the Generation of Ad-FCU1-GFP. LITR/RITR: left/right inverted 
terminal repeat, Ψ: packaging signal, E1AΔ24: deletion of pRb-binding region in E1A for cancer selective replication, E1B: 
immediate early genes, ΔE3: deletion of E3, fiber 5/3: HAdV-5 shaft/HAdV-3 knob fiber chimera, IRES: internal ribosomal 
entry site, FCU1: gene encoding prodrug converting enzyme with CD and UPRT activity, E4 gene, SA: splice acceptor site, 
GFP: gene encoding green fluorescent protein, pA: SV40polyA, HR: homologous region. 
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8. Discussion 
8.1. General Remarks 
Several clinical trials have shown that oncolytic adenoviruses are very well suited for cancer therapy 
featuring great safety and only very little side effects. (reviewed in [117]). These trials further 
revealed that no dose limiting toxicity was observed [109, 111, 162], as predicted when these agents 
were first developed [163]. Instead, after intravenous virus application, the oncolytic adenovirus 
delivery to the tumor site was insufficient due to liver sequestration and neutralization [113, 164]. 
Further, Phase 1/2 studies, where the oncolytic adenoviruses were injected intra-tumorally, resulted 
in inefficient oncolysis [109, 110, 162, 165]. Therefore, strategies to improve adenovirus delivery and 
tumor cell killing have to be exploited.  
Mesenchymal stem cells were exploited as carrier cells in this study, to deliver optimized oncolytic 
adenoviruses. Utilizing their shielding function and a natural tropism to tumors [128, 130] it was 
shown in previous studies that they are able to efficiently deliver oncolytic adenoviruses to tumors 
[125, 141, 166]. Furthermore it was shown that MSCs are productively infected by oncolytic 
adenoviruses and can serve as virus-propagating machinery while homing to the tumor [124, 167]. 
The system allows the circumvention of the named delivery problems, which however does not solve 
the need for improvement of the oncolytic efficiency. Enhancement of tumor cell killing can be 
achieved by modifications of the viral agents. 
In this study, modified oncolytic adenoviruses were tested for improved delivery by MSCs to 
pancreatic adenocarcinoma. Modifications were identified which featured i) improved transduction 
as well as replication and release in MSCs, as well as ii) improved oncolytic properties for killing of 
human pancreatic adenocarcinoma cells. This was achieved by genetic modifications including capsid 
modification for optimizing transduction, modification of apoptosis-regulating viral genes for 
optimizing viral replication and release kinetics, and therapeutic transgene insertion for bystander 
killing. The latter two had not been tested in in the context of a adenovirus carrier system before. 
The modified viruses have the potential to improve MSC-mediated virotherapy for pancreatic cancer.  
 
8.2. Transduction of MSCs and Tumor Cells With Capsid Variants 
In order to improve transduction, replication-deficient vectors with capsid variants Ad5, Ad5/3, and 
Ad5RGD were tested on MSCs as well as established and low-passage pancreatic adenocarcinoma 
cells. All viruses carried a CMV-Luciferase cassette and transduction efficiency was determined by 
comparing luciferase activities.  
 
In this study, transduction experiments in MSCs with Ad5 viral vectors showed comparably low 
transduction compared to Ad5/3 and Ad5RGD (Figure 12). This was in line with previous studies 
reporting that the primary receptor for HAdV-5, CAR, was poorly expressed on MSCs [140, 148, 151, 
168]. Further, in three out of four MSCs isolated from different donors, Ad5/3 was superior to 
Ad5RGD. Only in one case (Donor 2), Ad5/3 and Ad5RGD had comparable transduction rates. 
Previous reports, which compared the transducibility of MSCs with the three capsid variants, did not 
result in consistent observations. Though all agreed that either Ad5/3 or Ad5RGD generally improved 
transduction, some found Ad5RGD [124, 149], and others Ad5/3 [125] superior. This variability has 
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been analyzed and was shown to be dependent on MSC donor [124] and the applied viral dose [136]. 
With that background, it was remarkable that the identification of Ad5/3 as the best transducing 
capsid variant was so congruent between all 4 analyzed MSC donors. Perhaps, factors as the culture 
conditions (e.g. culture medium) or donor selection (e.g. age of the donors) have also influence on 
transduction with different capsid variants [146, 169]. However, as MSC origin and handling was 
often not described in detail in the publications, it is not possible to draw conclusions about the 
impact of these parameters.  
The number of transduced MSCs was visualized through infection with a fiber5/3, GFP-expressing 
oncolytic adenovirus and the observation of green-fluorescent cells 48 hours post-infection (Figure 
19). MSCs from different donors showed a high variability in the viral dose necessary for complete 
transduction. For Donor 3 infection with 2,500 TCID50/cell was sufficient (see Results section 7.5), 
while for Donor 2 infection with 10,000 TCID50/cell was not enough to transduce all cells. However, 
complete transduction was aimed for to obtain maximum delivery rates. Therefore, in future 
experiments with untested MSCs, it remains necessary to pre-test the optimal transduction dose and 
perhaps pre-select for better transducible MSCs.  
In order to reduce the amount of viral particles needed for complete transduction, Polybrene was 
tested as transduction helper (Figure 19). The positively charged Polybrene serves as bridge between 
the negatively charged cell surface and the adenovirus particle and therefore mediates improved 
transduction [170]. In pre-experiments, 8 µg/ml was identified as the optimal Polybrene 
concentration (from the range from 2 to 16 µg/ml Polybrene) for adenovirus transduction of the 
MSCs used in this study (data not shown). With 16 ng/ml Polybrene, no further improvement of 
transduction was observed compared to 8 ng/ml Polybrene. The use of Polybrene allowed to reduce 
the amount of viral particles about 10-fold to achieve similar transduction rates compared to 
transduction without Polybrene. The outcome was in line with previous studies, which reported a 
dose-dependent adenovirus transduction enhancement between 10- to 20-fold in different epithelial 
and endothelial established and primary cells [155, 170, 171] with the optimal dose between 4-8 
µg/ml Polybrene [155, 156, 170, 171]. Similar results were also obtained in a recent study from Zhao 
et al. [156], which tested the use of Polybrene for the transfer of an adenovirus vector into mouse 
pro-osteoblastic progenitor cells. Here, they saw a 10-fold improved transduction with 4.0 µg/ml 
Polybrene. Further, it was reported that Polybrene at higher doses interfered with MSC proliferation 
[171, 172]. However, the question whether virus replication and release might be affected by the use 
of Polybrene had never been addressed before. During the current study, analysis of replication and 
release kinetics of the virus after transduction with Polybrene gave indications that this possibility 
can be ruled out (Figure 20) and Polybrene as a feasible transduction helper was validated.  
Clinical or in vivo studies with Polybrene as transduction helper for delivery of oncolytic adenovirus 
by MSCs have not been performed so far. However, the feature of Polybrene, to significantly reduce 
the amount of virus particles needed for transduction, implies great potential for clinical applications. 
This can be illustrated by analyzing the set-up of a performed clinical delivery study. Garcia-Castro et 
al. [147] reports about an exploratory trial testing adenovirus delivery by MSCs. The number of MSCs 
used in this study was in line with those used for clinical trials of tissue repair [173-175] and were 
between 108 and 109 MSCs per patient and injection. The study used for infection 2,000 pfu/MSCs, 
which is also in line with the observations in the MSCs in Figure 19 in order to reach sufficient 
transduction. Assuming that Polybrene can reduce the amount of needed virus by about 10-fold, the 
amount could be reduced from about 1x1012 to about 1x1011 for a single injection. This number is in 
contrast to up to 1013 viral particles which were used during dose escalation of i.v. administered 
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adenovirus [111]. Therefore, by using Polybrene the amount of viral particles is highly feasible and 
handling becomes more convenient. 
 
Transduction experiments in established pancreatic adenocarcinoma cell lines and low-passage 
pancreatic adenocarcinoma cultures resulted in best transduction with the Ad5/3 adenoviral vector 
compared to Ad5 and Ad5RGD (Figure 13). This is in accordance to previous reports that adenoviral 
vectors with modified fiber5/3 [66] and fiber5RGD [67] improved transduction of various cancer cell 
lines [66, 68-70]. The primary receptor for Ad5, CAR, is weakly expressed in established pancreatic 
adenocarcinoma cell lines [64, 65]. Clinical trials using oncolytic viruses with HAdV-5 capsid showed 
the need for improvement of the viral vector [111], therefore, alternative capsid variants for 
improved infection present one option for improvement of the viral agent. Oncolytic viruses with 
fiber5/3 capsid modifications were tested in in clinical studies for i.t. and i.p. injections [165, 176, 
177].  In these trials, no severe side effects were observed and the virus was well tolerated.  
To visualize infection efficiency of low-passage pancreatic tumor cultures, the cells were infected 
with the fiber5/3 and GFP-expressing oncolytic virus Ad-GFP (Figure 29). The fluorescent pictures 
showed that the population was not completely infectable with as much as 1,000 TCID50/cell. In 
contrast, 10 TCID50/cell were sufficient to achieve full transduction of established pancreatic cancer 
cell lines (data not shown). This difference in infectibility of established and low-passage cells had 
been shown for Ad5 [150] and Ad5/3 [178] capsid variants before for malignant glioma. 
Furthermore, as already described in Results section 7.7, the investigated low-passage pancreatic 
cancer cultures JoPaca-1 and PacaDD-159 did not contain one homogenous population of cells. 
Images in Figure 29 also suggest that the different cell populations were not equally well infectable. 
The observed infection in a patch-like pattern seen may indicate that only one subpopulation of cells, 
which had grown as a colony on the plate, was infected. Assuming that this hypothesis is valid, it is 
likely that a subset of cells would remain non-infected in an in vivo setting and complete tumor 
targeting would not have been achieved. The 5/3 capsid variant was the most efficient of the tested 
capsid variants; however, in order to guarantee complete tumor eradication further strategies which 
perform bystander killing have to be exploited to target the non-infectable tumor cells.  
Based on the outcome of the transduction experiments in MSCs and pancreatic cancer cell cultures 
and the previous reports in the literature, the fiber5/3 background was chosen as modification for 
improved MSCs carrier cell-mediated delivery as well as improved subsequent oncolysis. 
 
8.3. Modification of the Viral Genome – ΔE1B19K 
As explained above, oncolytic adenoviruses need to be improved in order to achieve efficient tumor 
cell killing. Beside capsid modifications for improved transduction, adenoviral genes can be modified 
to obtain improved viral replication and release behavior. Known modifications that improve viral life 
cycle kinetics in tumor cells are the deletion of the early gene E1B19K [76-78, 81], the truncation of 
the i-leader [179], the truncation of the E3B [180], and overexpression of the ADP protein [59]. The 
mechanisms of interference are different and range from interference with apoptosis pathways 
(E1B19K, E3B), to earlier release (i-leader, [181]), and increased efficiency of host cell lysis (ADP). The 
E1B19K deletion was chosen as modification for this project. In contrast to the other listed 
modifications, which just alter viral life cycle kinetics, previous studies with E1B19K-deleted 
adenoviruses in tumor cells have shown that the amount of total produced viral progeny particle [79] 
as well as the amount of viral particles released from the host cell was significantly increased [79, 
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81]. The anti-apoptotic activity of the E1B19K protein and the pro-apoptotic activity of E1A [57, 58], 
are main mediators to balance host cell maintenance. This balance between pro- and anti-apoptotic 
factors is critical. On the one hand the virus needs to spread efficiently while on the other hand 
completion of the virus life cycle and therefore viable virus progeny production needs to be ensured. 
Other virus species have evolved analogous mechanisms to control their virus life cycles, as Epstein 
Barr virus or African swine fever virus [182, 183]. The deletion of E1B19K and therefore its anti-
apoptotic function leads to a more pro-apoptotic phenotype of the virus [77, 78]. This shows in 
improved viral life cycle kinetics in tumor cells as described above. In terms of more efficient delivery 
of modified oncolytic viruses by MSCs, this modification was the most promising strategy. However, 
there was no pre-existing data about replication and release behavior of an E1B19K-deleted 
adenovirus in MSCs. 
Experiments in MSCs from three different donors revealed that replication and release was 
significantly increased (Figure 15). At day 8 post-infection, Ad-Δ19K-Luc showed a 4 to 17-fold 
increase in total virus particle production (virus in cells and supernatant) and a 14 to 72-fold increase 
in released viral particles (virus in supernatant) compared to the control virus Ad-Luc. Further, the 
increase in release (up to 72-fold) exceeded the increase in total virus particle production (up to 17-
fold) by far, which indicates that enhancement of virus replication and release were two 
complementing mechanisms.  
The virus Ad-Δ19K-Luc was analyzed before in a study presented by Rohmer et al. [81]. There, 
improved viral kinetics were shown in the lung carcinoma cell line A549. Infection with Ad-Δ19K-Luc 
resulted in an increased viral release of 14.2-fold after 2 days and 243.6-fold after 4 days compared 
to Ad-Luc. However, the produced amount of total infectious viral particle was not altered compared 
to Ad-Luc. Increased induction of apoptosis was shown responsible for enhanced virus release. In 
other studies using a different virus, the viral burst of an E1B19K-deleted Ad5 in pancreas and 
prostate cancer cell lines was investigated. Here again, no difference in viral particle production was 
observed compared to an Ad5 wild type virus 3 days post-infection, although cancer cell killing was 
improved [76, 80]. Summarizing the results of the described studies, the E1B19K-deleted viruses 
resulted in increased cell killing without altering the amount of total virus particle in cancer cells 
between day 2 to 4 post-infection. This is in contrast to the burst assay in MSCs shown in Figure 15. 
Here, an increase in total virus infectious particle production compared to Ad-Luc was observed. In 
comparable time spans (2-4 days), MSCs infected with Ad-Δ19K-Luc resulted in an increase of 
infectious viral particles of 2-fold at day 2 post-infection and 5-fold at day 4 post-infection (numbers 
are averages of experiments in the three MSC donors). The mechanism by which the viruses were 
mediating increased replication and release in MSCs, e.g. increased induction of apoptosis as 
described in Rohmer et al. [81], remained to be elucidated. 
The improved replication and release kinetics in MSCs were further remarkable, as it was reported 
that untransformed somatic cells did not show increased sensitivity to E1B19K-deleted viruses [76, 
78, 80, 148]. On the contrary, the studies even suggested that E1B19K-deleted adenoviruses showed 
an impaired phenotype and therefore could contribute to tumor-specificity of virus replication in 
untransformed cells [76, 78, 80]. Therefore, the mechanism by which E1B19K-deleted adenovirus led 
to improved viral kinetics in MSCs must be one that is differently regulated in untransfomed somatic 
cells and MSCs, but remains to be elucidated.  
The time point, where most viruses had been released into the supernatant, varied between day 3 to 
4, depending on the donor. This time presents a key information for the system, as this needs to 
correlate with the homing time of MSCs to reach the tumor. The maintenance of migration ability of 
virus-infected MSCs was later tested in a migration experiment. However, the observations suggest 
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that the ΔE1B19K modification is very efficiently improving viral replication and release in MSCs and 
is therefore benefitting the aim to optimize MSC-mediated oncolytic adenovirus delivery.  
Ad-Δ19K-Luc-GFP was tested for improved oncolytic behavior compared to Ad-Luc-GFP in established 
and low-passage pancreatic adenocarcinoma cell lines and cultures. From the 4 tested established 
pancreatic cell lines, in three no oncolytic benefit was seen during infection with Ad-Δ19K-Luc-GFP 
compared to Ad-Luc-GFP. On the contrary, the oncolytic potential was even decreased (Figure 25). 
Only in Panc-1, the ΔE1B19K virus caused an approximately 10-fold increase in killing. Following 
infection of the low-passage pancreatic cancer cell culture JoPaca-1, Ad-Δ19K-Luc-GFP and Ad-Luc-
GFP showed similar oncolytic behavior, whereas for PacaDD-159 killing was about 10-fold improved 
with Ad-Δ19K-Luc-GFP (Figure 30).  
Therefore, it had to be concluded that there was a marked cell line variability for oncolytic 
improvement by Ad-Δ19K-Luc-GFP. Similar observations were already reported before, e.g. in Öberg 
et al [80], where the cell killing efficiency of an E1B19K-deleted HAdV-5 in 7 pancreatic and prostate 
cancer cell lines was determined by EC50 assay. Three of the cell lines showed worse, four improved, 
and one unaltered oncolytic behavior compared to the control virus. The authors proposed that this 
cell line dependency was connected to intact p53 or pRb pathways. If these were intact, the deletion 
of an anti-apoptotic gene and enhancement of the action of E1A [76] could alter the virus life cycle in 
an adverse way and cause reduced production of viral particles. This is identical to the earlier 
explained possible mechanism, how the ΔE1B19K deletion led to attenuation of the virus in 
untransformed cells (also see Introduction section 5.5.3). However, this explanation was not 
applicable for the observations in this study. Enhanced replication and release was observed in MSCs, 
which are untransformed cells with intact p53 and pRb pathways. Furthermore, for the analyzed 
established pancreatic cell lines it is known that they all have different mutations in p53 [184], while 
all were reported to have wild type pRb protein  [184, 185]. However, whether other proteins in the 
pRb pathways were mutated and thus pRb signaling was inactivated, remains unknown. Other 
studies reported the activation of apoptosis pathways by caspase-3 activation analysis and Annexin-V 
staining in infected cells, which were sensitive to ΔE1B19K-mediated improved oncolysis [76, 79, 81]. 
Therefore, it seems that the complex alterations of apoptosis pathways in cancer cells influence the 
sensitivity to the ΔE1B19K mutant oncolytic adenovirus. 
While infection of MiaPaCa-2 monolayers with Ad-Δ19K-Luc-GFP did not result in improved killing, 
infection of MiaPaCa-2 spheroids resulted in increased LDH release, which indicates increased cell 
death (Figure 28). This suggests that physiological relevant results about the benefit of the virus for 
cancer cell killing can only be obtained if models are exploited which resemble the 3D-tumor 
structure and that monolayer models might be insufficient (further explained in section 8.6).  
Being aware of the cell line-dependent sensitivity to Ad-Δ19K-Luc-GFP it might be worth thinking 
about a pre-screening system for tumor cells to define the susceptibility to this virus modification 
prior to treatment, e.g. in test infections of biopsies. Further, the delivery system aims for a 
combination of optimized viral delivery by MSCs and optimized oncolysis. As this virus showed more 
efficient replication and release kinetics in MSCs compared to the other viruses, the increased 
amount of delivered viral particles could result in an overall superiority, even if tumor cell lysis is not 
improved. Further experiments, especially in animal models, are necessary to evaluate the overall 
benefit and if the cell line dependent susceptibility proves to be relevant in vivo.  
In order to further improve tumor treatment, some studies investigated if the combination of 
ΔE1B19K adenoviruses with chemotherapeutics. Leitner et al. [76] showed that a ΔE1B19K 
adenovirus in combination with gemcitabine could further potentiate tumor cell killing. Further, 
Cherubini et al [82] reported that the combination of an E1B19K deleted adenovirus with a 
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chemotherapeutic agent could sensitize previously chemotherapy-resistant cancer cell lines to 
treatment. 
 
8.4. Modifications Through Transgene Insertions 
An alternative strategy to improve tumor cell killing, besides the modification of viral genes, is the 
insertion of transgenes into the viral genome. Arming strategies have been summarized in several 
reviews [87, 99]. In this project, the TRAIL protein was investigated. Expression of TRAIL enhanced 
tumor cell killing and delivery in TRAIL-sensitive cancer cells and MSCs, respectively.  
Further, by utilizing a sheddable, diffusable TRAIL bystander killing was achieved, which mediated 
killing of non-infected tumor cells. Another strategy of bystander killing was exploited by the 
generation of a virus that expressed the prodrug-converting enzyme FCU1, for 5-FC to 5-FU 
conversion.  
 
8.4.1. The Modified TRAIL-Expressing Oncolytic Adenoviruses 
The strong stromal reaction, which is present in pancreatic tumors [84], is a diffusion barrier for the 
oncolytic adenoviruses [86, 186]. To overcome this barrier, the gene for the secretable, diffusible 
TRAIL ligand was inserted into the late viral unit. After shedding, this TRAIL protein would be able to 
diffuse and reach parts of the tumor, which are not accessible for the virus, inducing bystander killing 
[187]. TRAIL is a broadly used biotherapeutic, which was shown to kill a wide range of cancer cells 
without affecting normal cells [188]. However, the half life of a homotrimeric, soluble TRAIL in the 
serum of non-human primates was determined to be 30 minutes and therefore very short [189]. In 
order to decelerate degradation kinetics, TRAIL was modified, e.g. by oligomerization for size 
increase, which resulted in a prolonged half life [188]. In this study, the gene encoding a full-length, 
homotrimeric, sheddable TRAIL was used. The combination of an optimized TRAIL variant and the 
expression of TRAIL by an oncolytic adenovirus directly at the tumor site, aimed for an optimized 
TRAIL effect.  
 
The acquired data shows that MSCs of different donors infected with TRAIL-expressing Adenovirus, 
Ad-TRAIL, showed up to a 5-fold increase in infectious virus particle production compared to the 
control virus Ad-Luc at day 8 post-infection (Figure 15). Further, the amount of released virus was 
much enhanced and up to 17-fold increased compared to the control virus. For Ad-TRAIL infected 
cells the amount of released infectious viral particle started to be greater than the amount of cell-
bound viral particles between day 5 to 8, while for the Ad-Δ19K-Luc this was between day 3 to 4. The 
difference could be explained with the fact that ΔE1B19K is a deletion in an immediate early protein, 
which causes enhanced viral replication from the start, whereas TRAIL is expressed late, and 
therefore a TRAIL-induced effect can only emerge towards the end of the virus life cycle. The 
observed enhanced kinetics compared to Ad-Luc were not as pronounced as the effect seen with Ad-
Δ19K-Luc. Ad-Δ19K-Luc resulted in 2- to 4-fold (depending on the donor) higher infectious produced 
viral particle titers than Ad-TRAIL at day 8 post-infection.  
The observed enhancement of replication and release kinetics with Ad-TRAIL compared to Ad-Luc 
were especially remarkable, as MSCs have been reported to be TRAIL-resistant [190, 191] like other 
untransformed cells [192]. Studies showed that in normal, untransformed cells the induction of only 
the extrinsic apoptosis pathway by TRAIL is often not sufficient to induce apoptosis [89]. Even though 
it was reported that the TRAIL receptor TRAIL-R2 as well as the decoy receptor TRAIL-R4 are 
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expressed on MSCs (some donor dependencies observed), neither recombinant nor adenoviral 
expressed TRAIL could induce cytotoxicity in these studies [191]. However, the results of the burst 
assay (Figure 15) suggest that MSCs from all three donors showed TRAIL-sensitivity resulting in 
enhanced Ad-TRAIL replication and release. The enhancement mechanism of Ad-TRAIL kinetics in 
MSCs remains to be elucidated. Preliminary experiments (data not shown) suggested increased PARP 
cleavage following infection with Ad-TRAIL-GFP compared to Ad-Luc-GFP. This could indicate 
increased induction of apoptosis by TRAIL and would contradict the previous reports about TRAIL-
insensitive MSCs. However, none of the described previous studies used a TRAIL-expressing oncolytic 
adenovirus, but TRAIL protein [190] or replication-deficient, TRAIL-expressing adenoviral vectors 
[191]. Therefore, the observed difference could be due to the different set-ups. The effect of TRAIL-
mediated increase in production of infectious viral particles was shown before in cancer cell lines 
[193-196]. These studies further showed by propidium iodide staining or Caspase-3/8 cleavage assays 
that the effect was mediated through increased induction of apoptosis. Further, Dong et al. [193] 
suggested that the increase of viral progeny production could be explained with the induction of 
alternative signaling pathways like Akt, NFκB, or JNK which are connected to pro-proliferative 
activity. Further studies need to clarify whether one of these mechanisms provides the explanation 
for the TRAIL-sensitivity of MSCs used in this study. 
 
Of the analyzed four established and two low-passage pancreatic cancer cell lines, three established 
and one low-passage cell line showed increased sensitivity to Ad-TRAIL-GFP compared to the control 
virus Ad-Luc-GFP. The non-TRAIL-sensitive cell lines showed a comparable oncolytic behavior than 
the control virus and no reduced cytotoxicity as described for Ad-Δ19K-Luc-GFP was observed (Figure 
25). 
Many publications described that established pancreatic cell lines showed different sensitivities to 
TRAIL [197, 198]. Even when comparing different publications using the same cell line, the outcome 
about the TRAIL sensitivity of this cell line varied greatly [197-199]. This indicates that changes in 
TRAIL sensitivity occur in long-term cell culture as well. Differences in TRAIL sensitivity have also been 
shown in patient tumors (reviewed in [89]). However, it has to be noticed that TRAIL resistance is 
often acquired during cancer development or treatment [200]. The mechanisms by which TRAIL 
induces apoptosis are very complex. It has been reported that there are p53-dependent and  
-independent mechanisms [89]. Neither the genetic status of p53 nor the expression of the death 
receptors TRAIL-R1 and TRAIL-R2 led to reliable predictions about TRAIL sensitivity [89]. It has been 
reported for primary pancreatic adenocarcinoma tissue that TRAIL sensitivity is connected to 
upregulated NFκB signaling levels (Khanbolooki, Nawrocki et al. 2006) and about 70% of pancreatic 
tumors show upregulated levels of NFκB signaling [201]. Therefore, a range in TRAIL sensitivity in the 
experiments was expected. However, the results of this study gave strong indications that the TRAIL 
delivery in therapeutic relevant concentrations by an oncolytic adenovirus is feasible and can 
improve lysis of TRAIL-sensitive cancer cell lines. In MiaPaCa-2 spheroids the LDH release was 
significantly increased compared to Ad-Luc infected spheroids (Figure 28). This indicated that the 
killing effect of TRAIL did lead to improved bystander tumor cell killing. In vivo experiments with the 
TRAIL-expressing oncolytic adenovirus have to be performed in order to analyze tumor killing in a 
physiological environment. Further, in vivo experiments need to be performed to analyze the 
features of TRAIL to overcome the tumor stroma as diffusion barrier for the virus, which was not 
analyzed in the course of this study. 
Considering that some tumors will be resistant to TRAIL, it was shown that therapeutic efficiency by 
TRAIL can still be achieved in some cases by the addition of sensitizers, which can reverse resistance. 
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Numerous substances have been tested, such as the NFκB-inhibitor sulforaphane [202], the 
proteasome-inhibitor bortezomib [203], the Akt-inhibitor Triciribine [204], or the quercetin derivative 
LY303511 [205],  just to name a few.  
 
8.4.2. The Modified FCU1-Expressing Oncolytic Adenovirus 
Treatment with 5-FU is one of the standard chemotherapy agents used for treating pancreatic ductal 
adenocarcinoma [14]. However, the treatment often does not achieve a sufficient therapeutic effect 
[106], because of resistance to 5-FU [206, 207]. The resistance can be due to the lack of salvage 
enzymes for 5-FU, which needs to be further metabolized to its active derivatives 5-dFMP and 5-
dFUMP [103]. Further, therapeutic active concentrations of 5-FU are often not reached using 
systemic application routes. Following continuous i.v. infusion of 5-FU, the plasma levels are around 
0.5 to 0.3 µM as reported in Shi et al. [207] and references therein. This concentration is lower than 
the EC50 values for most pancreatic cancer cells [105, 207, 208] and therefore leads to an intrinsic 
resistance against 5-FU in in vivo settings. The main issue here is the short half life of 5-FU in the 
blood of only about 10 minutes [209, 210]. Further, high doses of bolus or continuous i.v. injected 5-
FU led to dose-limiting toxicity, e.g. stomatitis, ataxia, and cardiac toxicity [211]. 
These in vivo limitations have to be considered when analyzing 5-FU sensitivity in cell culture. For 
established pancreatic tumor cell lines, the EC50 values in the literature vary greatly comparing 
different publications. For example, in case of MiaPaCa-2, they reach from 15.38 µM [105] to 4.63 
µM [207] in analogous experiments measuring TCID50 3 days after 5-FU application. For the MiaPaCa-
2 cell line used in this study an EC50 of about 0.05 µM was determined after 5 days incubation (Figure 
25, 7th lane). Here, the comparably high 5-FU sensitivity is due to the longer incubation time and was 
therefore not comparable to the mentioned values from the literature. Compared to the EC50 values 
in established pancreatic cancer cell lines, the values of low-passage pancreatic adenocarcinoma 
cultures were about 10-fold higher (Figure 30, 7th lane). The values were estimated with 1 and 0.5 
µM for JoPaca-1 and PacaDD-159, respectively. Therefore, the low-passage pancreatic cell lines from 
this study would already be intrinsically resistant to 5-FU in an in vivo setting when applying 5-FU 
systemically.  
 
Resistance to 5-FU can be overcome with two strategies: i. expression of a salvage enzyme to 
potentiate the effect of 5-FU and ii. the delivery of 5-FU to the tumor site avoiding lengthy system 
circulations of 5-FU. Further, toxic side effects caused by high concentrations of systemically applied 
5-FU need to be avoided [211]. These points were approached by the development of the FCU1/5-FC 
prodrug activation system [106]. FCU1, a combination enzyme of CD (catalyzes conversion of 5-FC to 
5-FU) and the 5-FU salvage enzyme UPRT, was first developed as a transgene for adenoviral vectors 
[106]. The idea was that an FCU1-encoding virus is injected intra-tumorally or targeted to the tumor 
site after systemic injection, transduces the tumor cells and locally expresses FCU1. The prodrug 5-FC 
is then applied systemically and becomes at the tumor site, where FCU1 is expressed, converted into 
5-FU and further to its active metabolites. 5-FC has compared to 5-FU a prolonged half life of 3-4 
hours [212]. 5-FC was reported to have relatively minor side effects, however, hepatotoxicity can 
occur through an unknown mechanism for concentrations >100 mg/l [212]. Through this strategy, 
higher concentrations of 5-FU can be reached at the tumor site compared to systemic 5-FU 
administration and therefore the therapeutic efficiency is increased. Compared to other prodrug 
systems as HSV-TK/Ganciclovir [213, 214], where direct cell-cell-contacts are necessary to mediate 
bystander killing, the membrane-diffusible 5-FU is better suited for tumors with strong stromal 
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reaction, where tumor parts might be separated by wide stretches of connective tissue, as it is the 
case in pancreatic tumors [100, 106]. 
In the delivery system in this project, the specific transfer of oncolytic adenoviruses by MSCs to the 
tumor site ensures the expression of FCU1 in proximity of the tumor. The systemic application of the 
prodrug 5-FC can then be timed in a way, that the conversion is initiated after the virus has been 
delivered to the tumor site. In this way, the toxic compound 5-FU is not present in the system during 
MSC infection and homing. Consequently, there is also no interference of 5-FU with virus replications 
and release in MSCs. Therefore, analysis of replication and release of Ad-FCU1-GFP in MSCs was not 
included in the studies, as it is expected to behave like the control virus Ad-Luc-GFP.  
In in vitro cytotoxicity experiments in established (Figure 25) and low-passage (Figure 30) pancreatic 
cancer cells, the conversion of 5-FC by the FCU1 expressing virus Ad-FCU1-GFP led to improved lysis 
in three out of the four investigated established cell lines. In case of the low-passage PacaDD-159 
culture, an improved killing was seen, in JoPaca-1 not. This indicates that the conversion of 5-FC by 
FCU1 was feasible in therapeutically relevant amounts and led to improved tumor cell killing in a 
subset of the tested cell lines and cultures. In case of BxPc-3 and AsPc-1, infection with as little as 0.1 
TCID50/cell was sufficient to express FCU1 in relevant amounts to convert 5-FC into 5-FU and cause a 
bystander killing effect. 
Similar observations have been previously described in experiments with the first adenovirus 
expressing FCU1 (replication-deficient, described in Erbs et al. [106]). The authors showed that a 
relative small amount of initially infected cells (10-20%) are sufficient to eventually observe 
cytotoxicity in the entire tumor cell population. Dias et al. [107] was the first study, which used an 
oncolytic FCU1-expressing adenovirus. Here, the amount of FCU1 was greatly increased compared to 
FCU1-expression by a replication-deficient adenoviral vector. However, it was noticed that high levels 
of 5-FU and its toxic products inhibited virus replication. Experiments analyzing inhibition of viral 
replication by 5-FU have not been performed in the course of the present study, but have to be kept 
in mind in order to assure efficient virus replication and oncolysis of the tumor cells. 
As already mentioned, the enzyme FCU1 does not only have CD activity to convert 5-FC into 5-FU, 
but also UPRT activity to convert 5-FU into its active metabolites. One study revealed that the 
sensitivity of pancreatic cancer cell lines to 5-FU can be greatly increased by co-treatment with a 
replication-deficient, UPRT-expressing adenovirus [105]. The increase in 5-FU sensitivity was 7.1-fold 
in MiaPaCa-2, and 20-fold in BxPc-3, proving the suitability of this salvage enzyme. Further, they 
showed significantly reduced tumor growth of pancreatic tumors in mice after treatment with the 
UPRT-expressing adenovirus and 5-FU compared to 5-FU alone. In the experiments during this thesis, 
the effects of the CD and UPRT activity were not distinguished from each other; however, both 
enzyme activities can be expected to have contributed to the improved killing by bystander effects. 
No FCU1-expressing adenovirus has entered a clinical trial yet. However, in one clinical trial the effect 
of the E1B55K-deleted oncolytic virus ONYX-015 alone or in combination with gemcitabine or 5-FU 
was tested in SCHNC (squamous cell head and neck cancer) [110]. The combination treatment 
resulted in superior outcome compared to chemotherapy treatment alone, which proved the 
potential of this combination. 
 
Overall, experiments with the modified viruses gave indications of improved killing of a subgroup of 
pancreatic cancer cells. It would be helpful to established pre-treatment personal screenings to 
analyze resistance and susceptibility prior to treatment start [215, 216]. This could be possible 
through test-treatment of tumor biopsies ex vivo prior to treatment [215] or the identifications of 
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markers, e.g. of 5-FU metabolizing enzymes in tumor biopsies for the prediction of chemosensitivity 
[216]. 
In order to further improve the viral agent, it could also be feasible to combine the analyzed 
modifications, namely to combine the E1B19K deletion, TRAIL insertion, or the expression of FCU1. 
Replication and release experiments in MSCs, homing, and cytotoxicity experiments would clarify, if 
an additional therapeutic effect could be achieved.  
 
8.5. Migration of Virus-Infected MSCs 
In order to verify delivery feasibility, it was important to show that infection of MSCs with the control 
virus or one of the modified viruses did not interfere with migration behavior of MSCs. Especially the 
observed improved release kinetics of Ad-Δ19K-Luc and Ad-TRAIL from MSCs needed to be 
compatible with the time the MSCs needed to reach the tumor site. Premature virus release, before 
the MSCs have reached the tumor, as well as inhibition of the migratory abilities of MSCs would 
make the delivery system useless.  
The maintenance of migration capacity of MSCs was shown in vitro in a transwell migration assay 
(Figure 24). The number of migrated cells of infected MSCs was compared to the number of cells of 
non-infected MSCs and showed the retaining of migration behavior for all virus variants. The chosen 
migration time of 40 hours corresponded to the time reported in the literature, for MSCs to home to 
tumors in an in vivo setting [142-144]. These studies tested the delivery of oncolytic adenovirus-
infected MSCs to different tumors and via different application routes in mice. Yong et al. [144] 
described the delivery of the virus (E1AΔ24, fiber5RGD) to intracranial glioma following carotid artery 
injection. Within one hour, the GFP-expressing virus-loaded MSCs were located to the tumor vessels, 
until day 2 they found GFP clusters in the tumor, and dispersion of the GFP signal was seen at day 3. 
In Xia et al. [143] following i.v. injection of virus-loaded MSCs, the MSCs were localized at the tumor 
periphery (breast cancer tumors in the mammary fat pad) 24 hours post-injection, and in the tumor 
parenchyma 72 hours post-injection. Komarova et al. [142] described the delivery of an adenoviral 
vector, which expressed luciferase as well as a tumor-targeting receptor. Homing was monitored 
following i.p. injection of transduced MSCs into mice with i.p. ovarian cancer xenografts. Here, the 
tumors were the major target and luciferase intensity had its maximum after 24 hours post-infection, 
allowing the conclusion that the virus-loaded MSCs had reached the tumor site after this time. From 
these studies can be concluded that the virus reached the tumor most likely within 2 days. Therefore, 
the virus release kinetic from MSCs (Figure 15), which revealed that the majority of viral particles 
were found in the supernatant 3-4 and 4- 8 days post-infection for Ad-Δ19K-Luc and Ad-TRAIL, 
respectively, are in accordance with the time MSCs need to migrate to the tumor site.  
Furthermore, the performed migration assay showed that migration behavior was not altered by the 
virus genome modifications. Other studies have investigated MSCs as delivery cells for adenoviruses 
and have performed similar experiments. Sonabend et al. [125] reported that MSCs infected with a 
replication competent oncolytic adenoviruses (tissue-specific CXCR4-promoter driven E1A) showed 
unaltered migration for 19 hours towards 10% FBS. Further, Treacy et al. [145] mentioned that the 
migration is not altered when MSCs are infected with a replication-deficient adenovirus expressing 
GFP. Oncolytic adenoviruses with modifications that enhance the viral replications and release 
kinetics have not been tested in terms of delivery by MSCs before.  
Worth mentioning is a study performed by Secchiero et al. [191], which analyzed migration of MSCs 
towards different stimuli. They found that migration of MSCs can be promoted by TRAIL-containing 
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medium in a transwell assay. They determined 100 pg/ml as the optimal TRAIL concentration. No 
improved migration with the Ad-TRAIL-GFP virus in the performed transwell migration assay was 
observed in Figure 24. This could be due to the difference of a steady medium gradient versus 
intrinsic TRAIL expression late in the viral life cycle, whose onset is not early enough to affect 
migration. However, it might be interesting to see in an in vivo setting if differences can be observed 
in terms of homing of Ad-TRAIL-GFP-infected MSCs or in tumor engraftment efficiency.  
From the obtained data it can be concluded that virus-infected MSCs maintained their migration 
independent from the genetic alterations they were carrying. It now remains to be elucidated if the 
tumor homing capacity can also be preserved in an in vivo situation, which has not been done in the 
course of this study. All of the viruses carry GFP, which intended to simplify monitoring and to allow 
the identification of virus-infected cells within tissues in further studies.  
For in vivo delivery studies, considerations have to be taken in terms of the application route. All the 
examples given above avoid systemic application that involves the pulmonary circulation. As MSCs 
are very big cells with a diameter of about 20 µm, it has been reported that they are prone to be 
trapped in capillary systems, which have a smaller diameter [217-219]. Therefore, the most 
reasonable and shortest application route should be chosen in order to avoid unspecific loss of MSCs. 
In terms of treatment of pancreatic cancer, this route could be i.p. or into suitable blood vessels in 
proximity to the tumor site.  
 
8.6. Modified Virus Infection of Spheroids 
The infection of MiaPaCa-2 spheroids with the modified oncolytic viruses resulted in altered spheroid 
shape and size and higher LDH release in case of the Ad-Δ19K-Luc-GFP and Ad-TRAIL-GFP-infected 
spheroids compared to Ad-Luc-GFP-infected spheroid controls.  
For the spheroid experiments, 5,000 MiaPaCa-2 cells were seeded, which formed spheroids with a 
diameter of about 1.5 mm. In case of the uninfected spheroids, the size increased to a diameter of 
about 2.4 mm within 8 days, indicating that cell proliferation was continuing during the time the 
spheroids were monitored. Spheroid model studies reported that spheroids of that size have a 
layered structure, composed of a necrotic core, a middle layer of quiescent cells, and a proliferating 
outside layer [158]. In diffusion studies it was shown that the limit of molecules (especially oxygen) is 
about 150-200 µm [220], which leads to nutrients depletion as well as accumulation of toxic residues 
in the core of the spheroid [221]. This situation closely resembles the avascular stages of early 
tumors [222]. Beside the tumor-mimicking 3D architecture they were also shown to have more 
physiological cell-cell-contacts than monolayer cultures as well as altered intercellular signaling, 
which were both shown to influence responses to drugs (reviewed in [158]). Further, several primary 
tumor cells cultured as spheroids showed increased chemotherapeutic resistance, invasiveness, and 
migration potential, indicating an enrichment in cancer stem cells [157, 223]. The same was observed 
in pancreatic tumor cell line spheroids [157]. Therefore, this model was very well suited to mimic 
viral spread of the oncolytic viruses in an in vivo situation and further gave an indication if cancer 
stem cell-targeting can be achieved. Because of the described differences between spheroid and 
monolayer cultures, it was not necessarily expected that oncolytic viruses behave the same in 
monolayers and spheroid preparations of the same cell line. This proved true for Ad-Δ19K-Luc-GFP. 
The virus did not improve oncolysis in MiaPaCa-2 monolayers (Figure 25), but showed an effect in 
MiaPaCa-2 spheroids (Figure 26). Importantly, the differences observed between spheroid and 
Discussion 74 
 
monolayer infection showed that further in vivo experiments need to clarify if the reduced oncolysis 
of ΔE1B19K deleted viruses seen in monolayers is a physiologic relevant issue. 
Images in Figure 26 show the progression of spheroid infection via GFP monitoring. It was observed 
that the virus infection started at the rim and slowly progressed to the inside, but spared the core 
area, which might be explained with an already necrotic core. By visually assessing the spheroid 
development over 8 days during virus infection, the following observations were made in comparison 
to the uninfected control: i. a smaller spheroid size of Ad-TRAIL-GFP-infected spheroids; ii. the 
disintegration of the spheroids following infection with Ad-Δ19K-Luc-GFP and Ad-TRAIL-GFP, which 
was most apparent in the diffuse rim areas; iii none of these effects were observed for spheroids 
infected with Ad-Luc-GFP and Ad-FCU1-GFP. The reduction in size following virus infection with Ad-
TRAIL-GFP-infected spheroids (Figure 27) was described before by Lam et al. [224] and was there 
attributed to viral replication and induced oncolysis. Oncolysis could also be suspected to cause the 
diffuse rim areas. Observations of disintegration were reported before for primary tumor spheroids 
treated with chemotherapeutics [202], as well as for treatment with oncolytic viruses [225]. The 
hypothesis that Ad-Δ19K-Luc-GFP and Ad-TRAIL-GFP infection led to increased spheroid lysis 
compared to the control virus Ad-Luc-GFP was further proven in an LDH assay (Figure 28). The 
observations indicate improved viral lysis due to the E1B19K-deletion for Ad-Δ19K-Luc-GFP and 
bystander killing through TRAIL-expression by Ad-TRAIL-GFP.  
An observation that was made during the LDH assay was a pronounced difference between the 
spheroid preparations (Figure 28). In case of spheroid preparation 1, the background LDH levels and 
therefore the percentage of dead cells were already high, which indicated advanced necrosis of 
spheroid cells independent of infection. The second preparation had much lower background LDH 
levels. It had been reported that size uniformity and a high level of equal conditioning of spheroids is 
very important, but also very difficult to accomplish [158]. Both greatly affects spheroid structure 
and therefore drug penetration [158]. Though there were no intentional differences in handling 
between the preparations, the difference in the spheroid viability occurred, confirming the 
importance of completely identical culture conditions of spheroids. Although the background levels 
of dead cells were different between the preparations, the absolute differences of the percentage of 
dead cells between mock and e.g. Ad-Δ19K-Luc-GFP were similar (experiment 1: 18%, experiment 2: 
23%). This proves that improved LDH release was due to virus effects and not a to the different 
spheroid preparations qualities. 
The observation that spheroid infection with Ad-Δ19K-Luc-GFP and Ad-TRAIL-GFP led to much higher 
LDH release and more pronounced physiological changes than infection with Ad-Luc-GFP and Ad-
FCU1-GFP, allowed the conclusion that viral gene modification and arming are necessary strategies to 
achieve efficient oncolysis [100]. Taken in account that MiaPaCa-2 are considered to have stem cell-
like features and further, cancer stem cells become enriched when cell lines are grown as spheroids, 
this would also allow to assume that the two viruses can target the tumor stem cell population. 
However, experiments in vivo have to finally clarify the physiologic oncolytic potential. 
 
8.7. Ideas for Further Optimization  
8.7.1. Improving Migration 
Knowing the mediators of MSC migration to tumors, it is reasonable to consider improvement of 
tumor homing and therefore delivery of oncolytic viruses by MSCs. MSCs are known to express a 
variety of growth hormones, chemokines, cytokines, and innate immune receptors [128]. They sense 
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the corresponding ligands, which are released by tumors and tumor microenvironments, and induce 
migration of MSCs along these gradients. 
One option could be the pre-treatment of ex vivo cultured MSCs with growth-factors prior to virus 
infection and systemic application. It was shown in several publications, that pre-incubation with 
different cytokines and growth factors, like IGF-1, EGF, SDF-1, or TNF-α, significantly enhanced 
migration in vitro [226, 227]. After MSCs were exposed to these stimuli, the corresponding receptors 
were up-regulated and further promoted migration [228].  
An increase in released stimulating growth factors and cytokines was achieved by prior irradiation of 
the tumor, which then improved MSC migration in vitro [229] and in mouse models [229-231]. 
Alternatively, MSCs can be genetically modified in order to overexpress certain chemokine or growth 
factor receptors to make them more sensitive [128].  
 
8.7.2. Improving Safety 
The homing properties of MSCs were widely investigated [128]. What is not so well understood is the 
role of MSCs once they have engrafted in the tumor stroma. In their normal physiological role of 
tissue repair, they start to differentiate and produce stimulating factor, like growth factors and 
cytokines [232], once they located to wounded tissue. 
In terms of engraftment into tumor stroma, these effects can be different. The factors, which are 
produced by MSCs (e.g. growth factors) have been connected to cancer progression. The 
differentiation to endothelial-like, fibroblast-like, or perivascular-like cells, which actively form blood 
vessels, suggests that they are precursor population of tumor-associated fibroblasts, endothelial 
cells, and pericytes [233]. 
Some studies claimed to have shown that MSCs can also be pro-tumorigenic because of their pro-
angiogenic, immune-suppressive and tumor promoting properties [130, 232]. This has been shown in 
several mouse models studies. Subcutaneous co-injection of murine MSCs with murine melanoma 
cells resulted in enhanced tumor growth compared to injection of tumor cells alone [234]. In another 
study, human MSCs were co-injected with human breast cancer cells subcutaneously into 
immunocompromised mice. There, MSCs promoted metastasizing without affecting primary tumor 
size [235]. MSCs were even suspected to have tumor-initiating potential [236]. 
Other studies presented data that strongly supported the hypothesis that MSCs have solely anti-
tumorigenic outcome. MSCs were tested in a mouse model using s.c. or i.p. injection alone or in co-
injection with human ovarian tumor cells. Here, neither tumor-initiation, nor tumor-promotion, nor 
adverse side effects (e.g. ascites, weight loss) caused by MSCs were observed [237]. Similar outcomes 
were also shown for several other tumor entities (reviewed in [232]). Kidd et al. [232] suggested that 
the pro-tumorigenic effect of MSCs was an artefact, as all studies, which have seen tumor or 
metastasis promotion, used a large excess of MSCs in relation to the tumor mass, which does not 
represent a physiological situation. All studies that have used lower amounts of MSCs did not see a 
tumor-promoting effect. However, the effect is not fully explained. 
Studies that tested MSCs as carrier cells for oncolytic adenoviruses never reported tumor increase or 
initiation in MSC-only controls or adenovirus-infected MSCs, though they did no experiments to 
explicitly rule out pro-tumorigenic behavior of the MSCs [124, 126, 141, 143, 144]. It is expected that 
MSCs infected with oncolytic adenoviruses will not survive longer than the end of the first viral life 
cycle. However, due to incomplete transduction, some non-infected MSCs might be systemically 
applied as well. This was also considered in a an exploratory clinical trial described in Garcia-Castro et 
al. [147], where oncolytic adenovirus-delivery by MSCs was investigated in children with 
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neuroblastoma. Here, MSCs were γ-irradiation with 30 Gy prior to infection and i.v. administration. 
Importantly, the study reported that irradiation of MSCs had no effect on infectibility with the virus, 
virus-replication in MSCs, or migration behavior of infected MSCs [147]. Therefore, irradiation of 
MSCs is a valid precaution method to contribute to improved safety while leaving the efficiency of 
the system unaltered.  
 
8.8. Conclusion and Outlook 
Summarizing this thesis, modifications of oncolytic adenoviruses, which were originally developed to 
improve killing of tumor cells, can efficiently increase virus replication and release from MSC carriers. 
The deletion of the E1B19K gene and the expression of the human TRAIL protein by an oncolytic 
adenovirus showed improved kinetics in MSCs of different donors, as well as improved killing in a 
subset of pancreatic cancer cell lines and low-passage pancreatic cultures. Further it was shown that 
tumor cell killing was improved by an oncolytic virus engineered to express the prodrug converting 
enzyme FCU1 after 5-FC addition. 
Experiments in a transwell migration assay gave a first indication that infection of MSCs with the 
modified viruses did not alter MSC migration behavior for 2 days post-infection, the time reported in 
the literature MSCs need for tumor homing in vivo. Therefore, the reported oncolytic adenoviruses 
Ad-Δ19K-Luc-GFP, Ad-TRAIL-GFP, and Ad-FCU1-GFP have the potential to improve MSCs carrier cell-
mediated virotherapy of pancreatic cancer. In vivo homing studies of MSCs loaded with the modified 
viruses to pancreatic ductal adenocarcinoma xenografts need to be performed in animals to verify 
the efficiency of the MSC delivery system. 
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9. Materials  
9.1. Cell Culture 
Name Supplier 
1,5-Dimethyl-1,5-diazaundecamethylene 
polymethobromide, hexadimethrine bromide 
(Polybrene) 
Sigma-Aldrich, Taufkirchen 
2-mercaptoethanol Sigma-Aldrich, Taufkirchen 
5-Fluorocytosine (5-FC) Sigma-Aldrich, Taufkirchen 
5-Fluorouracile (5-FU) Sigma-Aldrich, Taufkirchen 
Adenosine 5′-monophosphate disodium salt 
(AMP)  
Sigma-Aldrich, Taufkirchen  
 
Adenosine 5′-triphosphate disodium salt hydrate 
(ATP)  
Sigma-Aldrich, Taufkirchen  
 
Agarose Invitrogen, Karlsruhe 
Ammonium persulfate (APS) Sigma-Aldrich, Taufkirchen 
Ampicillin (Amp) Carl Roth, Karlsruhe 
Arabinosyl cytosine (AraC) Sigma-Aldrich, Taufkirchen 
Bactotryptone Carl Roth, Karlsruhe 
Bio-Rad DC Protein Assay Bio-Rad, Munich 
Bromophenol blue AppliChem, Darmstadt 
Caesium chloride (CsCl) AppliChem, Darmstadt 
Cell lysis buffer Promega, Madison, WI 
Crystal violet Carl Roth, Karlsruhe 
CytoSelect™ 24-Well Cell Migration Assay Cell Biolabs, San Diego, CA 
Detection Reagent 1 & 2 Thermo Fisher Scientific, Schwerte 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich, Taufkirchen 
Disposable PD-10 Desalting Columns GE Healthcare, Little Chalfont, UK 
Dithiothreitol (DTT) AppliChem, Darmstadt 
Dulbecco’s modified Eagles medium (DMEM 
GlutaMAXTM) 
Gibco, Life Technologies, Darmstadt 
Ethanol absolute (EtOH) VWR International, Bruchsal 
Ethidium bromide AppliChem, Darmstadt 
Ethylendiaminetetraacetic acid (EDTA) Sigma-Aldrich, Taufkirchen 
Ethylene glycol tetraacetic acid (EGTA)  Sigma-Aldrich, Taufkirchen  
Fetal bovine serum (FBS) PAA, Pasching 
Formaldehyde, 37 % Merck, Darmstadt 
GeneRulerTM 1 kb DNA ladder Fermentas, St. Leon-Rot 
Gentamycin Invitrogen, Karlsruhe 
Glucose AppliChem, Darmstadt 
Glycerol Carl Roth, Karlsruhe 
HEPES Gibco, Life Technolgies, Darmstadt 
Hoechst 33258 Invitrogen, Karlsruhe 
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Name Supplier 
IGEPAL NP-40 Sigma-Aldrich, Taufkirchen 
Isocove’s modified Dulbecco’s medium (IMDM) Gibco, Life Technologies, Darmstadt 
Isopropanol VWR International, Bruchsal 
Kanamycin (Kan) Sigma-Aldrich, Taufkirchen 
KSF medium (Keratinocyte SF medium) Gibco, Life Technologies, Darmstadt 
LB agar „Luria Miller“ Carl Roth, Karlsruhe 
Lipofectamine Reagent Invitrogen, Karlsruhe 
Lithium chloride (LiCl) Carl Roth, Karlsruhe 
Luciferin PJK GmbH, Kleinblittersdorf  
Luria Bertani medium “Lennox” (LB) Carl Roth, Karlsruhe 
Magnesium chloride (MgCl2) Carl Roth, Karlsruhe 
Magnesium sulfate (MgSO4) Carl Roth, Karluhe 
Methanol  VWR International, Bruchsal 
Modified Eagle’s minimum essential medium 
(OptiMEM) 
Gibco, Life Technologies, Darmstadt 
N,N,N’,N’-tetra-methylethylenediamine 
(TEMED) 
Sigma-Aldrich, Taufkirchen 
Nonhematopoietic stem cell expansion medium 
(NH medium) 
Miltenyi Biotec, Bergisch Gladbach 
PageRulerTM Prestained Protein Ladder Fermentas, St. Leon-Rot 
Penicillin Invitrogen, Karlsruhe 
Penicillin/Streptomycin  Gibco, Life Technolgies, Darmstadt 
Phenylmethylsulfonyl fluoride (PMSF) AppliChem, Darmstadt 
Phosphate buffered saline (PBS) Gibco, Life Technolgies, Darmstadt 
PKH26 Red Fluorescent Cell Linker Kit  Sigma-Aldrich, Taufkirchen 
Potassium chloride (KCl) Sigma-Aldrich, Taufkirchen 
Roswell Park Memorial Institute medium (RPMI-
1640) 
Gibco, Life Technologies, Darmstadt 
Rotiophorese Gel 30 Carl Roth, Karlsruhe 
Skim milk powder Carl Roth, Karlsruhe 
Sodium acetate Sigma-Aldrich, Taufkirchen 
Sodium chloride (NaCl) Carl Roth, Karlsruhe 
Sodium deoxycholate BD Biosciences, Heidelberg 
Sodium dodecyl sulfate (SDS) Sigma-Aldrich, Taufkirchen 
Sodium fluoride Sigma-Aldrich, Taufkirchen 
Sodium orthovanadate Sigma-Aldrich, Taufkirchen 
Super Killer TRAIL Axxora, Farmingdale, NY 
Triton X-100 Carl Roth, Karlsruhe 
Trizma base (tris) Sigma-Aldrich, Taufkirchen 
Trizma hydrochloride (tris-HCl) Sigma-Aldrich, Taufkirchen 
Trypan Blue Solution Sigma-Aldrich, Taufkirchen 
Trypsin-EDTA, 0.05 % Gibco, Life Technolgies, Darmstadt 
Tween 20 Sigma-Aldrich, Taufkirchen 
Yeast extract Carl Roth, Karlsruhe 
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9.2. Buffers  
9.2.1. Nucleic Acid and Agarose Gel 
Name Ingredients 
50x TAE buffer 2 M tris 
1M sodium acetate 
62.5 mM EDTA 
pH 8.5 
10x DNA loading buffer 0.1 % (w/v) bromophenol blue 
50 % (v/v) glycerol 
0.1 M EDTA 
0.2 pH 8.0 
Agarose gel solution 1 x TAE buffer 
1-2 % (w/v) agarose 
1 µg/ml ethidium bromide 
 
9.2.2. Acrylamide Gel 
Name Ingredients 
4x protein loading dye 200 mM tris-HCl  
400 mM dithiothreitol 
8 % (w/v) SDS 
0.4 % (w/v) bromophenol blue 
40 % glycerol 
10 % (w/v) 2-mercaptoethanol 
pH 6.8 
RIPA buffer 10 mM tris-HCl 
150 mM NaCl 
1 % (v/v) IGEPAL NP-40 
1 % (w/v) sodium deoxycholate 
0.1 % (w/v) SDS 
1 mM PMSF 
20 mM sodium fluoride 
2 mM sodium orthovanadate 
pH 7.5 
4x seperating buffer 1.5 mM tris-HCl 
0.04 % (w/v) SDS 
pH 8.8 
4x stacking buffer 0.5 M tris-HCl 
0.4 % (w/v) SDS 
pH 6.8 
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Name Ingredients 
12.5% seperating gel 3 ml bi-distilled water 
2.25 µl 4 x seperating buffer 
3.75 Rotiophorese Gel 30 
60 µl 10 % (w/v) APS 
12.5 µl TEMED 
4% stacking gel 5.15 ml bi-distilled water 
2.1 ml 4 x stacking buffer 
1.1 ml Rotiophorese Gel 30 
60 µl 10 % (w/v) APS 
17.5 µl TEMED 
10x running buffer 2 M glycine 
250 mM tris 
1 % (w/v) SDS 
 
9.2.3. Western Blot 
Name Ingredients 
10x TBS 250 mM tris-HCl 
1.5 M NaCl 
pH 7.4 
1x transfer buffer 25 mM tris 
192 mM glycerol 
20% (v/v) methanol 
Western blot blocking solution  1x TBS 
0.3 % (v/v) Tween 20 
5 % skim milk powder 
Western blot washing buffer  1x TBS 
0.3 % (v/v) Tween 20 
 
9.3. Virus Purification and Viral Particle Determination 
Name Ingredients 
Caesium chloride solution (1.27 g/cm3) 500 ml bi-distilled water 
227.2 g caesium chloride 
pH 7.8 
Caesium chloride solution (1.41 g/cm3) 500 ml bi-distilled water 
304.6 g caesium chloride 
pH 7.8 
TE buffer 0.1 % SDS 
1mM EDTA 
10 mM tris-HCl 
pH 7.4 
Virus lysis buffer 100 µM TE-buffer 
0.5 % (w/v) SDS 
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9.4.  Others 
Name Ingredients 
Crystal violet staining solution 70 % (v/v) ethanol 
2 % (w/v) crystal violet 
Hoechst 33258 staining solution 1:2000 in PBS 
Triton X-100 permeabilization solution 0.5 % (v/v) in bi-distilled water 
Formaldehyde fixation solution 4 % (v/v) in bi-distilled water 
Luciferase assay substrate 1 M tris-HCl (pH 7.8) 
0.25 M EGTA (pH 8.3) 
200 mM ATP 
100 mM DTT 
1 M MgSO4 
200 mM AMP 
10 mM luciferin 
 
9.5. Bacterial Strains 
Name Description 
Escherichia coli BJ5183 Genotype: endA1, sbcBC, recBC, galK, met, thi-1, 
bioT, hsdR (Stratagene, Amsterdam). 
Escherichia coli XL-1 blue Genotype: recA1 endA1 gyrA96 thi-1 hsdR17 
supE44 relA1 lac [F´ proAB lacIqZΔM15 Tn10 
(Tetr)]  
 
9.6. Cell Lines 
Name Description Culture Medium Source 
HEK 293 Human embryonic kidney 
cells  
DMEM/5% G. Fey (Erlangen, 
Germany)  
A549 Human lung 
adenocarcinoma 
epithelial cell line  
DMEM/5% ATCC (Manassas, USA)  
C8161 Human melanoma cell 
line 
DMEM/5% [238] 
MiaPaCa-2 Human pancreatic 
adenocarcinoma cell line 
DMEM/5% AG Herr, University 
Heidelberg 
BxPc-3 Human pancreatic 
adenocarcinoma cell line 
DMEM/5% AG Herr, University 
Heidelberg 
Panc-1 Human pancreatic 
adenocarcinoma cell line 
RPMI/5% C. Cziepluch, DKFZ 
Heidelberg 
AsPc-1 Human pancreatic 
adenocarcinoma cell line 
RPMI/5% C. Cziepluch, DKFZ 
Heidelberg 
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Name Description Culture Medium Source 
JoPaca-1 Low-passage human 
ductal adenocarcinoma 
cell line 
IMDM/10% J. Hoheisel, DFKZ 
Heidelberg 
PaCaDD-159 Low-passage human 
ductal adenocarcinoma 
cell line 
PacaDD medium C. Pilarsky, TU 
Dresden 
MSC different donors Primary cells NH medium University Hospital 
Heidelberg 
 
9.7. Media 
Name Ingredients 
LB medium 25 g/l LB powder dissolved in bi-distilled water, 
sterile 
Containing either 1 mg/ml ampicillin or 50 µg/ml 
kanamycin 
LB agar 15 g/l LB agar „Luria Miller“ dissolved 
in  LB medium containing antibiotics 
SOC medium 2% bactotryptone pH 7.0  
0.5% yeast extract  
10mM NaCl  
2.5mM KCl  
10mM MgSO4 
10mM MgCl2 
20mM glucose 
DMEM/2% DMEM GlutaMAXTM (already supplemented with 
4500 mg/L glucose, 25mM HEPES, sodium 
bicarbonate, and L-Ala-L-Gln) 
2% FBS 
100 U/ml penicillin 
100 µg/ml streptomycin 
DMEM/5% DMEM GlutaMAXTM  
10% FBS 
100 U/ml penicillin 
100 µg/ml streptomycin 
RPMI/2% RPMI-1640 medium (already supplemented 
with L-glutamine and sodium bicarbonate) 
2% FBS 
100 U/ml penicillin 
100 µg/ml streptomycin 
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Name Ingredients 
RPMI/5% RPMI-1640 medium  
5% FBS 
100 U/ml penicillin 
100 µg/ml streptomycin 
IMDM/2% IMDM medium (already supplemented with L-
glutamine) 
2% FBS 
100 U/ml penicillin 
100 µg/ml streptomycin 
IMDM/10% IMDM medium (already supplemented with L-
glutamine) 
10% FBS 
100 U/ml penicillin 
100 µg/ml streptomycin 
PacaDD medium Ration 2:1 of DMEM GlutaMAXTM supplemented 
with 20% FBS and KSF medium 
100 U/ml penicillin 
2.5 mg/ml gentamycin 
 
9.8. Plasmids  
Name Description Origin 
pGL3-BPSA-Luc pGL3-basic containing the human beta globin splice 
acceptor sequence (BPSA), the firefly luciferase 
gene (Luc), and a polyA sequence 
Quirin et al. [93] 
 
pSΔ24  adenovirus transfer vector which contains a 
mutant E1A gene with a 24 bp deletion of 
nucleotides 923 – 946 corresponding to amino 
acids LTCHEAGF of E1A to prevent binding and 
inactivation of pRB 
Suzuki et al., 2002 [161] 
 
pSΔ24-GFP adenovirus transfer vector which contains a 
mutant E1A gene with a 24 bp deletion, and a GFP 
gene introduced via an splice acceptor site 
downstream of the E4 gene 
See section 7.8.2 
pSΔ24-E1B19K-   adenovirus transfer vector which contains a 
mutant E1A gene with a 24 bp deletion, the 
E1B19K deletion was derived by PCR with 
oligonucleotides 19K-5′ (5′-CGA GGA CTT GCT TAA 
CGA GC-3′) and 19K-3′ (5′-GGA CGG AAG ACA ACA 
GTA GC-3′) from Ad337 
Rohmer et al. [81] 
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Name Description Origin 
pSΔ24-ΔE1B19K-
GFP   
adenovirus transfer vector which contains a 
mutant E1A gene with a 24 bp deletion, the 
deletion of E1B19K, and the GFP gene introduced 
downstream of E4 via a splice acceptor site  
See section 7.8.4 
pGL3-IRES-Luc pGL3-basic containing an internal ribosomal entry 
site, the firefly luciferase gene (Luc), and a polyA 
sequence  
[93] 
pGL3-IRES-TRAIL pGL3-basic containing an internal ribosomal entry 
site, the full-length TRAIL gene, and a polyA 
sequence 
See section 7.8.5 
pfiber5/3 ΔE3 
IRES Luc 
adenovirus transfer vector containing a chimeric 
5/3 fiber, the full-length firefly luciferase gene (Luc) 
inserted via an internal ribosomal entry site 
downstream of the fiber, and the deletion of the 
E3 gene 
Generated in the 
Nettelbeck lab 
pfiber5/3 ΔE3 
IRES TRAIL 
adenovirus transfer vector containing a chimeric 
5/3 fiber, the full-length TRAIL gene inserted via an 
internal ribosomal entry site downstream of the 
fiber, and the deletion of the E3 gene 
See section 7.8.5 
pVK500 5/3 ΔE3 
IL  
plasmid containing the HAdV-5 genome with a 
chimeric 5/3 fiber, the deleted E3 region and the 
firefly luciferase gene (Luc) inserted via an internal 
ribosomal entry site downstream of the fiber 
[81] 
pVK500 5/3 ΔE3 plasmid containing the HAdV-5 genome with a 
chimeric 5/3 fiber and a deleted E3 region 
Generated in the 
Nettelbeck lab 
pVK500 Δ24 plasmid containing the HAdV-5 genome with 
partial deletion of the fiber gene, a 24 bp deletion 
in the E1A region  
Generated in the 
Nettelbeck lab 
pVK500 5/3 Δ24 
IRES FCU1 
plasmid containing the HAdV-5 genome with a 
chimeric 5/3 fiber, with partial deletion of the fiber 
gene, a 24 bp deletion in the E1A region, and 
inserted FCU1 via an internal ribosomal entry site 
Generated in the 
Nettelbeck lab 
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9.9. Viruses 
Name Description Origin 
Ad5 Replication-deficient hAdV-5, ΔE1, ΔE3, luciferase 
gene under CMV promoter control 
[67] 
Ad5/3 Replication-deficient hAdV-5, ΔE1, ΔE3, modified 
fiber hAdV-5 fiber and hAdV-3 knob, luciferase 
gene under CMV promoter control 
[67] 
Ad5RGD Replication-deficient hAdV-5, ΔE1, ΔE3, modified 
fiber RGD peptide introduced into HI-loop, 
luciferase gene under CMV promoter control 
(Dmitriev, Krasnykh et al. 
1998) 
Ad-GFP hAdV-5/3, 24 aa deletion in E1A, ΔE3, GFP 
downstream of E4 via splice acceptor site 
See section 7.8.2 
Ad-Luc hAdV-5/3, 24 aa deletion in E1A, ΔE3, firefly 
luciferase gene (Luc) downstream of the fiber gene 
via internal ribosomal entry site 
[81] 
Ad-Δ19K-Luc hAdV-5/3, 24 aa deletion in E1A, ΔE3, ΔE1B19K, 
firefly luciferase gene (Luc) downstream of the 
fiber gene via internal ribosomal entry site 
[81] 
Ad-TRAIL hAdV-5/3, 24 aa deletion in E1A, ΔE3, human TRAIL 
gene downstream of the fiber gene via internal 
ribosomal entry site 
See section 7.8.5 
Ad-Luc-GFP hAdV-5/3, 24 aa deletion in E1A, ΔE3, firefly 
luciferase gene (Luc) downstream of the fiber gene 
via internal ribosomal entry site, GFP downstream 
of E4 via splice acceptor site 
See section 7.8.3 
Ad-Δ19K-Luc-GFP hAdV-5/3, 24 aa deletion in E1A, ΔE3, ΔE1B19K, 
firefly luciferase gene (Luc) downstream of the 
fiber gene via internal ribosomal entry site, GFP 
downstream of E4 via splice acceptor site 
See section 7.8.4 
Ad-TRAIL-GFP hAdV-5/3, 24 aa deletion in E1A, ΔE3, human TRAIL 
gene downstream of the fiber gene via internal 
ribosomal entry site, GFP downstream of E4 via 
splice acceptor site 
See section 7.8.6 
Ad-FCU1-GFP hAdV-5/3, 24 aa deletion in E1A, ΔE3, FCU1 gene 
downstream of the fiber gene via internal 
ribosomal entry site, GFP downstream of E4 via 
splice acceptor site 
See section 7.8.7 
Ad-CMV-GFP Replication-deficient hAdV-5/3, ΔE1, ΔE3, GFP 
under CMV promoter control 
provided by Igor Dmitriev 
and David Curiel 
Ad-CMV-FCU1 Replication-deficient hAdV-5, ΔE1, ΔE3, FCU1 
under CMV promoter control 
Provided by Phillippe Erbs  
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9.10. Antibodies 
Name Description Dilution Supplier 
Adenovirus fiber 
monomer and 
trimer 
Mouse monoclonal [4D2] 1:500 Abcam, Cambridge, UK (ab3233) 
Adenovirus Type 5 
hexon 
Rabbit polyclonal 1:500 Abcam, Cambridge, UK (ab24240) 
TRAIL Rabbit, polyclonal 1:500 Invitrogen, Karlsruhe 
Anti-yCD Sheep, polyclonal 1:200 AbD Serotec, Düsseldorf 
Anti-EGFP Mouse IgG1, monoclonal 
(clones 7.1 and 13.1) 
1:10,000 Roche, Mannheim 
Anti-β-actin Mouse IgG2a, monoclonal 
(clone AC-74) 
1:50,000 Sigma-Aldrich, Taufkirchen 
Anti-mouse-HRP Goat, polyclonal 1:2,000 Cell Signaling Technologies, Danvers, 
MA 
anti-sheep-HRP Rabbit, polyclonal 1:8,000 Thermo Fisher Scientific, Life 
Technologies, Schwerte 
Anti-rabbit-HRP Goat, polyclonal 1:2,000 Cell Signaling Technologies, Danvers, 
MA 
 
9.11. PCR Primers 
Name Sequence (5’-3’) 
Delta 24 aaagccagcctcgtggcaggtaag 
SeqITR cgggaaaactgaataagaggaagtga 
E3-rev ggcaaggaggtgctgctgaataaac 
E3-for ctgctagttgagcgggacaggggac 
3knob ttaatgtagaactatactttgatgc 
5knob aggcagtttggctccaatatctgg 
Seq Mfe Fiber tgtataagctatgtggtggtgggg 
GFP-N1 f2 cgccaccatggtgagcaag 
3’ pShuttle rv cggatccttatcgattttaccac 
hTRAIL fw gatcccatggctatgatggaggtcc 
hTRAIL rv2 gcatctagatcattagccaactaaaaagg 
E1B-rev  gcggacggaagacaacagtag 
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9.12. Sequencing Primers 
Name Sequence (5’-3’) 
E1B-rev  gcggacggaagacaacagtag 
3knob ttaatgtagaactatactttgatgc 
3’ pShuttle rv  cggatccttatcgattttaccac 
Seq Mfe Fiber tgtataagctatgtggtggtgggg 
3‘E4_fw gagctatgctaaccagcgtagcc 
E4p_rev attgaagccaatatgataatgaggg 
midGFP_fw tacaactacaacagccacaacg 
5‘GFP_fw cccggtgaacagctcctcgccc 
5´RITR_rev gaacctgaaacataaaatgaatgc 
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10. Methods 
10.1. DNA Methods 
10.1.1. Polymerase Chain Reaction (PCR) 
Amplification for test PCRs were done with Taq-Polymerase (Invitrogen, Life Technologies, 
Darmstadt). In order to amplify fragments for cloning (GFP and TRAIL) the Precisor High-Fidelity-
Polymerase was used (BioCat, Heidelberg). The reagents were taken from the Taq Polymerase Kit 
(Invitrogen, Life Technologies, Darmstadt). dNTPs were obtained from Bioron, Ludwigshafen. The 
reaction mixes were set up according to the manufacturer’s manual as summarized below. 
 
 Taq PRECISOR 
10 x PCR buffer 1x 1x 
50 mM MgSO4-solution  1.5 mM - 
10 mM dNTPs 200 µM 400 µM 
DMSO - 3.5% 
20 µM primer forward 1 µM 160 nM 
20 µM primer reverse 1 µM 160 nM 
DNA template 1 µl 20 ng 
Polymerase 2.5 U 1U 
Total volume 25 µl 25 µl 
 
The PCR reactions were performed in a T3000 Thermocycler (Biometra, Jena). An outline of the PCR 
program is given below. Annealing temperatures were chosen according to the temperature 
determined from primer lengths, base composition, and individual optimization.  
 
 Cycles Temperature Time 
Denaturation 1x 96°C 3 min 
Denaturation  96°C 30 sec 
Annealing 30x 55-66°C 30 sec 
Extension  72°C 1 min 
Final extension 1x 72°C 10 min 
Cooling 1x 4°C ∞ 
 
PCR results were analyzed by agarose gel electrophoresis (see section 10.1.3). For further cloning, 
the fragments were purified using the Qiagen® PCR-purification kit (Qiagen, Hilden) as described in 
the manual. 
 
10.1.2. Restriction Enzyme Digestion 
Amplified PCR products or plasmid vectors were treated with restriction enzymes in the 
corresponding buffers provided by the companies (Fermentas, St. Leon-Rot, and New England 
Biolabs, Frankfurt am Main). The digestion reactions were performed for 4 hours at 37°C, if not 
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indicated otherwise in the manuals of the enzymes. The digestion created DNA fragments with 
“sticky” overhang ends.  
 
10.1.3. Gel Electrophoresis 
Following restriction enzyme digestion, the fragments were separated and analyzed by gel 
electrophoresis. The gel was prepared, solving 1% agarose gel in 1x TAE buffer. The DNA fragments 
were prepared adding 1x DNA loading buffer, were applied on the gel, and separated at 100 V for 1 
hour. As a size standard, GeneRuler™ 1 kb DNA ladders were applied in one lane on the same gel. 
DNA fragments were visualized using UV light at 265 nm with a Gel Stick “Touch” (INTAS, Göttingen). 
For further cloning, the required fragments were excised from the gel using a scalpel. 
 
10.1.4. Cloning DNA Fragments into Plasmid Vectors 
DNA insert fragments and vector DNA were digested (see section 10.1.2), and the vector ends were 
de-phosphorylated using FastAP™ alkaline phosphatase (Fermentas, St. Leon-Roth) to prevent 
religation during cloning. Digested vectors and inserts were purified using QIAquick® Gel Extraction 
Kit (Qiagen, Hilden). Inserts were introduced into the plasmid vector by using T4 DNA Ligase (Thermo 
Scientific, Schwerte). A ratio of linearized vector and DNA insert of 1:3 to 1:5 was used. 100 ng of 
vector DNA was used and the amount of insert calculated accordingly. The ligation was done in 20 µl 
total volume using 1 µl of T4 DNA Ligase. The ligation mix was incubated for 1 hour at 22°C and 
further for 10 min at 65°C to stop ligation. 1.5 µl of the ligation mix was then electroporated into XL-1 
Blue as described in section 10.1.6.  
 
10.1.5. Production of Electro-Competent Bacteria and Transformation 
E. coli XL-1 Blue bacteria from the stock were inoculated in 10 ml LB-medium containing tetracylin 
and incubated at 37°C overnight while shaking at 220 rpm. The next day, 3 x 1L LB medium were 
inoculated with the pre-culture. Incubation was stopped, when optical density reached 0.5 – 0.6 at 
600 nm. Suspension was incubated 15 min on ice and centrifuged for 10 min at 4,000 rpm. The pellet 
was resolved in 50 ml bi-distilled water, centrifuged for 10 min at 5,000 rpm, and washed in 50 ml bi-
distilled water again. After the final centrifugation for 10 min at 5,000 rpm, the pellet was 
resuspended in 20 ml cold glycerol (10% v/v). Aliquots of 50 µl were stored at – 80°C. 
Transformation efficiency of the generated bacteria was tested. Electro-competent bacteria were 
transformed with 1 ng of a defined plasmid (procedure see section 10.1.6). 1, 10, and 100 µl of the 
transformation was plated and incubated overnight at 37°C. 24 hours later, the colonies were 
counted and the transformation efficiency calculated using the following formula: 
Transformation efficiency = (colony / [ng] transformed DNA) x (total volume / plated volume) 
For electro-competent E. coli XL-1 Blue the reference transduction efficiency was 1.0 x 109 μg. 
 
10.1.6. Transformation by Electroporation 
Plasmids were transformed into electro-competent E. coli XL-1 Blue.  
For each sample, 50 µl of competent bacteria were thawed on ice. 1-50 ng of a plasmid for re-
transformation in 1-2 µl or 2-3 µl of a ligation mix were added to the bacteria. The mix was incubated 
on ice for one minute. Then, the samples were transferred into pre-chilled electroporation cuvettes. 
A cuvette was placed in an electroporator and pulsed at 2.5 kV for 4.5 - 5.5 milliseconds. Immediately 
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after transformation, the celled were transferred into 1 ml of SOC medium. After shaking at 37 °C for 
30 min, 500 µl, 200 µl, and 100 µl of the bacteria solution were spread on LB agar dishes containing 
the relevant antibiotic for selection. Plates were incubated overnight at 37°C. Single colonies were 
picked about 15 hours later. 
 
10.1.7. Homoglogous Recombination 
In order to modify the adenoviral genome, homologous recombination between a shuttle plasmid 
(pShuttle or pfiber) and the viral backbone plasmids (pVKs) was performed via homologous 
recombination. 
4 μg of the respective shuttle plasmid was linearized by PmeI and backbone plasmids. For 
homologous recombinations with pfiber plasmids, pVKs were digested with SwaI in 50 µl. Both 
reactions were performed for 4 hours at 37°C. Afterwards, 2 µl of FastAP™ alkaline phosphatase 
(Fermentas, St. Leon-Roth) were added and samples were incubated for another 45 min at 37°C. 
Then, DNA was purified by precipitation. Lithium chloride to a final concentration of 500 mM and 
afterwards 2.5-fold volumes of 100% ethanol were added. The samples were centrifuged at 13,000 
rpm for 20 min, the supernatant was aspirated, the pellets were washed in 0.5 ml of 70% EtOH, 
centrifuged again, and then resuspended in 30 μl of bi-distilled water. The protein concentration in 
the samples was determined by measurement with a NanoDrop ND-1000 UV/VIS spectrophotometer 
(Peqlab, Erlangen). 
Homologous recombination was carried out using 100 ng of linearized pVK backbone plasmid, and 
600 ng of linearized shuttle plasmid (pfiber or pShuttle). Both were mixed and added to 50 µl of 
electro-competent BJ5183 bacteria. The solution was transferred to a cooled cuvette, was placed in 
an electroporator, and pulsed at 2.5 kV for 4.5-5.5 milliseconds. Immediately after transformation, 
the celled were transferred into 1 ml of SOC medium. The solution was incubated at 30°C for 30 min 
and then spread on LB agar dishes containing the appropriate antibiotic. The plates were incubated 
at 30°C. Successfully recombined genomes were forming colonies, which started to appear 20 hours 
post-plating. Single clones were picked and analyzed via restriction enzyme digestion (see section 
10.1.2) for correct sequence organization.  
 
10.1.8. Isolation of Plasmid DNA for Analysis 
Following generation of new constructs by cloning or homologous recombination, the correct 
genome organization was verified. Following transformation, single clones were picked from the agar 
plate and were inoculated in 5 ml LB medium supplemented with the relevant antibiotic and 
incubated overnight in a shaker at 180 rpm and 37°C (normal cloning) or 30°C (homologous 
recombination). Bacteria were harvested by centrifugation at 1,000 rpm for 10 min. For normal sized 
plasmids (<15 kb), DNA was isolated using the AxyPrep™ Plasmid Miniprep Kit (Axygen Biosciences, 
Union City, CA) according to the manufacturer’s protocol.  
Larger plasmids (>15 kb, e.g. adenoviral genomes) were purified by a column-free protocol using 
buffer solutions from the QIAprep® Plasmid Midi Kit (Qiagen, Hilden). After centrifugation, the pellets 
were resuspended in 250 μl of buffer P1 supplemented with RNase A (provided by the kit) and lysed 
by adding 250 μl buffer P2. Samples were incubated for 5 min at room temperature to allow lysis. 
Then, 350 μl of buffer P3 was added. Bacterial cell debris was removed by centrifugation at 13,000 
rpm for 10 min and supernatants were mixed with 750 μl isopropanol. After mixing, precipitated DNA 
was pelleted at 13,000 rpm for 30 min at 4°C and washed with 70% (v/v) ethanol. Supernatants were 
aspirated and DNA was resuspended in 50 μl bi-distilled water.  
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The purified plasmids were subsequently characterized by restriction enzyme digestion (see section 
10.1.2) with suited enzymes and buffers (Fermentas, St.Leon-Rot, and New England Biolabs, 
Frankfurt am Main) following gel electrophoresis (see section 10.1.3). The key viral genome 
segments of correct candidates were sequenced using the GATC Biotech Sanger service (GATC 
Biotech, Konstanz).  
 
10.1.9. Quantitative Isolation of Plasmid DNA 
For larger scale plasmid isolation regardless of plasmid size, correct single clones from a re-
transformation or frozen stock were inoculated in 100 ml LB medium supplemented with the 
appropriate antibiotic and incubated overnight in a shaker at 180 rpm at 37°C (normal cloning) or  
30°C (homologous recombination). Plasmid DNA was isolated using the QIAGEN® Plasmid Plus Midi 
Kit (Qiagen, Hilden) according to the manufacturer’s instructions. DNA precipitates were dissolved in 
200 - 500 μl bi-distilled water, characterized by restriction enzyme digestions as descried in section 
10.1.2, and subsequently stored at -20°C. 
 
10.2. Cell Culture 
10.2.1. Maintenance of Cells 
Human established pancreatic tumor cell lines MiaPaCa-2 and BxPc-3 (kindly provided by Ingrid Herr, 
University Hospital Heidelberg) were cultured in DMEM/5% (containing 5% heat-inactivated fetal 
bovine serum (FBS)). AsPc-1 and Panc-1 (provided by Celina Cziepluch, DKFZ, Heidelberg) were 
cultivated in RPMI/5%.  A549 (lung carcinoma cell line) and HEK293 were cultivated in DMEM/5%. 
Absence of mycoplasma was confirmed every three months. Cells were used until passage 30.  
JoPaca-1 and PacaDD-159 were cultures in PacaDD medium (see Materials section 9.7). JoPaca-1 
cultures were used in passages 9 to 11 and PacaDD-159 cultures in passages 11 to13. 
MSCs were provided and characterized by the group of Ingrid Herr (University Hospital Heidelberg). 
They were isolated from bone marrow of healthy patients, both male and female between 20 to 30 
years old, by Ficoll’s dense centrifugation and attachment to plastic surfaces. Further, they were 
characterized by their differentiation potential into chondrogenic, adipogenic, and osteogenic 
lineages [131, 133]. For about 3 passages, MSCs were expanded and then frozen by cryo-
preservation, stored, and re-thawed prior to usage. The MSCs obtained from the group of Ingrid Herr 
were between passages 3-5 and were used until passage 9. They were cultured in NH medium. 
All cells were grown at 37°C and 5% CO2 humidified atmosphere. For splitting, the cells were once 
washed with 10 ml of PBS, detached with 4 ml of Trypsin-EDTA and then split 1:3 (for MSCs and low-
passage pancreatic carcinoma cultures) or 1:10 (for established pancreatic cancer cell lines). 
 
10.2.2. Cryo-Preservation and Thawing 
Cells from a 10-cm plate were trypsinized, centrifuged at 1,000 rpm for 10 min, and resuspended in 4 
ml of FBS containing 10% (v/v) DMSO. 1 ml aliquots in Cryo tubes (Nunc, Thermo Fisher Scientific, 
Schwerte) were stored NALGENE™ Cryo 1°C Freezing Container (Nunc, Thermo Fisher Scientific, 
Schwerte) overnight before moving to long-term storing at -196°C in liquid nitrogen. 
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10.2.3. Cell Number Determination 
Viable Cells were counted using a Neubauer chamber. After trypsinization, cells were diluted and 
stained with trypan blue solution and applied into the chamber. At least 4 big squares were counted 
and the number of vital cells calculated using the following formula: 
cells/ml = average of cell number in large squares x dilution factor x 104. 
 
10.3. Recombinant Adenoviruses 
The cloning strategies were described in detail in Result section 7.8.1. Ad5 has been described as 
Ad5Luc1 in Krasnykh et al. [67]. Ad5/3 has been described as Ad5/3Luc1 in Krasnykh et al. [67]. 
Ad5RGD was described as Ad5lucRGD in [239]. Ad-Luc and Ad-Δ19K-Luc were described as 
Ad5/3.19K+.IL and Ad5/3.19K+.IL, respectively, in Rohmer et al. [81]. Ad-CMV-GFP was kindly 
provided by Igor Dmitriev and David Curiel. Prodrug convertase FCU1-encoding Ad-CMV-FCU1 was 
described in Erbs et al. [106]. 
All other viruses were generated in the course of this study.  
GFP from pEGFP-N1 (Clontech, Mountain View, CA) was cloned into pSΔ24 [161], generating pSΔ24-
GFP. pSΔ24-GFP was recombined with pVK500 5/3 ΔE3 to generate Ad-GFP (for details see also 
Results section 7.8.2). Ad-Luc-GFP was generated by homologous recombination of pSΔ24-GFP and 
pVK500 5/3 ΔE3 IL (see Rohmer et al. [81] and Results section 7.8.3). In order to generate Ad-Δ19K-
Luc-GFP, the E1B19K deletion from pSΔ24-E1B19K- [81] was introduced into pSΔ24-GFP, resulting in 
pSΔ24-E1B19K-GFP. The deletion of E1B19K had been generated by PCR with oligonucleotides 19K-5′ 
(5′-CGA GGA CTT GCT TAA CGA GC-3′) and 19K-3′ (5′-GGA CGG AAG ACA ACA GTA GC-3′) from Ad337 
as described in Rohmer et al. [81]. pSΔ24-E1B19K-GFP was recombined with pVK500 5/3 ΔE3 IL to 
generate Ad-Δ19K-Luc-GFP (see also Results section 7.8.4).  
Full-length TRAIL was provided by Ingrid Herr (University Hospital Heidelberg) and cloned into pGL3-
IRES-Luc [93] replacing the luciferase gene. The resulting pGL3-IRES-TRAIL plasmid was subcloned 
into pfiber5/3 ΔE3 IRES Luc to obtain pfiber5/3 ΔE3 IRES TRAIL. Homologous recombination with 
pVK500 Δ24 resulted in the genome of Ad-TRAIL (see also Results section 7.8.5). Homologous 
recombination of pSΔ24-GFP and pVK500 5/3 ΔE3 IRES TRAIL (both generated above) resulted in the 
genome of Ad-TRAIL-GFP (see also Results section 7.8.6).  
Recombination of pVK500 5/3 d24 IRES FCU1 and pSΔ24-GFP generated the genome for Ad-FCU1-
GFP (see also Results section 7.8.7). 
Viruses were PacI digested and transfected with Lipofectamin (Invitrogen, Karlsruhe) into A549 cells 
(see also section 10.3.1). The viruses were amplified in A549 cells and subsequently purified by CsCl 
equilibrium density gradient ultracentrifugation (see also sections 10.3.2 and 10.3.3). Accuracy of 
genome sequences was confirmed by PCR. Viral particles concentration was determined by optical 
density measurement at 260 nm (see also section 10.3.4). Infectious virus particles were determined 
by TCID50 assay on A549 or HEK293 cells for replication-competent or -deficient viruses, respectively 
(see also section 10.3.5).  
 
10.3.1. Preparation of Virus DNA and Transfection 
6 µg of modified pVK plasmid containing the full adenovirus genome was digested with PacI 
overnight at 37°C in 150 µl. 2 µl were used for a control agarose gel separation, to check the excision 
of a 3kb fragment. The linearized DNA was precipitated by adding 3.5x volumes of Isopropanol. After 
centrifugation at 13,000 rpm for 20 min at 4°C, 3.3x volumes of EtOH (70%) were added and samples 
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were centrifuged again with 13,000 rpm for 10 min at 4°C. The DNA was resuspended in 30 µl bi-
distilled water. 2500 ng of linearized DNA was mixed with 250 µl of OptiMEM and 1 µl of Plus 
Reagent (Solution A) and incubated for 15 min at room temperature. Another 250 µl of OptiMEM 
was supplied with 20 µl of Lipofectamine (Invitrogen) (Solution B) and incubated for 15 min as well. 
Solutions A and B were mixed and incubated for another 20 min at room temperature.  
The day before transfection, 1.5 x 106 A549 cells were seeded in a T25 flask. Prior to transfection, the 
cells were washed once with PBS, 250 µl OptiMEM were added, the transfection solution was added, 
and incubated for 4 hours. Then, the transfection solution was removed and 5 ml of DMEM/2% were 
added.  
 
10.3.2. Virus Propagation 
After transfection (see section 10.3.1), half of the medium in the T25 flask was removed every two 
days and replenished with fresh medium. This was repeated until a cytopathic effect was observed. 
When cells were lysed, cells and supernatant were harvested and subjected to three freeze-thaw 
cycles. The cell debris was removed by centrifugation at 13,000 rpm for 10 min at 4°C. From the 
obtained 5 ml of virus-containing medium, 4 x 1 ml were aliquoted and frozen at -80°C. 1 ml was 
distributed on one 14-cm plate with A549 cells (70% confluent) in DMEM/2%. After 48 hours, when 
cells were detached, the cells were harvested in 5 ml of supernatant and the described freeze-thaw 
cycle was repeated. In the next steps the amount of plates used for infection was scaled up to 5 x and 
finally to 20 x 10-cm plates, following the same infection and harvesting procedure as described 
above. 48 hours-post infection of 20 plates of A549 cells, the cells were again harvested in 5 ml of 
supernatant, freeze-thawed three times, and the obtained 5 ml of virus solution were used for 
purification. 
The 48 hour post-infection time point for harvesting the infected A549 cells was crucial. The cells had 
detached, but the virus was not released. However, for the viruses containing two transgenes, a 
longer replication cycle was observed and the harvesting time point was delayed to 3 days post-
infection.  
 
10.3.3. Virus Purification 
Two ultracentrifuge tubes (Herolab, Wiesloch) were prepared for density centrifugation. A gradient 
was loaded containing 3 ml of CsCL, 1.4 g/cm3 at the bottom, 5ml of CsCl 1.27 g/cm3 on top and 
finally 2.5 ml of the virus solution was added. The tubes were centrifuged (Sorvall WX Ultra 80, 
Thermo Scientific, Schwerte) for 4h at 32,000 U at 4°C.   
Afterwards, the viral band was harvested and purified using a PD-10 column (GE Healthcare, Little 
Chalfont, UK). Prior to the purification steps, the column was equilibrated with 25 ml of PBS. The 
harvested viral band was filled up to 2.5 ml with PBS and applied on the column. Another 500 µl of 
PBS was added. All the throw-flow liquid up to this point was discarded. The virus was eluted with 2 
ml PBS and collected in a tube containing 200 µl of glycerol. The virus was mixed with the glycerol, 
aliquoted, and stored at –80°C. 
 
10.3.4. OD260 Measurement for Physical Viral Particle Determination 
To determine the physical viral particles concentration, the virus was diluted 1:5, 1:10 and 1:20 in 
viral lysis buffer, containing 0.5% SDS. The viruses were inactivated by incubation at 56°C for 10 min. 
Then, OD260 was measured at 260 nm using a NanoDrop ND-1000 UV/VIS spectrophotometer 
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(Peqlab, Erlangen) and the viral particles concentration was calculated by using the formula as 
reported by [240, 241]: vp/ml = OD260 x 20 x viral dilution x 1.1 x 1012. 
 
10.3.5. 50% Tissue Culture Infectious Dose 50 (TCID50) Assay 
In order to determine infectious viral particle titers, the tissue culture dose 50 (TCID50) assay was 
performed. 10,000 A549 cells or HEK293 cells were plated in 96-wells in 100 µl DMEM/2%. A549 cells 
were used for replication-competent viruses. HEK293 cells were used for replication-deficient 
viruses, as they are stably transformed with sheared Ad5 genome and therefore substitute the 
missing E1 gene and allow viral replication. The day after plating, the cells were infected with 100 µl 
of serial diluted virus in 10-fold replicates. The virus was diluted 10-5 to 10-12 TCID50/cell in DMEM/2%. 
On each plate, the remaining wells were used as uninfected controls. 14 days post-infection, the 
number of wells showing cytopathic effect through plaque formation was assessed by bright-field 
microscopy. The TCID50 titer was calculated by the reported formula [242]:  
TCID50/ml = 101 + 1 × (sum of positive wells-0.5) 
The ratios of physical virus particles to infectious virus particles were between 13 and 65. This ratio 
provided information about the quality of the virus preparation. High ratio numbers mean that a 
higher amount of physical viral particles is needed to obtain the same number of infectious viral 
particles compared to lower ratio numbers. The calculations for infections were mostly based on the 
TCID50 titers. However, high amounts of physical, but uninfectious viral particles can themselves 
induce a cytopathic effect. Therefore, in order to compare different viruses tested in one experiment, 
the ratios should be similar. Therefore, if the ratio exceeded 80, the virus preparation was repeated. 
 
10.3.6. Genome and Transgene Expression Verification of Generated Viruses 
Virus genome organization was verified by control PCRs. E1A, E3, fiber, the deletion of E1B19K, and 
the inserted transgenes GFP and TRAIL were analyzed (see for pipetting scheme section 10.1.1 and 
for primer sequences Materials section 9.11). Gene modifications were verified by PCRs under the 
following conditions: 
 
Analyzed modification/ 
transgene insertion 
Primers 
Annealing 
temperature 
Fragment sizes 
E1AΔ24 
Delta 24 
60°C 
Wild type E1A: 
Δ24:   
630 bp 
no band SeqITR 
ΔE1B19K 
E1B-rev  
60°C 
Wild type E1B19K:  
ΔE1B19K:   
1829 bp 
1684 bp SeqITR 
ΔE3 
E3-rev 
60°C 
Wild type E3:  
ΔE3:  
2836 bp 
156/207 bp E3-for 
3 knob 
3knob 
62°C 
 489 bp 
Seq Mfe Fiber 
5 knob 
5knob 
62°C 
 521 bp 
Seq Mfe Fiber 
GFP 
GFP-N1 f2 
58°C 
 1007 bp 
3’ pShuttle rv 
TRAIL 
hTRAIL fw 
58°C 
 858 bp 
hTRAIL rv2 
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Further, transgene expression was confirmed by luciferase assay (see section 10.5.1), visual GFP 
expression, or immunoblots (GFP, TRAIL, FCU1, see section 10.5.2 - 10.5.6) 
 
10.4. Recombinant Virus Techniques 
10.4.1. Transduction with Replication-Deficient Capsid-Modified Viruses 
Cells were seeded in 48-well plates (50,000 for established pancreatic cell lines, 25,000 for low-
passage pancreatic cell cultures, and 10,500 cells for MSCs) in normal maintenance medium. 24 
hours later, they were transduced in 100 µl DMEM/2% or 100 µl NH medium with replication 
deficient viruses (established and low-passage pancreatic cancer cells: 100 vp/cell, MSCs: 1,000 
vp/cell) in triplicates. 2 hours post-infection, cells were washed twice with PBS and 500 µl DMEM/5% 
or 500 µl NH medium were added. 48 hours post-infection, cells were lysed for a subsequent 
luciferase activity assay (see section 10.5.1). 
 
10.4.2. Burst Assay in MSCs 
10,500 MSCs were seeded in 48-well plates in 500 µl NH medium. 24 hours later, the cells were 
infected with a virus titer of 1,000 TCID50/cell in 100 µl NH medium in triplicates. 2 hours post-
infection cells were washed twice with PBS and 500 µl NH medium were added to each well. After 2, 
4, 6, and 8 days supernatant and cells were harvested separately. The total 500 µl of supernatant 
were harvested and centrifuged at 1,000 rpm for 10 min to remove residual, floating cells. 
Supernatant and cell pellet were separated. The remaining cells in the well were scraped and 
reunited with the floating cells obtained before. The cells were washed twice with PBS and finally 
resuspended in 250 µl NH medium. Cells and supernatant were freeze-thawed three times. Cell 
samples were subsequently centrifuged at 15,000 rpm for 10 min to precipitate cell debris. Total 
virus amount in cells and supernatant were titrated by TCID50 assay on A549 cells as described in 
section 10.3.5. 
 
10.4.3. Cytotoxicity Assay in MSCs 
10,500 MSCs were seeded in 48-well plates in 500 µl in NH medium. 24 hours later the cells were 
infected with serial dilutions between 100 and 0.001 TCID50/cell of virus in 100 µl NH medium. After 
incubation at 37°C for 2 hours, 400 µl fresh NH medium were added. 14 days post-infection, the 
plates were stained with a crystal violet solution. The medium was removed and 50 µl of crystal 
violet solution was added to each well. Plates were incubated at room temperature for 30 min and 
subsequently the plates were rinsed under tub water until all unbound dye was removed. The plates 
were dried and scanned using a Perfection V500 Photo scanner (Epson, Meerbusch). 
 
10.4.4. Infection of MSCs with Ad-GFP with and without Polybrene 
 10,500 MSCs were plated in a 48-well plate in 500 µl NH medium. 24 hours later, the cells were 
infected with Ad-GFP between 100 and 10,000 TCID50/cell in 100 µl of NH medium or NH medium 
containing 8 ng/ml Polybrene (Sigma-Aldrich, Taufkirchen). 2 hours post-infection, the medium was 
removed and 500 µl of NH medium were added. The cells were incubated 48 hours at 37°C. 
Afterwards, the medium was aspirated, 200 µl of 4% Formaldehyde in PBS was added to each well, 
and incubated for 10 min at room temperature for fixation. Then, 200 µl of 0.5% (v/v) Triton X-100 in 
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bi-distilled water was added for permeabilization and incubated for 10 min at room temperature. 
Finally, the cells were stained with 200 µl Hoechst 33258 (1:2000 in bi-distilled water) for 10 min at 
room temperature. The dye was removed, the wells were washed once with 500 µl of bi-distilled 
water, and 500 µl of bi-distilled water/well were added. Fluorescence pictures were taken using a 
BIOREVO BZ-9000 fluorescence microscope (KEYENCE, Neu-Isenburg). 
In pre-experiments, MSCs were transduced with Ad-GFP in medium containing 2, 4, 8, and 16 ng/ml 
Polybrene. 8 ng/ml was determined as the lowest concentration mediating optimized transduction.  
 
10.4.5. Burst Assay in MSCs with Medium Containing Polybrene 
10,500 MSCs were seeded in 48-well plates in 500 µl NH medium. 24 hours later, the cells were 
infected with a virus titer of 1,000 TCID50/cell in 100 µl NH medium or with 100 TCID50/cell in 100 µl 
NH medium containing 8 ng/ml Polybrene in triplicates.  
In order to obtain the input titer two hours post infection, the supernatant was removed, cells were 
washed twice with PBS, scraped, transferred to a new tube, centrifuged, and resuspended in 250 µl 
NH medium. The wells, which were meant to be harvested at day 4 post-infection, were washed 
twice with PBS at 2 hours post-infection and 500 µl of NH medium were added. Cells and supernatant 
samples at day 4 were harvested as described in section 10.4.2. The samples were freeze-thawed 
three times. Cell samples were subsequently centrifuged at 15,000 rpm for 10 min to precipitate cell 
debris. Total virus amount in cells and supernatant were titrated by TCID50 assay on A549 cells as 
described in section 10.3.5. 
 
10.4.6. Infection of MiaPaCa-2 with Supernatant from Infected MSCs for XTT assay 
10,000 MiaPaCa-2 cells were plated in 96-well plates in 100 µl DMEM/5%. 24 hours later the medium 
was removed and the cells were infected either with titrated virus-containing supernatant from 
infected MSC or purified virus. From the burst assay (see section 10.4.5), supernatant from Donor 
4/day 4 were titrated by TCID50 assay on A549 and then serial dilutions between 1.0 and 0.0001 
TCID50/cell in 100 µl DMEM/2% were used for infection of MiaPaCa-2. Further, MiaPaCa-2 cells were 
infected with the same TCID50 titers of purified virus. All infections were done in triplicates.  
 
10.4.7. Migration Assay of Virus-Infected MSCs 
Staining 
24 hours before the start of migration, the MSCs were stained red with PKH26 red-fluorescent dye 
(Sigma-Aldrich, Taufkirchen) in suspension. 4 x 106 MSCs were washed one in serum-free medium, 
centrifuged with 800 rpm for 5 min and then resuspended in 750 µl Diluent C (provided by the kit). 
The cells were immediately mixed with dye solution (3 µl dye in 750 µl Diluent C) and incubated for 2 
min. Then, 1.5 ml of FBS were added. After centrifugation (800 rpm, 5 min), the cells were 
resuspended in DMEM/10%, washed once in DMEM/10%, and were finally resuspended in 
DMEM/2%FBS. The cells were counted and 7.6 x 105 cells/well were plated in 5 wells of a 12-well 
plate. 
Infection / Start Migration 
The next day, the 5 wells with MSCs were infected with 2,500 TCID50/cell in 2 ml DMEM/2% with 
either one of the modified virus or mock-infected with DMEM/2%. After 2 hours of incubation at 
37°C, the cells were washed twice with PBS. The cells were trypsinized and washed with DMEM/2%. 
The cells from each of the 5 infections (4 viruses + 1 mock) were resuspended in 1.8 ml of DMEM/2%. 
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For analysis of migration of virus-transduced MSCs, CytoSelect™ 24-Well Cell Migration Assay (12 µm, 
Colorimetric Format, Cell Biolabs, San Diego, CA) was used. Transwells were prepared by pipetting 
500 µl DMEM/10% into the lower well of the 24-well plate. 1 x 105 MSCs in 300 µl DMEM/2% were 
added into the upper well. As controls, 0.5 x 105 MSCs/well for every infection condition (4 viruses + 
1 mock) were plated in a 24-well plate. All transwell and control conditions were done in triplicates. 
Stop Migration / Fluorescence Pictures 
38 hours after the start of migration, the cells from the upper side of the transwell membrane were 
scraped with a cotton swab. Fluorescent pictures of the migrated cells at the lower side of the 
membrane were taken with a BIOREVO BZ-9000 fluorescence microscope (KEYENCE, Neu-Isenburg). 
Additionally, fluorescent images of the 24-well controls were taken. For all insert and control well 
samples, three images were taken following an identical pattern.  
Membrane Staining 
The transwell membranes were stained with crystal violet as described in the manual and bright-field 
pictures were taken. The membranes were incubated for 10 min with 400 µl of the staining solution. 
Afterwards, the inserts were washed in a beaker of water and were air-dried. Bright-field pictures of 
the crystal violet stained, migrated cells on the lower side of the transwell membranes were taken 
with a BIOREVO BZ-9000 fluorescence microscope (KEYENCE).  
Each insert was transferred to a clean well and 200 µl of extraction solution were added. The inserts 
were incubated for 10 min at room temperature. Afterwards, 100 µl of the extracted solutions were 
transferred to a new 96-well plate and the dye intensity was measured at OD560 with a SPECTROstar 
Nano microplate reader (BMG Labtech, Ortenberg). The means of measured OD 560 values of the 
triplicates of each of the 5 conditions (4 viruses + mock) were blotted. 
 
10.4.8. Infection of MiaPaCa-2 for Western blot Sample Generation 
50,000 MiaPaCa-2 cells were plated in 6-wells in 3 ml DMEM/5%. 24 hours later transduced with 10 
TCID50/cell of the respective virus in 1 ml DMEM/2%. 2 hours post-infection 2 ml of medium 
containing 5% were added. 48 hours post-infection cells were scraped and centrifuged (800 rpm, 5 
min). Preparation of cell lysates is further described in sections 10.5.2 and 10.5.3. 
 
10.4.9. Virus Infection Testing AraC as Virus Genome Replication Inhibitor 
50,000 A549 cells were seeded in DMEM/2% in 500 µl in 48-wells. One day later, they were 
transfected with 100 TCID50/cell in DMEM/2% in 100 µl. The infection was stopped two hours later by 
adding DMEM/5% or DMEM/5% containing 25 µg/ml AraC. AraC was replenished every 12 hours by 
adding AraC into the wells, without changing the medium. 30 hours post-infection, GFP was 
monitored by fluorescence imaging using Leica DFC 350 FX (Leica Microsystems, Wetzlar).  
 
10.4.10. Cytotoxicity Assay in Established and Low-Passage Pancreatic Cancer Cells 
50,000 (established pancreatic cancer cells) or 25,000 cells (low-passage pancreatic cancer cultures) 
were seeded in 48-well plates in 500 µl in the respective medium (MiaPaCa-2, BxPc-3: DMEM/5%; 
Panc-1, AsPc-1: RPMI/5%; JoPaca-1: IMDM/10%; PacaDD-159: PacaDD medium). 24 hours later the 
cells were infected with serial diluted virus between 100 and 0.001 TCID50/cell in media containing 
2%FBS. After incubation at 37°C for 2 hours, 400 µl fresh medium were added (MiaPaCa-2, BxPc-3: 
DMEM/5%; Panc-1, AsPc-1: RPMI/5%; JoPaca-1: IMDM/10%; PacaDD-159: PacaDD medium). 5 days 
prior to staining 5-FC and 5-FU at final concentration between 10 mM and 0.1 µM were added in 100 
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µl DMEM/2%. 100 µl medium were added to untreated wells for volume adjustment. 6 days 
(MiaPaCa-2 and AsPc-1), 8 days (BxPc-3 and Panc-1), or 12 days (JoPaca-1, PacaDD-159) post-
infection plates were stained with crystal violet as described in section 10.4.3.  
 
10.4.11. Infection of Low-Passage Pancreatic Tumor Cell Lines with Ad-GFP 
25,000 JoPaca-1 and PacaDD-159 cells were seeded in 500 µl IMDM/2% and PacaDD medium, 
respectively. 24 hours post-plating, cells were infected with serial dilutions between 1 and 1,000 
TCID50/cell of Ad-GFP in IMDM/2% or PacaDD medium. 2 hours post-infection, the infection solution 
was removed and 500 µl of IMDM/10% or PacaDD medium were added. 48 hours post-infection, the 
medium was aspirated, 200 µl of 4% Formaldehyde in PBS was added to each well, and incubated for 
10 min at room temperature for fixation. Then, 200 µl of 0.5% (v/v) Triton X-100 in bi-distilled water 
was added for permeabilization and incubated for 10 min at room temperature. Finally, the cells 
were stained with 200 µl Hoechst 33258 (1:2000 in bi-distilled water) for 10 min at room 
temperature. The staining solution was removed and the wells were washed once with 500 µl of bi-
distilled water. Fluorescence pictures were taken using a BIOREVO BZ-9000 fluorescence microscope 
(KEYENCE, Neu-Isenburg). 
 
10.4.12. Spheroid Infection and GFP Monitoring  
5,000 MiaPaCa-2 cells were seeded in a round-bottom 96-well plate in 100 µl 
DMEM/2%FBS/1%HEPES containing 0.5% methylcellulose. The spheroids were provided by the group 
of Ingrid Herr (University Hospital Heidelberg). 24 hours post-seeding, the cells had cumulated at the 
bottom of the well and only wells with proper formation of a single spheroid were used for infection. 
The spheroids were infected with virus in 100 µl DMEM/2%FBS/1%HEPES or mock-infected with 
DMEM/2%FBS/1%HEPES in triplicates. The virus spread in the spheroids was monitored via 
observation of GFP expression. Pictures were taken 0, 2, 4, 6, and 8 day post-infection with a 
BIOREVO BZ-9000 microscope (KEYENCE, Neu-Isenburg).  
 
10.5. Biochemical and Immunological Protein Methods 
10.5.1. Luciferase Assay 
48 hours post-infection (see section 10.4.1), medium was removed, and cells were washed once with 
PBS. 100 µl of cell culture lysis buffer (Promega, Madison, WI) was added and incubated at room 
temperature for 20 min. 20 µl (established pancreatic cancer cell lines) or 50 µl (low-passage 
pancreatic cancer cultures and MSCs) of cell lysates were transferred to a solid white 96-well flat-
bottom polystyrene microplate (Thermo Scientific Nunc, Schwerte). Luciferase activity in relative 
luminescence units (RLU) was determined by using a reporter assay system (Promega). Utilizing the 
injection system of a Synergy2 microplate reader (BioTek, Bad Friedrichshall), 50 µl of luciferase 
substrate were added. After a delay of 2 sec, luciferase activity was measured for 10 sec. Wells 
containing only lysis buffer were used as background controls.  
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10.5.2. Preparation of Protein Lysates for TRAIL, FCU1, and GFP Immunoblots 
48 hours post-infection (see section 10.4.8) cells were scraped, transferred to a tube, centrifuged 
(800 rpm, 5 min), and the pellets were subsequently lysed in 100 µl of RIPA buffer. After incubation 
on ice for 30 min, the samples were centrifuged again (15,000 rpm, 5 min) and the supernatant 
transferred to a new tube. 
 
10.5.3. Preparation of Protein Lysates for Fiber/Hexon Immunoblots 
For generation of protein lysates for fiber/hexon protein detection, the cells were scraped, 
transferred to a tube, centrifuged (800 rpm, 5 min), and subsequently 100 mM tris (stock 1 M) was 
added. The tubes were shaken for 30 min at 4°C. Subsequently, 3 µl of 5 M NaCl and the samples 
were centrifuged (5 min, 1,000 rpm, 4°C). The supernatants was transferred to new tubes and the 
samples were strictly kept at 4°C for further steps.  
 
10.5.4. Measuring Protein Concentration 
Protein concentration in the protein lysate samples were determined by the Bradford method. The 
lysate samples were diluted 1:4 in bi-distilled water. For a standard curve, a series of 10-fold dilutions 
of BSA was prepared ranging from 1.0 to 0.1 µg/µl.  
In a semi-micro F-bottom cuvette (greiner bio-one, Frickenhausen) the diluted samples were mixed 
with 100 µl of Solution A (Dc Protein Assay, Bio-Rad, Munich) and vortexed. Next, 800 µl of Solution B 
were added, vortexed, and the cuvettes were incubated for 30 min at room temperature. Protein 
concentrations were measured at 750 nm by using a 4050 Ultrospec II UV/Vis Spectrophotometer 
(LKB Biochrom, Cambridge, UK). The protein concentrations of the samples were calculated based on 
the standard curve. 
 
10.5.5. SDS PAGE 
Lysates containing 30 µg (fiber/hexon) or 50 µg (others) total protein were mixed with 4x SDS sample 
buffer. Proteins were incubation at 96°C for 10 min for denaturation. After cooling, the samples were 
shortly centrifuged. They were loaded on a polyacrylamide gels comprised of a 12.5% separating gel 
and a 4% stacking gel. For a size standard, 5 μl of the PageRuler™ Prestained Protein ladder were 
added in a separate lane on the same gel. Electrophoresis was performed in 1x running buffer at 100 
V until the bromophenol blue front had reached the bottom of the gel or, for proteins with large 
sizes like fiber/hexon, until the marker bands corresponding to the expected sizes had reached the 
middle of the gel. 
 
10.5.6. Western Blot Analysis 
After protein separation, the acrylamide gel was stacked with a nitrocellulose membrane between 
Whatman filter papers (Whatman, Dassel) in a wet blot chamber (Bio-Rad, Munich).  All components 
were soaked in 1x transfer buffer before. The proteins were allowed to be transferred to the 
nitrocellulose membrane for 1 hour at 0.8 mA/cm2. 
After blotting, the membrane was incubated in Western blot blocking solution overnight at 4°C (for 
y-CD western blot) or for 1 hour at room temperature (all others) on a rocking platform. The blot was 
afterwards washed three times for 10 min with Western blot washing buffer. Afterwards membranes 
were incubated with primary antibody diluted in Western blot washing buffer for 1 hour at room 
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temperature. For dilutions see Materials section 9.10. Afterwards, membranes were again washed 
three times for 10 min with Western blot washing buffer and then incubated with HRP-coupled 
secondary antibody diluted in Western blot washing buffer for 1 hour at room temperature. For 
dilutions see Materials section 9.10. Finally, the blots were washed again as described above and the 
chemoluminometric reaction was initiated by adding Pierce ECL Western Blotting Substrate (Thermo 
Fisher Scientific, Schwerte). Super RX Fuji Medical X-Ray Films (Fujifilm Corporation, Tokyo, Japan) 
were exposed to the blots for various time spans and subsequently developed using a Curix 60 
processor (AGFAR HealthCare, Bonn, Germany)  
Subsequently, each membrane was subjected to staining for β-actin as loading control. Therefore, 
the membranes were washed three times with Western blot washing buffer and subsequently 
incubated with diluted antibody against β-actin for 1 hour at room temperature. Afterwards, the 
procedure was followed as described above.  
 
10.5.7. XTT Assay 
Infected MiaPaCa-2 cells (see section 10.4.6) were analyzed 8 days post-infection by XTT assay. The 
assay was performed using the Cell Titer 96® AQueous One Solution Cell Proliferation Assay System 
(Promega, Madison, WI). 
The reagent solution was prepared as described in the manufacturer’s protocol by mixing buffer and 
substrate solution. 25 µl of the mix were added to each well and the plates were incubated for 2 
hours at 37°C in a humidified atmosphere. Afterwards, the plates were read out at 477 nm and 620 
nm (reference wavelength). Background absorption measured in wells with medium only was 
subtracted from each value. Further, values measured at 620 nm were subtracted from values at 477 
nm for each well. Blots showing measured absorbance units were generated. Mock-infected cells 
were used as control for maximal cell vitality. 
 
10.5.8. LDH Assay  
Spheroids were infected in triplicates with the modified viruses or mock-infected as described in 
section 10.4.12 and cultured over 8 days. After 4 and 6 days an LDH assay was performed using the 
CytoTox96® Non-Radioactive Cytotoxicity Assay (Promega, Madison, WI). At day 4 and day 6 post-
infection, 30 µl of spheroid supernatant was withdrawn from each infected and mock-infected well. 
After every withdrawal, the volume was replenished with 30 µl DMEM/2%FBS/1%HEPES.  
For every time point, 3 additional mock-infected spheroids were used as positive complete lysis 
control. To these complete lysis control wells, 10 µl of lysis solution buffer supplied by the assay kit 
was added and the cells were incubated for 30 min at 37°C to allow complete lysis. Then 30 µl of of 
the total lysis control as well as 30 µl of supernatant from the infected and mock-infected spheroids 
were transferred to a 96-well plate. Further, 3 wells containing only medium were used for 
background absorbance determination. 30 µl of substrate (supplied by the kit) were added to each 
well as described in the manufacturer’s protocol and incubated for 30 min at room temperature. 
Afterwards, 30 µl of stop solution was added and absorbance measured at 592 nm. The background 
values were subtracted from all values and the percentage of dead cells were calculated by setting 
total lysis control as 100% dead cells. 
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10.5.9. Spheroid size determination 
Spheroid sizes were determined using the program Histo®, which was generated and provided by Dr. 
Wolfgang Groß (group Ingrid Herr, University Hospital Heidelberg). The bright-field pictures taken 
from infected or mock-infected spheroids at day 6 were loaded and an “Area, free hand border” 
drawn around the outer spheroid border. By subsequent selection of the inner area, the program 
determined the spheroid surface area in pixels. Area determinations were done for three spheroids 
for every condition and means and standard deviations were calculated.  
 
10.6. Statistical Analysis 
All statistical analyses were performed using GraphPad Prism 5.0 software (GraphPad Software, La 
Jolla, CA). One-way analysis of variance (1way ANOVA) and subsequent Bonferroni’s Multiple 
Comparison Test was used to compare multiple means with each other.  
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